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3Abstract
Burkholderia pseudomallei, the causative agent of melioidosis, has evolved
multiple strategies to facilitate survival in the environment and can cause
serious disease in the human host. The lipoprotein BPSL3147 (VacJ) was
previously shown to be important in the growth and survival of B.
pseudomallei in an in vivo mouse model and a VacJ transposon mutant was
highly attenuated. This work has focused on elucidating the role of VacJ as a
virulence determinant in B. pseudomallei. The gene was characterized using
bioinformatic and genetic techniques, utilizing comparisons with B.
thailandensis to study the in vivo and in vitro roles. In this study a rationally
defined B. pseudomallei VacJ deletion mutant was constructed, verified and
evaluated. The VacJ mutant was able to colonize mice organs during the
initial infection phase, but was unable to sustain the infection. In in vitro
assays the VacJ mutant did not display any defect in early steps of the
intracellular lifecycle. However, VacJ appears to play a contributory role to
human serum resistance, as evidenced by the serum susceptibility of an
acapsular B. pseudomallei ∆BPSL3147 mutant and B. thailandensis VacJ
mutants. Taken together, VacJ contributes to virulence by affecting the outer
membrane of B. pseudomallei and B. thailandensis affecting serum
resistance sensitivity. The B. pseudomallei VacJ mutant was also
investigated for potential as a live attenuated vaccine and displayed partial
protection against a lethal challenge in an acute intranasal mice infection
model.
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1. Chapter 1 – Introduction
1.1 The Burkholderia genus
The Burkholderiaceae family lies within the β-Proteobacteria class and is
comprised of members from several genera including Burkholderia and
Ralstonia (Garrity, 2005). The Burkholderia genus is comprised of more than
60 species (Estrada-de los Santos et al., 2013) which can occupy a wide
range of ecological niches including soil, water, plant roots, amoebae and
animals (Inglis et al., 2000, Coenye et al., 2003, Sprague and Neubauer,
2004, Compant et al., 2008, Khan et al., 2013). There are two sub-lineages
within the Burkholderia genus based on 16S rRNA sequence and multilocus
sequence analyses (MLSA) (Brett et al., 1998, Estrada-de los Santos et al.,
2013). One of these sub-lineages comprises soil, water and plant-associated
species (group A); and the other sub-lineage contains several Burkholderia
species that are known to be pathogenic in humans, along with some
environmental and plant pathogenic species (group B, Figure 1.1) (Estrada-
de los Santos et al., 2013). Among the pathogenic Burkholderia,
Burkholderia pseudomallei, the causative agent of melioidosis, and
Burkholderia mallei, the causative agent of glanders, are important because
of the potentially life-threatening clinical features of these diseases. The
Burkholderia cepacia complex bacteria are another medically important
group of opportunistic pathogens that primarily affect patients with cystic
fibrosis. Amongst the many diverse species classified within the Burkholderia
genus, B. pseudomallei is found to be most closely related to the equine-
associated obligate pathogen B. mallei and the avirulent environmental
16
saprophyte Burkholderia thailandensis based on 16S rRNA similarity and
MLSA (Brett et al., 1998, Estrada-de los Santos et al., 2013).
Figure 1.1. Phylogenetic relationships among some Burkholderia
species.
The maximum likelihood tree inferred from the concatenated alignment of
atpD-gltB-lepA-recA-16S rRNA genes shows the phylogenetic relationships
among some Burkholderia species. (Adapted from (Estrada-de los Santos et
al., 2013)).
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1.1.1 Burkholderia pseudomallei
B. pseudomallei is a Gram-negative, rod-shaped bacillus with rounded ends
which ranges from 0.5 - 1 x 1.5 - 4 µm in dimension and occurs as single or
paired cells (Garrity, 2005). It is an environmental saprophyte found in rice
paddies, stagnant waters and moist tropical soils. Optimal growth conditions
for this bacterium include aerobic conditions, 37°C growth temperature and a
pH of 6.5 to 7.5. It can also survive as a facultative intracellular pathogen and
is associated with disease in a range of hosts including human, mammals,
birds, reptiles and amoeba (Inglis et al., 2000). It is a metabolically versatile
organism and can utilize a wide variety of organic compounds as sources of
carbon and energy for growth. It can undergo morphology switching and
display up to seven major colony morphotypes in response to environmental
stress (Chen et al., 2003a, Chantratita et al., 2007a, Tandhavanant et al.,
2010). It is intrinsically resistant to many antibiotics and there is no licensed
vaccine available (Cheng and Currie, 2005b).
B. pseudomallei has a large, complex genome for a bacterium of
approximately 7.04 - 7.25 Mb comprised of two chromosomes with an overall
G+C content of 68 %. Computational analysis of protein coding genes in the
first sequenced strain of B. pseudomallei, strain K96243, predicted  5737
coding sequences (Holden et al., 2004, Winsor et al., 2008, Nandi and Tan,
2012). Chromosome 1 (4.07 Mb) contains a relatively high proportion of
genes involved in core housekeeping functions, while chromosome 2 (3.17
Mb) contains a high proportion of accessory genes associated with
environmental adaptation (Holden et al., 2004, Sim et al., 2008).
Comparative analysis of multiple B. pseudomallei genomes revealed that the
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core- and pan-genome consists of 4909 and 7500 predicted coding
sequences respectively, with a significant amount of genetic variation
between strains (Nandi et al., 2010, Losada et al., 2010). B. pseudomallei
appears to have acquired several strain specific genomic islands (GIs),
including pathogenicity islands and prophages through horizontal gene
transfer events (Tuanyok et al., 2007, Ronning et al., 2010). These GIs
exhibit striking deviations in sequence composition (GC content, dinucleotide
composition) from the general genome backbone. Twelve GIs were identified
on chromosome 1, and four were identified on chromosome 2 (Holden et al.,
2004). B. pseudomallei also has a high number of tandem and simple
sequence repeats (SSRs) (U'Ren et al., 2007), most of which occur within or
close to genes encoding surface or secreted proteins that may directly
interact with host factors during pathogenesis or with other environmental
factors (Han et al., 2009). There is a significant amount of genomic variation
amongst B. pseudomallei isolates including variability in GIs between
different strains and the SSRs, and this may be related in part to the
variability in disease outcome (Tuanyok et al., 2008, Tumapa et al., 2008).
The extensive B. pseudomallei genome encodes a large number of factors
that likely contribute to its various niche preferences, biological phenotypes,
broad host range and its ability to cause disease. For example, B.
pseudomallei K96243 has at least 10 operons that can code for components
of resistance-nodulation-cell-division (RND) efflux pumps, which are
recognized as major causes of multi-drug resistance in Gram-negative
bacteria. Expression of these RND pumps can be induced by exposure to
toxic compounds (Kumar et al., 2008a). The genome also has several
19
clusters of secondary metabolite genes that may produce metabolites,
lipopeptides and siderophores to promote survival in soil against competing
microorganisms. The B. pseudomallei genome encodes many virulence
factors such as several type IV pili (TFP) and fimbrial clusters (Holden et al.,
2004, Essex-Lopresti et al., 2005), a number of type III secretion systems
(T3SS) and type VI secretion systems (T6SS), surface carbohydrates such
as the capsular polysaccharide (CPS) and lipopolysaccharide (LPS). A more
detailed presentation of these B. pseudomallei virulence factors is provided
in Section 1.8.
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1.1.2 Burkholderia mallei
B. mallei, the causative agent of glanders, carries many genotypic and
phenotypic similarities to B. pseudomallei, but is an obligate pathogen and
cannot persist outside its mammalian hosts (horses and other solipeds)
(reviewed in (Galyov et al., 2010)). It has a similar, but smaller genome of
about 5.7 Mb (5.23 – 5.84 Mb) compared to B. pseudomallei and is
considered to have evolved from an ancestral strain of B. pseudomallei
(Godoy et al., 2003). While the majority of genes retained by B. mallei share
99 % DNA-DNA sequence identity with B. pseudomallei, a large number of
insertion sequence (IS) elements are found in the B. mallei genome. These
IS elements are thought to have mediated extensive genome-wide
rearrangements that resulted in many pseudogenes compared to B.
pseudomallei, and contribute to phenotypic and physiological differences
(Nierman et al., 2004, Kim et al., 2005a). Many of the functional genes
associated with environmental survival in B. pseudomallei are absent or
disrupted in B. mallei (Losada et al., 2010). For example, in B. mallei, genes
associated with flagellum biogenesis (flip) and the flagellum motor (motB) are
disrupted by a 65-kb insert flanked by insertion elements and a frameshift
mutation respectively, rendering it non-flagellated and non-motile (Nierman
et al., 2004). Historically, B. mallei was used as a bioweapon during the
World Wars I and II (Wheelis, 1998, Rotz et al., 2002, Whitlock et al., 2007),
and is also classified as a Tier 1 select agent in the National Select Agent
Registry (United States).
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1.1.3 Burkholderia thailandensis
B. thailandensis is an environmental saprophyte that carries many
phenotypic similarities to B. pseudomallei but is much less virulent
(Wuthiekanun et al., 1996, Brett et al., 1998, DeShazer, 2007). To date, only
four cases of human diseases caused by B. thailandensis have been
reported, two in Southeast Asia (Dharakul et al., 1999, Lertpatanasuwun et
al., 1999) and two in the Southeastern United States of America (Glass et al.,
2006). B. thailandensis has a broadly similar genome (6.15 – 6.73 Mb) to B.
pseudomallei and B. mallei, and has a number of orthologues of known
virulence factors such as the type IV pili genes, bsa type 3 secretion system
(T3SS-3), and five out of the six type 6 secretion systems (T6SS-1, -2, -3, -5,
-6) (Yu et al., 2006). Similar to B. pseudomallei, B. thailandensis is resistant
to many antibiotics, can infect cells, survive intracellularly, cause
multinucleated giant cell formation, and can cause lethality in Syrian golden
hamsters, BALB/c mice and C576 BL/6 mice, albeit at a much higher dose)
(Brett et al., 1997, DeShazer, 2007, Schwarz et al., 2010) . Unlike B.
pseudomallei, B. thailandensis contains a functional L-arabinose assimilation
operon (which is largely deleted in B. pseudomallei) and xylose metabolism
gene clusters and does not usually produce a capsular polysaccharide. The
introduction of the full arabinose operon into genetically modified B.
pseudomallei resulted in a downregulation of gene expression in T3SS
genes, and a reduction of virulence when those strains were exposed to
arabinose (Moore et al., 2004). The finding suggests that these arabinose
assimilation genes may be considered antivirulence genes. As the capsule is
an important virulence factor in B. pseudomallei, this was predicted to
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correlate to the avirulence of B. thailandensis. However, a variant B.
thailandensis isolate, E555, that has acquired the B. pseudomallei capsular
polysaccharide biosynthesis gene cluster does not display enhanced
virulence in murine infection assays (Sim et al., 2010), indicating that other
virulence factors are also important in the in vivo infection model. Studies
have linked the bsa T3SS and T6SS-5 to B. thailandensis virulence in a
pneumonic murine infection model (Haraga et al., 2008, Schwarz et al.,
2010).
1.2 Melioidosis, the disease and risk factors
B. pseudomallei is the causative agent of melioidosis, a potentially fatal
disease first described by Whitmore and Krishnaswami in 1911 in Burma
(Whitmore and Krishnaswami, 1912). Melioidosis can infect humans
(Whitmore and Krishnaswami, 1912, Stanton et al., 1924) and many species
of animals (Lewis and Olds, 1952, O'Brien et al., 2003). Infection can occur
following bacterial inoculation through the skin, ingestion, or inhalation (White,
2003, Limmathurotsakul et al., 2014). A wide variety of clinical symptoms
may ensue, with manifestations ranging from low-grade chronic infection to
acute septicaemia. Inhalation of B. pseudomallei is associated with a more
severe disease presentation and can lead to pneumonia and septic shock.
The bacteria may also be disseminated to distant sites, causing concomitant
pneumonia and abscesses in multiple organs, including the liver and spleen,
bone, skin, prostate, and brain stem tissue (Puthucheary et al., 1992, Currie
et al., 2000b, White, 2003, Kumar et al., 2008b). Disseminated pneumonia is
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present in 50 % of acute cases and is often associated with high mortality
(Currie et al., 2000b). Melioidosis is difficult to treat, and the disease may
relapse even with extensive antibiotics treatment (Currie et al., 2000b,
Limmathurotsakul et al., 2006, Limmathurotsakul and Peacock, 2011). Upon
resolution of the acute phase, chronic melioidosis can occur in which
symptoms persist for many months, even years. Chronic melioidosis is found
in < 15 % of cases (Currie et al., 2000a), where subacute presentations
similar to tuberculosis are described.
Risk factors for disease progression include underlying conditions such as
diabetes mellitus, chronic renal disease and chronic lung disease,
immunosuppression and excessive alcohol consumption (Currie et al., 2004,
Leelarasamee and Bovornkitti, 1989, Suputtamongkol et al., 1999). In
addition, the risk of acquiring the disease may increase in people with
occupational or recreational exposure to moist soil or surface water (e.g. rice
farmers, agricultural workers, construction labourers, adventure travellers,
military personnel and a variety of indigenous groups) (Cheng and Currie,
2005a).
Asymptomatic chronic infections may sometimes develop into a more acute
form of infection after a period of latency, with one case documenting
reactivation 62 years after the initial exposure (Ngauy et al., 2005). The
disease may relapse even with extensive antibiotic treatment. The risk of
relapse is associated with the choice and duration of oral antimicrobial
therapy (Currie et al., 2000a, Limmathurotsakul et al., 2006,
Limmathurotsakul and Peacock, 2011).
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Currently, there is no licensed human vaccine for protection against
melioidosis. Due to its potential to pose a severe threat to human health, B.
pseudomallei is classified as a biosafety level 3 pathogen and is listed as a
Tier 1 select agent and potential bioterrorism threat by the U.S. Centers for
Disease Control and Prevention (CDC) and the Animal and Plant Health
Inspection Service (APHIS).
1.3 Geographical distribution and epidemiology
Melioidosis is endemic in Southeast Asia and Northern Australia, with
sporadic cases reported in other tropical regions (Currie et al., 2008, Dance,
2000, Le Hello et al., 2005). B. pseudomallei, can be found in the
environment in endemic regions, particularly in rice fields in Northeast
Thailand (Wuthiekanun et al., 2009, Limmathurotsakul et al., 2010b), Laos
(Rattanavong et al., 2011) and in soil and water samples in Northern
Australia (Brook et al., 1997) (Figure 1.2). A review by the Detection of
Environmental B. pseudomallei Working Party (DEBWorP) showed ‘definite’
evidence for the presence of environmental B. pseudomallei in 17 countries
(Figure 1.2) (Limmathurotsakul et al., 2013). Clinical and environmental
isolates of B. pseudomallei demonstrate virulence in animal models of
infection (Brett et al., 1997, Smith et al., 1997). B. thailandensis, previously
classified as B. pseudomallei-like strains with the ability to assimilate L-
arabinose (Ara+) but with attenuated virulence in animal models, was first
discovered in the environment of endemic areas in Northeast and central
Thailand (Wuthiekanun et al., 1996). A subsequent phylogenetic study
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classified these Ara+ isolates as B. thailandensis (Brett et al., 1998). B.
thailandensis can also be found in Northern Australia (Levy et al., 2008).
The incidence of melioidosis is closely correlated with rainy seasons
(Suputtamongkol et al., 1994, Cheng et al., 2008a). Each year, about 3000 to
4000 cases of clinical melioidosis are estimated to occur throughout Thailand
(Wongratanacheewin and Sirisinha, 2012). The highest number of
melioidosis cases is reported in Northeast Thailand, where it accounts for 20 %
of all community-acquired septicaemias, with a mortality rate of 40 % in
patients who receive treatment (Chaowagul et al., 1989, White, 2003). In
Northern Australia, the overall mortality rate of culture-positive patients is
about 20 – 25 % (Currie et al., 2000b, Malczewski et al., 2005, Cheng and
Currie, 2005b).
In Northeast Thailand, approximately 80 % of the children develop antibodies
to the bacteria by the age of four (Kanaphun et al., 1993, Cheng et al.,
2008b). In one study, antibodies against the environmental B. thailandensis
were found in a small percentage of patients with melioidosis in Thailand
(Tiyawisutsri et al., 2005). In a separate study, Gilmore et al. (Gilmore et al.,
2007) demonstrated that the sera from culture-positive patients in Northern
Queensland will cross-react with B. thailandensis. There are relatively low
rates of seropositivity (5 % – 12.8 %) within populations in Northern Australia
compared to that recorded in Northeast Thailand or among immigrants from
Southeast Asia to Queensland (29 %) (Ashdown and Guard, 1984, Currie et
al., 2000b). Despite that, melioidosis remains the most common cause of
severe community-acquired pneumonia in parts of Northern Australia (Currie
et al., 2000b, Cheng and Currie, 2005b).
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Melioidosis is considered to be an emerging disease, as it is being reported
and recognised increasingly in many countries where it has not been
previously described (Currie et al., 2008). These countries include China,
Taiwan (Chen et al., 2010), Sri Lanka (Corea et al., 2012), Africa (Borgherini
et al., 2006, Katangwe et al., 2013) and Columbia (Montufar et al., 2011).
The apparent emergence is probably due to a combination of factors
including better recognition and diagnostic ascertainment of the disease
(Dance, 2000, Currie et al., 2008), increase in prevalence of conditions such
as diabetes that enhance susceptibility to the disease (Antony et al., 2010),
and climate change (Currie and Jacups, 2003, Chierakul et al., 2005, Cheng
et al., 2006).
Figure 1.2. The worldwide distribution of melioidosis.
Stars indicated areas with reported outbreaks and/or presence of B.
pseudomallei in temperate and subtropical regions in France, Italy, Australia
and Southwest Australia (Reproduced from (Limmathurotsakul et al., 2013)).
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1.4 Diagnosis and treatment
Timely diagnosis and identification of B. pseudomallei is critical to ensure
optimal therapy. Microbiological culture remains the standard method for the
diagnosis of melioidosis and treatment of melioidosis cases are currently
based on definitive isolation of the organism on culture from blood, urine,
sputum, pus or other clinical specimens (Lipsitz et al., 2012). B.
pseudomallei grows well in most routine laboratory media but a selective
medium such as Ashdown agar (Ashdown, 1979) or Burkholderia cepacia
agar (Peacock et al., 2005) can aid in isolation of B. pseudomallei by
suppressing overgrowth of normal microbiota in nonsterile specimens.
Presumptive identification of B. pseudomallei involves simple bench tests in
order to confirm an oxidase positive, Gram-negative bacillus, resistant to
gentamicin and colistin, sensitive to amoxicillin-clavulanic acid, with a
characteristic colonial morphology (reviewed in (Glass and Walsh, 2012)).
Further definitive identification can be made using biochemical tests (API
20NE and Vitex II from bioMérieux Inc.), molecular detection or fatty acid
profiling. Rapid diagnostic methods have been proposed, and include latex
agglutination assays (Anuntagool et al., 2000) and polymerase chain
reactions (PCR). A study performed by Wuthiekanun (Wuthiekanun et al.,
2002) recommended using a latex agglutination assay that involves
polyclonal and monoclonal antibodies against a 200 kDa exopolysaccharide
for the confirmation of B. pseudomallei from blood culture specimens.
Serological diagnosis can support a clinical diagnosis or aid in identifying
disease relapse by quantifying the human antibody response after exposure
to B. pseudomallei. Common serological methods include the indirect
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haemagglutination assay (IHA), the immunofluorescent antibody test (IFAT)
and enzyme linked-immunosorbent assay (ELISA), which uses antigens
derived from heat-killed bacteria, whole-killed organism, and a crude
sonicated, protein extract respectively (Alexander et al., 1970, Ashdown et
al., 1989). However the IHA may have limited role in serological diagnosis in
endemic areas due to the presence of antibodies in apparently healthy
individuals (Appassakij et al., 1990). Other serological methods using
antibodies raised against cell wall components such as LPS, 30 kDa protein,
exopolysaccharides (EPS) (Tiyawisutsri et al., 2005, Chantratita et al.,
2007b), the outer membrane protein (OmpA) (Allwood et al., 2008) and
truncated flagellin (Chen et al., 2003b), have limited efficiency since there is
cross-reactivity with related Burkholderia species and may not provide better
sensitivity and specificity.
A number of PCR diagnostic tests targeting bacterial genes such as the 16S
rDNA, LPS, and T3SS1 clusters, have been developed for the direct
detection of B. pseudomallei in clinical specimens and identification of
isolates (Rattanathongkom et al., 1997, Haase et al., 1998, Meumann et al.,
2006). These methods are rapid and specific, but require improvement in
sensitivity for detection in clinical specimens (Kunakorn et al., 2000, Gal et
al., 2005).
Treatment of severe melioidosis involves an initial intensive treatment phase
(10-14 days) followed by a prolonged oral eradication phase (3-6 months) to
reduce the risk of relapse. In general, the treatment involves the parenteral
administration of ceftazidime or meropenem, with or without trimethoprim-
sulfamethoxazole (TMP-SMX) (Lipsitz et al., 2012). With timely diagnosis,
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institution of appropriate antibiotic therapy and access to state-of-the-art
intensive care therapy, mortality in a patient without risk factors is unlikely
(Currie et al., 2000a). However, in many locations where such treatment
resources are limited, mortality from septicaemic melioidosis remains high
(Chaowagul et al., 1989, Limmathurotsakul et al., 2006).
There has been on-going interest in the development of vaccines to protect
against melioidosis, although there is yet no licensed human vaccine. In
endemic areas, many apparent healthy individuals developed antibodies
reactive to B. pseudomallei from a young age, suggesting some levels of
protective immune responses may be present (Wuthiekanun et al., 2006).
Yet, relapse of melioidosis in patients is common and prior exposure to the
bacterium does not protect susceptible individuals from re-infection
(Maharjan et al., 2005, Limmathurotsakul et al., 2006). The innate immune
system appears to be critical for the initial containment of infection, but
successful elimination of the intracellular pathogen is likely to be critically
dependent on the activation of cell-mediated immune (CMI) responses
governed by type 1 T helper (Th1) cells, which can prevent the invasion of
host cells or detect intracellular pathogens and eliminate them (Kaufmann,
1993, Inglis and Sagripanti, 2006). Humoral responses are also considered
to contribute significantly to the development of host protection to melioidosis,
as evidenced by correlation of high titres of B. pseudomallei specific
immunoglobulins (Ig) to improved clinical outcome (Wiersinga et al., 2006,
Sarkar-Tyson and Titball, 2010). Even though immunization of animals with
the capsule, LPS, live attenuated vaccines, killed whole-cell lysates or sub-
unit vaccines confers partial protection against melioidosis, none of these
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methods generate sterilizing immunity (Sarkar-Tyson and Titball, 2010, Choh
et al., 2013). Thus a more complete understanding of the immune responses
required to protect against infection is central to the development of a B.
pseudomallei vaccine. The Burkholderia research community continues to
identify and characterize B. pseudomallei antigens in search of promising
targets for preventive strategies against melioidosis and for diagnostic
assays. It is possible that even if sterile immunity is not achievable, vaccines
could be used in conjunction with antibiotics or other therapeutics to treat
melioidosis patients and to prevent relapse.
1.5 Antimicrobial Drug resistance
B. pseudomallei is intrinsically resistant to many antimicrobial drugs,
including first, second and third-generation cephalosporins, aminoglycosides,
penicillins and polymyxin. It is usually susceptible to ceftazidime, the
carbapenem antibiotics, amoxicillin-clavulanate (AMC), doxycycline and
trimethoprim-sulfamethoxazole (TMP-SMX) (Wiersinga et al., 2012,
Schweizer, 2012a). Primary ceftazidime resistance has been reported very
rarely in isolates from Thailand (Wuthiekanun et al., 2011), Malaysia (Raja,
2008), and Singapore (Tan and Tan, 2008). A large study in Thailand
revealed no evidence of primary or acquired carbapenem resistance in B.
pseudomallei isolates (Wuthiekanun et al., 2011), but a small number of
carbapenem-resistant isolates were reported in Singapore (Tan and Tan,
2008) and Malaysia (Raja, 2008, Ahmad et al., 2013) .
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The antibiotic resistance mechanisms of B. pseudomallei range from
exclusion from the bacterial cell due to permeability properties of the Gram-
negative cell envelope (Nikaido, 2003), enzymatic inactivation, target
deletion and efflux from the cell (Schweizer, 2012a, Schweizer, 2012b). The
LPS of B. pseudomallei is modified by 4-amino-4-deoxy-L-arabinose, which
presumably contributes to intrinsic high-level polymyxin B resistance (Novem
et al., 2009). Maintenance of an intact LPS outer core oligosaccharide region
also contributes to resistance to cationic antimicrobial peptides (Burtnick and
Woods, 1999). Mechanisms involved in resistance to ceftazidime and other
β-lactams (e.g. AMX, targets the periplasm) have been linked to the
overproduction and mutation in the class A penA β-lactamase. Ceftazidime
resistance has also been associated with the deletion of the penicillin binding
protein 3 (BPSS1219). In Gram-negative bacteria, efflux pumps transport
their substrates across the cytoplasmic membrane and can expel their
substrates into the external milieu (Tal and Schuldiner, 2009, Nikaido and
Pagès, 2012). The AmrAB-OprA efflux pump plays a role in the intrinsic
aminoglycoside and macrolide resistance in many B. pseudomallei isolates
(Moore et al., 1999). The BpeEF-OprC efflux pump contributes to intrinsic
resistance to macrolides, fluoroquinolones, tetracyclines and
chloroamphenicol (Chan and Chua, 2005, Mima and Schweizer, 2010).
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1.6 Modes of persistence – environmental and clinical lifestyles
B. pseudomallei is a versatile organism that is able to persist in the
environment as well as colonise a host and cause disease. It can survive for
prolonged periods in harsh environmental conditions such as desiccation,
fluctuating temperatures, high salt, and lack of nutrients (Wuthiekanun et al.,
1995, Chen et al., 2003a, Inglis and Sagripanti, 2006, Shams et al., 2007,
Tandhavanant et al., 2010, Larsen et al., 2013). It is naturally found in moist
soil and surface water environments (White, 2003, Cheng and Currie, 2005b)
where factors such as ingestion by amoebae (Inglis et al., 2000) and other
natural predators may explain the range of determinants B. pseudomallei has
developed through evolutionary time in its repertoire to survive within hosts
cells. Humans are likely accidental hosts for the bacterium. However, very
little is known about the underlying mechanisms that contribute to B.
pseudomallei pathogenesis in mammalian hosts and there are likely many
new factors that have yet to be identified and characterized.
During an infection, B. pseudomallei must first overcome various host
defence mechanisms prior to reaching their cellular targets. For example,
bacteria entering the respiratory tract would encounter a number of
antimicrobial components such as lysozyme, complement proteins,
defensins and cathelicidins. B. pseudomallei is known to be resistant to the
killing action of defensins and complement but is susceptible to cathelicidin
LL-37 (Wikraiphat et al., 2009). B. pseudomallei can adhere to, invade and
replicate within a variety of eukaryotic cells, including phagocytic cells and
epithelial cell lines derived from alveolar, bronchial, laryngeal and oral
tissues, and exhibit an intracellular lifestyle (Harley et al., 1998).
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Figure 1.3 Intracellular lifecycle of B. pseudomallei and B. mallei.
(Reproduced from (Galyov et al., 2010))
B. pseudomallei can adhere to host cells by utilizing a pili encoded by pilA to
mediate bacterial cell-cell interaction, which increases adhesion of
microcolonies (Boddey et al., 2006). Other bacterial factors involved in
adhesion to nonphagocytic cells include the adhesins BoaA and BoaB
(Balder et al., 2010), the LPS and flagella (Inglis et al., 2003, Lu et al., 2012,
Gan et al., 2012). The bacteria then enter the cell via phagocytosis or by
inducing its own uptake into nonphagocytic cells. There is some evidence
suggesting that the presence of the bacterial capsule can interfere with the
uptake of B. pseudomallei by human neutrophils by limiting complement
protein C3 deposition on the bacterial surface (Woodman et al., 2012). Upon
uptake, the bacterium first enters into primary phagosomes before secreting
Bsa type III secretion system (T3SS-3) effectors to promote the disruption of
vacuolar membranes (Stevens et al., 2002). The bacterium then escapes
into the cytosol, and hijack the host cell actin polymerization machinery for
motility (Stevens et al., 2005b). B. pseudomallei evades killing by host
cellular defences such as autophagy, induces nitric oxide synthase (iNOS),
nitric oxide and proinflammatory cytokine production (Utaisincharoen et al.,
2001) and replicates within the cytosol. The bacterium then induces plasma
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membrane fusion, causing the formation of multinucleated giant cells
(MNGCs) (Kespichayawattana et al., 2000). The bacteria may spread to
adjacent cells through the formation of actin-based membrane protrusions
that can lead to either direct internalization into the adjacent cell (Stevens et
al., 2005b) or to fusion and formation of MNGCs (Kespichayawattana et al.,
2000). This ability to cause eukaryotic cells to fuse and undergo
morphological changes analogous to those observed during
osteoclastogenesis is not well understood. The intracellular lifestyle of B.
pseudomallei is thought to enhance its survivability and latency in hosts by
allowing the bacteria to evade the host immune system.
Identifying additional bacterial features or ‘virulence factors’ that enable B.
pseudomallei to establish itself within a host and enhance its potential to
cause disease may shed light on the various aspects of the bacterial life
cycle and hopefully provide information on the nature of B. pseudomallei as a
pathogen in mammalian hosts. In this context, the virulence factors are
defined as genes and proteins that enable initial colonization, dissemination
and/or immune evasion.
1.7 Methods used for the identification of virulence factors
Strategies used to identify virulence factors that contribute to the
pathogenicity of B. pseudomallei include genomic comparison, transposon
mutagenesis and in vivo expression technology (IVET). Prior to the
availability of genome sequences, comparative studies using subtractive
hybridisation between the virulent B. pseudomallei and the similar, but
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relatively avirulent B. thailandensis revealed a number of candidate genes
that are unique to B. pseudomallei (Brown et al., 2000, Reckseidler et al.,
2001). By inspecting sequenced genomes, candidate virulence factors can
also be predicted by analogy to other pathogens (Holden et al., 2004).
Methods utilizing transposon mutants (signature-tagged mutagenesis (STM)
and transposon-directed insertion-site sequencing (TraDIS)) have been used
to identify B. pseudomallei genes important for in vitro and in vivo virulence
(DeShazer et al., 1998, Atkins et al., 2002a, Pilatz et al., 2006, Cuccui et al.,
2007, Moule et al., 2014). IVET is a method of identifying genes which are
upregulated under specific conditions, such as those important for survival
within macrophages (Shalom et al., 2007).
1.8 Selected virulence factors
B. pseudomallei has a number of virulence factors that allow it to enable
initial colonization, dissemination and/or immune evasion and hijack the host
cell machinery for its survival, replication, spread and persistence (Galyov et
al., 2010). Some of the key virulence factors for Bps include the capsule,
type IV pili (TFP), quorum sensing molecules, LPS O-antigenic
polysaccharide, type III secretion system (Bsa T3SS), type VI secretion
system (T6SS), flagellin, and type III and type IV O-polysaccharide (O-PS).
These major virulence factors are deemed important for various stages of the
bacterial intracellular lifecycle. However, a holistic understanding of how the
bacterium interacts with the host and the complex nature of the bacterial life
cycle remains to be elucidated (Allwood et al., 2011). A more comprehensive
understanding of how B. pseudomallei exploit host cells will provide
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invaluable insights into pathogenesis of melioidosis and aid in the
development and improvement of novel therapeutics and vaccines. Some of
the major B. pseudomallei virulence factors are described as follows.
1.8.1 Surface polysaccharides: Capsule and lipopolysaccharides
Surface-associated molecules such as the capsule and LPS are structures
that constitute the outermost layer of the bacteria cell and are often involved
in mediating direct interactions between the bacteria and its environment.
The capsule of Gram-negative bacteria is composed of highly hydrated
polyanionic polysaccharides that are linked to the cell surface of the
bacterium via covalent attachments to either phospholipid or lipid-A
molecules, or may be associated with the cell in the absence of a membrane
anchor (Roberts, 1996). The capsular polysaccharides (CPS) can be homo-
or heteropolymers composed of repeating monosaccharides joined by
glycosidic linkages, and are often antigenic. Capsules have various roles
including determining access of molecules to the cell membrane, resistance
to specific and non-specific host immunity, mediating adherence to surfaces,
and prevention of desiccation (Roberts, 1996). Capsules have been deemed
as important virulence determinants in a wide range of bacterial pathogens
including Escherichia coli K1 (Robbins et al., 1974), Streptococcus spp.
(Smith et al., 1999), Actinobacillus pluropneumoniae (Ward et al., 1998),
Haemophilus influenzae (Kroll et al., 1993) and Pasteurella multocida (Boyce
and Adler, 2000).
The LPS is a major outer membrane component of Gram-negative bacteria,
and has an essential barrier function in protection against harsh
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environments and toxic compounds, as well as in signalling host innate
immune responses (Caroff and Karibian, 2003). It is composed of an outer
O-antigenic polysaccharide (O-PS) or oligosaccharide, and an inner core
oligosaccharide that is covalently linked to the lipophilic moiety termed lipid A
(bacterial endotoxin). The O-PS is diverse in length and composition
amongst different Gram-negative bacteria species, and typically determines
serotype specificity (Alexander and Rietschel, 2001). The polysaccharide
moiety plays protective roles, such as evasion of complement attack or
camouflage with common host carbohydrate residues, while the lipid A
moiety is associated with immunostimulatory activity (Rietschel et al., 1994,
Matsuura, 2013). A recent study confirmed that B. pseudomallei LPS triggers
TLR4-dependent immune activation, particularly in human whole blood, and
suggested that LPS play an important role in stimulating the host response in
melioidosis, particularly in the stimulation of TNF-α (Chantratita et al., 2013).
During an infection, host cells may produce proinflammatory cytokines upon
recognition of LPS, but overstimulation of the host cells by LPS can lead to
septic shock (Leon et al., 2008).
B. pseudomallei expresses at least four surface polysaccharides, two of
which (capsule and LPS) have been shown to be important for virulence
(DeShazer et al., 1998, Reckseidler et al., 2001, Holden et al., 2004, Cuccui
et al., 2007, Sarkar-Tyson et al., 2007). The B. pseudomallei capsule
contains the distinct type I O-PS moieties, which is an unbranched
homopolymer with the structure -3)-2-O-acetyl-6-deoxy-β-D-manno-
heptopyranose-(1- (Perry et al., 1995, Reckseidler et al., 2001). The capsule
is an important virulence factor, particularly in intraperitoneal and intranasal
38
murine infection models, as mutants deficient in capsule expression are
avirulent in mice and Syrian hamsters and are unable to survive in blood
(Reckseidler et al., 2001, Lazar Adler et al., 2009, Cuccui et al., 2012).
Although the capsule is essential for B. pseudomallei to cause disease, the
molecular mechanisms and interactions with the host are not fully
understood. The capsule plays a role in reducing complement factor C3b
deposition, thus allowing the bacteria to evade the host innate immune
response such as the complement cascade and opsonin-dependent
phagocytosis (Reckseidler-Zenteno et al., 2005). However, an acapsular B.
pseudomallei mutant was resistant to killing by 30 % normal human serum,
presumably because they still express LPS, a factor that contributes to
serum resistance (Woodman et al., 2012). Introduction of purified B.
pseudomallei capsule enhances the survival of serum-sensitive strains in
normal human serum as well as increased the in vivo virulence of an
acapsular mutant (Reckseidler-Zenteno et al., 2005). A recent study
suggests that the capsule confers some degree of resistance against
intracellular killing by human macrophages (Wikraiphat et al., 2009), while
another study suggests that the capsule hampers internalization of B.
pseudomallei into nonphagocytic cells but does not seemed to play a role in
intracellular replication or cytotoxicity in these cells (Phewkliang et al., 2010).
Taken together, these studies imply that the capsule is a major virulence
factor that affects in vivo virulence, survival in blood, phagocytosis and in
vitro survival within phagocytes, thus allowing for the bacteria to survive and
colonise in order to establish acute and/or chronic infections.
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The capsule is also required for virulence in the closely related B. mallei
(DeShazer et al., 2001), and is generally absent in the avirulent B.
thailandensis. However, two variant strains of B. thailandensis (CDC3015869
and E555) were recently shown to encode and express a B. pseudomallei-
like CPS but they did not display enhanced virulence in mice, suggesting
other factors are required to act in concert for full virulence in mammals (Sim
et al., 2010).
Four distinct antigenic types of B. pseudomallei LPS have been reported:
typical (type A), atypical (type B and B2) and rough types (Anuntagool et al.,
2006, Tuanyok et al., 2012). The serotype A LPS of B. pseudomallei
contains the type II O-PS moiety which is an unbranched heteropolymer with
repeating D-glucose and L-talose units with the structure -3)-β-D-
glucopyranose-(1-3)-6-deoxy-α-L-talopyranose-(1-, in which approximately
33 % of the L-6dTalp residues bear 2-O-methyl and 4-O-acetyl substituents
whereas the other L-6dTalp residues bear only 2-O-acetyl substituents
(Perry et al., 1995, DeShazer et al., 1998). The LPS of the avirulent B.
thailandensis is highly similar to that of B. pseudomallei (type A) and is cross
reactive to sera obtained from B. pseudomallei infections (Anuntagool et al.,
1998, Ngugi et al., 2010, Tuanyok et al., 2012). In a recent study, the B.
thailandensis LPS confers partial protection against melioidosis in a mouse
model of infection (Ngugi et al., 2010).
The B. pseudomallei LPS is a major virulence factor that affects in vivo
virulence in intraperitoneal animal models (hamsters, guinea-pigs and infant
diabetic rats) and contributes to human serum sensitivity and survival in rat
and guinea-pig infection models (DeShazer et al., 1998). The LPS also
40
contributes to in vitro survival in human macrophages (Wikraiphat et al.,
2009). This is likely due, at least in part, to the suppression of cytokine
secretion (IFN-β) and inducible nitric oxide synthase (iNOS), which leads to
the reduction in bactericidal activity (Arjcharoen et al., 2007). The LPS is also
involved in conferring resistance to cationic antimicrobial peptides (polymyxin
B) (Burtnick and Woods, 1999, Rosenfeld and Shai, 2006). Despite the
apparent virulence deficits of LPS mutants in animal models and in vitro
assays, clinical isolates which express no detectable O-antigen and display
no reduction in resistance to killing by human sera have been identified
(Anuntagool et al., 2006).
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1.8.2 Secretion systems
Many pathogens utilize protein secretion systems to interact with their
environments and host cells. To date, six general classes of protein secretion
systems have been described for Gram-negative bacteria, some of which are
shared with Gram-positive bacteria (reviewed in (Tseng et al., 2009)). A
unique type VII system has been described for Gram-positive bacteria. The
main features of the known secretion systems are summarized in Figure 1.4
(Tseng et al., 2009). In the case of Gram-negative bacteria, the secreted
proteins are either exported across the inner and outer membrane in a single
step via the type I, type III, type IV or type VI pathways, or first exported into
the periplasmic space via the Sec or two-arginine (Tat) pathways and then
translocated across the outer membrane via the type II or type V machinery.
The proteins exported by these systems may provide in vitro and in vivo
growth advantage to pathogens (Sun et al., 2010, Russell et al., 2014).
Figure 1.4 Summary of known bacterial secretion systems
Only the basics of each secretion system are sketched. HM: Host membrane;
OM: outer membrane; IM: inner membrane; MM: mycomembrane; OMP:
outer membrane protein; MFP: membrane fusion protein. ATPases and
chaperones are shown in yellow  (Reproduced from (Tseng et al., 2009).
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1.8.2.1 Type 3 secretion systems
Type 3 secretion systems (T3SSs) are complex bacterial structures that act
as unique protein translocation systems to inject bacterial proteins (effectors)
into the host cell cytoplasm, bypassing the extracellular milieu (Ghosh, 2004,
Coburn  et al., 2007). A subset of T3SS secreted proteins (translocators)
mediate the delivery of effector proteins across bacterial and host cell
membranes. The effectors can alter host cell functions, including causing
changes to the host cell cytoskeleton to promote attachment and invasion of
the bacteria, interfering with cellular trafficking processes, inducing
cytotoxicity and barrier dysfunction, and immune system subversion. The
T3SSs have been linked to infection progression and virulent outcome for
many Gram-negative pathogens (Coburn  et al., 2007).
B. pseudomallei T3SS translocator and effector proteins were initially
identified based on sequence similarity to those found in other bacterial
species such as Salmonella and Shigella species (Attree and Attree, 2001).
B. pseudomallei has at least three loci encoding putative T3SSs clusters
(Rainbow et al., 2002), with the Bsa (Burkholderia secretion apparatus)
T3SS (T3SS-3) playing a major role in virulence, invasion of non-phagocytic
cells, escape from endocytic vacuoles into the cytoplasm, and avoiding
degradation by the host lysosomal system, and multinucleated giant cell
(MNGC) formation (Stevens et al., 2002, Stevens et al., 2004). For MNGC
formation to occur, bacteria must escape the phagosome and be motile
within the host cell cytosol, thus Bsa T3SS is likely to be involved in this
process primarily due to its role in upstream intracellular events such as
escape from endocytic vacuoles (French et al., 2011). Translocator proteins
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BipB, BipC and BipD, are important for bacterial virulence in both in vivo and
in vitro studies, but did not appear to induce protective properties against B.
pseudomallei challenge (Stevens et al., 2004, Druar et al., 2008). The
inability of these T3SS proteins to act as protective antigens suggests that
the proteins are either expressed in low levels during infection or that the
antibodies do not have access to the predominantly intracellular bacteria
(Druar et al., 2008). The effector proteins BopE and BopA were shown to be
important for subversion of host cell mechanisms, particularly in invasion of
epithelial cells and phagocytic cell survival respectively, but are not required
for virulence in the BALB/c mice infection model (Stevens et al., 2003,
Stevens et al., 2004, Cullinane et al., 2008, Gong et al., 2011). The T3SS-3
is an important virulence determinant of B. pseudomallei pathogenesis, but
the precise mechanisms for the role of the various components of the system
in host-pathogen interactions is likely to be complex and remain to be
elucidated.
1.8.2.2 Type 6 secretion system
The type 6 secretion system (T6SS) is the most recently identified protein
secretion system in Gram-negative bacteria (Pukatzki et al., 2006). It forms a
needle-like injection device which closely resembles the bacteriophage tail
and secretes effectors that appears to have anti-eukaryotic properties or
antibacterial activity (Coulthurst, 2013). T6SSs are encoded by large,
variable gene clusters, but they contain 13 ‘core’ essential and conserved
genes (TssA-TssM), which are believed to encode the basic secretion
apparatus. This nomenclature encompasses previously identified T6SS-
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associated genes including hcp (hemolysin co-regulated protein), vgrG
(valine glycine repeat proteins), icmF (intracellular multiplication factor)
(Coulthurst, 2013).
The B. pseudomallei K96243 encodes six T6SS gene clusters, the B. mallei
ATCC23344 genome encodes four gene clusters and the B. thailandensis
E264 genome encodes five T6SS clusters (Shalom et al., 2007, Schell et al.,
2007). T6SS clusters 1 to 3 are present in all three species, cluster 4 is only
unique to B. pseudomallei and B. mallei, and cluster 5 is found in B.
pseudomallei and B. thailandensis. To date, the T6SS-1 (BPSS1496-1512),
present in all three organisms, is the best characterised and has been shown
to be a major virulence factor in B. pseudomallei and B. mallei. T6SS-1 was
shown to be induced inside murine macrophages, involved in intracellular
replication and MNGC formation, and important for bacterial virulence in
mice (Pilatz et al., 2006, Shalom et al., 2007, Chen et al., 2011, French et al.,
2011, Toesca et al., 2014).
1.8.3 BimA motility
During the intracellular lifecycle, B. pseudomallei and B. thailandensis enters
primary phagosomes and then secretes Bsa T3SS effectors to promote the
disruption of vacuolar membrane. Once in the cytosol, the bacterium induces
its own propulsion by polymerising actin at one bacterial pole, a process
known as actin-based motility (Stevens et al., 2005b). Actin-based motility is
associated with intercellular spread in several intracellular bacterial
pathogens (Stevens et al., 2006, Yoshikawa et al., 2009). The Burkholderia
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intracellular motility factor, BimA, was identified through in silico analysis and
was shown to mediate intracellular actin polymerization (Stevens et al.,
2005b, Sitthidet et al., 2008). The formation of bacteria-tipped actin-rich
membrane protrusions aids, in part, in the intercellular spread into adjacent
cells. A B. pseudomallei BimA mutant exhibited attenuation in a murine
model of melioidosis (Sitthidet et al., 2011). B. thailandensis also appears to
exhibit a BimA-dependent intracellular actin-based motility, and motility
defects associated with B. pseudomallei BimA mutants can be
complemented with the expression of B. thailandensis bimA (Stevens et al.,
2005a).
1.8.4 Flagella and pili
Flagella are filamentous protein structures attached to the cell surface that
provide swimming movement and motility to the bacterial cell, facilitating
adhesion and invasion in some strains. Pili are short, hair-like structures on
bacterial surfaces that are often involved in adherence of bacterial cells to
surfaces. Type IV pili (TFP) are important for virulence in many Gram-
negative bacteria as they can facilitate bacterium-bacterium interactions that
result in microcolonies and/or biofilms, and enhance protection from host
defences (Strom and Lory, 1993, Craig et al., 2004). Motility and adhesion
properties facilitate bacterial colonization of host tissues and have been
implicated in bacterial pathogenesis (Chua et al., 2003).
The B. pseudomallei flagella are required for the adhesion and invasion of
the free living amoeba Acanthamoeba astronyxis (Inglis et al., 2003) but the
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importance of the flagella in causing virulence in mammalian models remains
debatable. The flagellum is not required for virulence in the Syrian hamster
or diabetic rat intraperitoneal infection model, and conflicting data exist for
the BALB/c mice intraperitoneal infection model (DeShazer et al., 1997,
Chua et al., 2003, Wikraiphat et al., 2009). Even though an aflagellate
mutant was able to retain its ability to invade A549 lung epithelial cells in vitro,
the mutant displayed attenuation of virulence in BALB/c mice intranasal
infection model (Chua et al., 2003). It is possible that the flagella have an
important role in virulence, but the role can be overcome or subverted in
more acute infection models, such as diabetic rats or hamsters.
The B. pseudomallei K96243 genome is reported to encode eight potential
type IV pili (TFP)-associated loci (Essex-Lopresti et al., 2005). A B.
pseudomallei K96243 mutant with a defective type IV A pilin gene, pilA,
displayed reduced virulence in a BALB/c mice infected via the intranasal
route but not the intraperitoneal route, indicating a possible role in initial
epithelial cell attachment (Essex-Lopresti et al., 2005). Expression of pilA
appears to be differentially regulated and PilA have different roles between B.
pseudomallei strains 08 and K96243 (Boddey et al., 2006). The pilA gene
plays a role in adherence of K96243 strain to epithelial cells and bacterium-
bacterium interaction (formation of microcolonies) in the 08 strain, which
increases the number of bacteria in association with host cells (Essex-
Lopresti et al., 2005, Boddey et al., 2006). Given that there are many
putative TFP-associated loci in B. pseudomallei, it is possible that the
expression of pili is regulated in a complex manner and that different pili may
mediate interactions with specific host receptors (Essex-Lopresti et al., 2005).
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1.9 Bacterial lipoproteins
Bacterial lipoproteins are a set of membrane proteins that serve diverse roles,
including those involved in pathogenesis. Lipid modification of bacterial
proteins facilitates the anchoring of hydrophilic proteins to hydrophobic
surfaces such as the cell wall phospholipids (PL), where the protein can
function. Many bacterial lipoproteins have been shown to exhibit pleiotropic
effects on cellular physiology and perform various roles including
colonization, evasion of host defences, immunomodulation, nutrient uptake,
signal transduction, outer membrane stability, adhesion, conjugation,
transport, and contributing to antibiotic resistance (reviewed in (Kovacs-
Simon et al., 2011)). Lipoproteins of numerous pathogens have also been
promoted as vaccine candidates (Kovacs-Simon et al., 2011).
In prokaryotes, membrane lipoproteins are initially translated into pre-
prolipoproteins with a precursor signal peptide at the N-terminus, which
directs the protein through the membrane and is then proteolytically cleaved.
The signal peptide consists of approximately 20-30 amino acids, mostly
hydrophobic in nature, and then ending in a highly conserved lipobox
sequence with an invariant cysteine residue ([LVI][ASTVI][ASG]C) (Inouye et
al., 1977). The lipobox sequence is essential for correct protein processing
(Figure 1.5). The invariant cysteine residue is first modified through the
covalent attachment of a diacylglycerol moiety to the thio group on the side
chain, catalysed by the enzyme lipoprotein diacylglyceryl transferase (Lgt),
resulting in a prolipoprotein (Figure 1.6, (Babu et al., 2006)). After lipidation,
the prolipoprotein is cleaved by a specific lipoprotein signal peptidase (signal
peptidase II, Lsp or SPase II), and leaves the cysteine residue of the lipobox
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as the new amino-terminal residue (Tokunaga et al., 1982). In Gram-
negative bacteria, the cleaved prolipoprotein is acylated by an attachment of
an amide-linked acyl group to the N-terminal cysteine residue, catalysed by
lipoprotein N-acyl transferase (Lnt), resulting in a triacylated mature
lipoprotein (Gupta et al., 1993). The diacylglyceryl and acyl group are derived
from membrane phospholipids and provide tight anchorage of the lipoprotein
to the membrane (Hantke and Braun, 1973).
Figure 1.5 Schematic of a typical lipoprotein sequence
A typical lipoprotein sequence of an n-region with positively charged amino
acids in the initial residues, a hydrophobic h-region with 7 to 22
predominantly hydrophobic and uncharged residues, and c-region with a
consensus lipobox sequence [LVI][ASTVI][ASG], along with the invariant
cysteine residue (Babu et al., 2006).
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Figure 1.6 Biosynthesis of bacterial lipoproteins.
Reproduced from (Kovacs-Simon et al., 2011).
Mature lipoproteins are localized to various sites within the cell wall, including
the periplasmic face of the inner or outer membranes by the lipoprotein
localization machinery (Lol), which consists of an LolCDE complex, an ATP-
binding cassette (ABC) transporter and the periplasmic chaperone, LolA
(Tokuda and Matsuyama, 2004, Tokuda, 2009, Kovacs-Simon et al., 2011).
The amino acids adjacent to the conserved cysteine at the +2, +3 and +4
positions have a role in determining localization of the lipoprotein in the outer
membrane (Yamaguchi et al., 1988, Narita and Tokuda, 2007, Silva-Herzog
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et al., 2008). All of the known lipoproteins in E. coli face the periplasm (Bos
et al., 2007), but lipoproteins are present on the outer leaflet of the outer
membrane in some Gram-negative bacteria (Kovacs-Simon et al., 2011).
Lipoproteins contribute to the integrity of the cell wall. The outer membrane
(OM) of Gram-negative bacteria is separated from the inner membrane
phospholipid bilayer by an aqueous periplasm and a thin peptidoglycan layer.
The outer membrane is largely asymmetrical, with mostly LPS presently in
the outer leaflet and phospholipids in the inner leaflet, forming an effective
barrier against toxic environments (Nikaido, 2003). The lipid A portion of LPS
produces a lipid interior of very low fluidity, which makes the LPS/PL layer
less permeable to lipophilic molecules and most antibiotics (Nikaido, 2003).
The Braun (muerin) lipoprotein, an abundant cell envelope protein in many
Gram-negative bacteria, binds to peptidoglycan via a peptide bond and is
embedded into the outer membrane by covalent linkages, contributing to cell
wall integrity (Silhavy et al., 2010, Dramsi et al., 2008).
Lipoproteins are required for virulence in many pathogenic bacteria. In
Mycobacterium tuberculosis the Mce (mammalian cell entry) family of
proteins enable the pathogen to invade mammalian cells (Casali and Riley,
2007), the Streptococcus pneumoniae PsaA (pneumococcal surface
adhesion A) plays a role in adhesion to epithelial cells and resistance to
oxidative stress (reviewed in (Kovacs-Simon et al., 2011)). Other examples
of lipoproteins that are involved in pathogenesis include the Braun lipoprotein
in Yersinia pestis (Sha et al., 2008), the M. tuberculosis 19-kDa
lipoglycoprotein (potent inducer of Toll-like receptor 2 [TLR2] and pleiotropic
effects on immune response) (Pai et al., 2003, Wilkinson et al., 2009), the
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Neisseria meningitidis GNA1870 (also called the factor H binding protein
[fHBP], contributes to resistance to serum-mediated killing and antimicrobial
peptide binding) (Madico et al., 2006, Seib et al., 2009), and Borrelia
burgdorferi OspE (serum resistance) (Hellwage et al., 2001). In some of
these cases, disruption of these lipoproteins in pathogens has led to
attenuation of virulence in animal models of infection (Henao-Tamayo et al.,
2007, Sha et al., 2008). However, to date, lipoproteins in B. pseudomallei
have not been well studied. Within the Burkholderia genus, the
peptidoglycan-associated lipoprotein (PAL), OpcL and the outer membrane
lipoprotein SlyB (or PCP, PAL cross-reactive protein) protein are conserved
in all representatives of the B. cepacia complex and contribute to membrane
integrity (Plesa et al., 2006, Plesa et al., 2004). A STM study by Cuccui et al.
(2007) (Cuccui et al., 2007) identified a VacJ orthologue (BPSL3147) in B.
pseudomallei as being important for in vivo virulence. Since lipoproteins have
been shown to be important in infection and disease progression in many
bacteria, understanding the roles that they play in B. pseudomallei may
present as novel opportunities to understand Burkholderia pathogenesis and
design novel therapeutic agents. Furthermore, immunogenic surface-
exposed lipoproteins have been shown to be protective against a number of
bacterial pathogens, and may have an important role to play in the future
development of vaccines (Edelman et al., 1999, Grode et al., 2002). Further
understanding of the roles of lipoproteins may contribute to future
development of novel antibacterials.
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1.10 VacJ/MlaA family lipoproteins
Recently, Malinverni and Silhavy (2009) characterized a novel mechanism
involving a highly conserved Mla (maintenance of OM lipid asymmetry) ABC
transport system, with a lipoprotein component (MlaA/VacJ), that impacts cell
surface phospholipids and aids in the maintenance of the OM asymmetry in
E. coli (Malinverni and Silhavy, 2009). The Mla system has a predicted
import function, which prevents the accumulation of phospholipid
accumulation in the outer leaflet of the outer membrane. Accumulation of
phospholipids in the outer leaflet indicates packing disruptions of the OM and
reduces the barrier function (Nikaido, 2005). Mutations of the components in
the Mla system results in increased OM permeability, but the defect can be
compensated with the increased expression of another OM protein, PldA, a
phospholipase that destroys surface-exposed phospholipids (Malinverni and
Silhavy, 2009). Mutation of MlaA orthologues also affects the OM integrity in
H. influenzae (Nakamura et al., 2011), Shigella flexneri (Carpenter et al.,
2014) and Acinetobacter baumannii (R. Stabler, personal communication).
The MlaA lipoprotein of the Mla pathway contributes to virulence in some
bacteria. The 28 kDa VacJ (virulence associated chromosome locus J)
lipoprotein was first identified in S. flexneri (Suzuki et al., 1994) and it is
orthologous to MlaA in E. coli. VacJ/MlaA is thought to contribute to virulence
by playing a role in intercellular spread through an undefined mechanism
(Suzuki et al., 1994). Many pathogens retain the ability to survive in human
blood serum, where they will encounter bactericidal antibodies and
complement activity. The VacJ/MlaA orthologue in H. influenzae contributes
to serum resistance in acapsular, non-typeable strains (NTHi), allowing the
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bacterium to adapt to inflammation encountered during infection of the lower
respiratory tract (Nakamura et al., 2011). Nakamura et al. (Nakamura et al.,
2011) suggested that modulation of phospholipid levels in the outer
membrane affects the packing of the H. influenzae lipooligosaccharide
molecules, which in turn limits the accessibility of oligosaccharide epitopes
that are recognized by bactericidal antibodies in the complement system. In
these bacteria, the VacJ family of lipoproteins contribute to the maintenance
of the outer membrane structure and stability, which in turn, contribute to
pleiotropic phenotypes such as resistance to detergents and bactericidal
antibodies, and possibly affect other virulence factors that are important for
survival in niche environments.
1.11 Project aims
The principle objective of this project was to evaluate the role of the
lipoprotein VacJ, in Burkholderia pathogenesis.
This objective can be broadly summarized in the following specific aims:
1) To predict potential role(s) of VacJ through bioinformatics analyses
2) To generate mutants, biochemical tools and reagents to evaluate the
role(s) of VacJ for in vitro and in vivo virulence
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2. Chapter 2 – Materials and Methods
2.1 Chemicals and Reagents
All reagents were purchased from Sigma-Aldrich Company Ltd (Dorset, UK)
unless otherwise stated. Media used to grow bacteria and cell lines in this
study are listed in Table 2.1. Buffer components are defined in Appendix 1.
Milli-Q grade water (Millipore, Billerica, USA) was used to prepare media and
buffers that were then autoclave sterilized at 121°C for 20 minutes.
2.2 Biosafety containment level 3 safety protocols
B. pseudomallei was handled using containment level 3 laboratory
procedures. All techniques carried out under biosafety containment level 3
conditions in conjunction with risk assessment forms were approved by the
Faculty Safety Office. Novel techniques to be carried out on B. pseudomallei
K96243 were first attempted under standard laboratory conditions with B.
thailandensis E264 to assess potential risks. Versions of all newly developed
protocols have been stored electronically and are available for use by
approved workers.
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2.3 Bacteria and Cell lines
2.3.1 Bacterial strains and culture conditions
The bacterial strains and plasmids used in this study are described in Tables
2.2 – 2.3. All bacterial strains were routinely grown at 37°C in Luria bertani
(LB) agar or LB broth with 200 rpm shaking. When required, antibiotics were
added to the medium at the following concentrations: ampicillin (Amp) 100
μg/ml; kanamycin (Km) 50 μg/ml (for E. coli), 400 μg/ml (for Burkholderia
mutants); chloroamphenicol (Cm) 30 μg/ml; tetracycline (Tet) 20 μg/ml;
zeocin (Zeo) 100 μg/ml. E. coli MFD cultures were supplemented with 0.3
mM diaminopimelic acid (DAP). Frozen bacterial stocks were maintained at -
70°C and prepared by mixing an equal volume of saturated bacterial culture
and 50 % glycerol.
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Table 2.1 Growth media used in this study
Media Composition Source
LB broth, Miller Per litre: 10 g tryptone, 5 g
yeast extract, 10 g sodium
chloride
Becton, Dickinson &
Company, Franklin Lakes,
USA
LB agar, Miller Per litre: 10 g tryptone, 5 g
yeast extract, 10 g sodium
chloride, 15 g agar
Becton, Dickinson &
Company, Franklin Lakes,
USA
Sucrose Agar Per litre: 10 g tryptone, 5 g
yeast extract, 100 g sucrose,
15 g agar
Becton, Dickinson &
Company, Franklin Lakes,
USA
Growth media for J774A.1 Dulbecco’s modified eagle
medium (DMEM) containing
4.5 g/L glucose, 4 mM L-
glutamine and 3.7 g/L
sodium bicarbonate, 10 %
foetal calf serum
Sigma-Aldrich
Growth media for A549 Gibco® F-12K (Kaighn’s)
Medium (Invitrogen), 10 %
foetal calf serum
Invitrogen
Super Optimal broth with
catabolite repression (SOC)
medium
2 % tryptone, 0.5 % yeast
extract, 10 mM NaCl, 2.5 mM
KCl, 10 mM MgCl2, 10 mM
MgSO4, 20 mM glucose
Bioline
Cation-adjusted Mueller-
Hinton broth (CAMHB)
Per litre: approximate
formula
3 g beef extract, 17.5 g acid
hydrolysate of casein, 1.5 g
starch; supplemented to
achieve 20 to 25 mg Ca++ /L
and 10 to 12.5 Mg++ /L
Becton Dickinson
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Table 2.2 List of strains used in this study
Strain Description Reference
B. pseudomallei strains
K96243 Clinical isolate isolated from a 34-year old female diabetic patient with melioidosis in Thailand in 1996; KmR,
ZeoR, GmR
(Sarkar-Tyson et al., 2007)
K96243 ΔBPSL3147 K96243 derivative; unmarked deletion of bpsl3147 This study
7A1 K96243 derivative; Tn5::bpsl3147; KmR (Cuccui et al., 2007)
13H8 K96243 derivative; Tn5::wcbB; KmR (Cuccui et al., 2007)
13H8 ΔBPSL3147 K96243 derivative; Tn5::wcbB, unmarked deletion of bpsl3147; KmR This study
B. thailandensis strains
E264 Soil isolate from rice field in Central Thailand; KmR, ZeoR, GmR A. Scott (DSTL)
E264 ΔBTH_I3001 E264 derivative; unmarked deletion of bth_i3001 This study
E264 ΔBTH_II2351 E264 derivative; unmarked deletion of bth_ii2351 This study
E264 DB E264 derivative; unmarked deletions of bth_i3001 and bth_ii2351 This study
ΔBTH_I3001 + pMEKVacJBT E264 derivative; unmarked deletion of bth_i3001; containing the complementation construct pMEK VacJBT;
KmR
This study
ΔBTH_I3001 + pMEVacJBT E264 derivative; unmarked deletion of bth_i3001; containing the complementation construct pME VacJBT; TetR This study
DB + pMEKVacJBT E264 derivative; unmarked deletion of bth_i3001 and bth_ii2351; containing the complementation construct
pMEK VacJBT; KmR
This study
E. coli strains
Top10 For propagation of pJET or pGEM-T plasmid; F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15
ΔlacX74 recA1 araD139 Δ(ara leu) 7697 galU galK rpsL (StrR) endA1nupG
Life Technologies
MFD Conjugative donor of λpir-dependent suicide replicon pDM4 and its derivatives; K-12 wild-type strain RP4-2-Tc::[
ΔMu1::aac(3)IV-ΔaphA-Δnic35-ΔMu2::zeo] ΔdapA::(erm-pir) ΔrecA
(Ferrières et al., 2010)
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Table 2.3 List of plasmids used in this study
Plasmid Description Reference / Source
pGEM®-T Easy Vector Cloning vector, AmpR Promega
pJET1.2/blunt Cloning vector, AmpR Fermentas
pDM4 λpir-dependent suicide replicon for allelic exchange in Burkholderia; R6K ori, RP4 Mob ;
sacBR; cat, CmR
Milton 1996
pDM4-∆vacJBp Mutagenesis construct for B. pseudomallei (for mutagenesis of bpsl3147). This study
pDM4-∆vacJBt Mutagenesis construct for B. thailandensis (for mutagenesis of bth_i3001). This study
pME6032 Shuttle vector with orip15A, oripVS1, IPTG inducible tac promoter (Ptac), stably replicates in E.
coli, B. pseudomallei and B. thailandensis, TetR
(Heeb et al., 2002)
(A gift from Dr. Jo
Stevens)
pME VacJBT Complementation vector pME6032 derivative, contains full length bth_i3001 This study
pMEK pME6032 derivative, TetR cassette replaced with KmR cassette from pUT-mini-Tn5 Km2
[76] at the BamHI and XbaI sites.
This study
pMEK VacJBT Complementation construct pMEK derivative, contains full length bth_i3001 This study
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2.3.2 Cell lines and culture conditions
J774A.1 BALB/c murine macrophage cells (ATCC® TIB-67™) and A549
human lung epithelial cells (ATCC® CCL-185™) were routinely cultured in
Dulbecco’s modified Eagle’s medium supplemented with 10 % foetal calf
serum (FCS) and F-12K (Kaighn’s) medium supplemented with 10 % foetal
calf serum respectively. Both cell lines were cultured at 37°C under a
humidified atmosphere with 5 % CO2.
2.4 Bioinformatics tools
Alignment tools
1. National Centre for Biotechnology Information Basic Local Alignment Search
Tool (NCBI BLAST)
 http://blast.ncbi.nlm.nih.gov/
2. The Wellcome Trust B. pseudomallei BLAST server
 http://www.sanger.ac.uk/cgi-bin/blast/submitblast/b_pseudomallei
3. ClustalW  : Alignment of protein sequences
 http://www.ebi.ac.uk/Tools/msa/clustalw2/
4. Artemis (release 12.0)
 http://www.sanger.ac.uk/resources/software/artemis/
5. BioEdit
 http://www.mbio.ncsu.edu/bioedit/bioedit.html
Primer Designing Tool
 http://www.ncbi.nlm.nih.gov/tools/primer-blast/
Prediction of protein characteristics
1. PSORTb version 3 (Yu et al., 2010).
 http://www.psort.org/psorb/
2. Lipoprotein prediction tool (Rahman 2008)
 http://www.cbs.dtu.dk/services/LipoP/
3. DOLOP (Babu 2006)
 http://www.mrc-lmb.cam.ac.uk/genomes/dolop/
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2.5 Molecular Biology
2.5.1 DNA extraction and purification
Bacterial genomic DNA was isolated using ArchivePure DNA purification kit
(5 Prime, GmbH), and plasmid DNA was isolated from E. coli strains using
the QIAprep miniprep kit (Qiagen) according to manufacturer’s instructions.
DNA fragments were purified using the QIAquick gel extraction kit or
QIAquick PCR purification kit (Qiagen). DNA quality was assessed using
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, USA) and by agarose gel electrophoresis.
2.5.2 Oligonucleotide primers
Custom oligonucleotides were synthesized by Life Technologies. Primers
used in this study are listed in Tables 2.4 – 2.8.
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Table 2.4 Oligonucleotide primers used for the construction of unmarked in-frame B. pseudomallei and B. thailandensis
mutants.
Oligonucleotide and sequence (5’ to 3’)a Target region
VacJ Left Fwd tttTCTAGAGCAGCCCCGCAAAACGGTTG Left flank of bpsl3147
VacJ Left Rev CGCAAGCGGCATACGAGAGAAGCGGCGTCGACGGTTCCAAGT
VacJ Right Fwd ACTTGGAACCGTCGACGCCGCTTCTCTCGTATGCCGCTTGCG Right flank of bpsl3147
VacJ Right Rev tttTCTAGAGGCGCGTTCTGGTCGCAGAT
BT_VacJ_F1X ttttctagaCCGCGCTTTTGCGTGCTCTT Left flank of bth_i3001
BT_VacJ_R1M acgAGAGAAGAAGCGAGGGGAAgAAACGATTCTGACGGCGGCCG
BT_VacJ_F2M CGGCCGCCGTCAGAATCGTTTcTTCCCCTCGCTTCTTCTCTCGT Right flank of bth_i3001
BT_VacJ_R3X ttttctagaAGCCTTTTCTGGGATGACGATG
BT_VacJ2_F1X ttttctagaCAAGAACCTGCCGCCGCAGA Left flank of bth_ii2351
BT_VacJ2_R1M GGACGATGCGCCGATGAGGCCCGACGCGGTGGTTCGCAT
BT_VacJ2_F2M ATGCGAACCACCGCGTCGGGCCTCATCGGCGCATCGTCC Right flank of bth_ii2351
BT_VacJ2_R2X ttttctagaCTTCGTCGGCGTCGAGCTCG
aEngineered restriction sites (XbaI) are underlined.
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Table 2.5 PCR primers for screening deletion mutant (B. pseudomallei)
PCR Primer name Primer sequence (5’-3’)
L 3147 BT_VacJ_L TGACCTGCTTGTGTGAGTCGATGCC
BT_VacJ_R3X TTTTCTAGAAGCCTTTTCTGGGATGACGATG
pDM4-3147 pDM4_seqF TGTGGAATTCCCGGGAGAGCTCA
VacJ Seq R3 AGGCATCGTGAGCAGCTT
L 3147 LR BT_VacJ_L TGACCTGCTTGTGTGAGTCGATGCC
BT_VacJ_R CGCGAGCGGCATACGAGAGAAGA
BPSL3146 bpsl3146 F CACGATGCCTGCTTGCCCGA
bpsl3146 R TCCTTGCCGCGCTGTTCTCG
BPSL3147b bpsl3147 F2 AGGTACGCGTTGCGCACGAA
bpsl3147 R2 CGACCAAGGGCGACCCGTTC
BPSL3148 bpsl3148 F CACGATCGCCGACTGCGTCA
bpsl3148 R CTCGCGCTGAAGGTCGGCAA
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Table 2.6 PCR Primers for screening deletion mutant (B. thailandensis)
PCR Primer name Primer sequence (5’-3’)
*pDM4-3001 pDM4_seqF TGTGGAATTCCCGGGAGAGCTCA
VacJ Seq R3 AGGCATCGTGAGCAGCTT
*I 3001 LR BT_VacJ_L TGACCTGCTTGTGTGAGTCGATGCC
BT_VacJ_R CGCGAGCGGCATACGAGAGAAGA
#pDM4-2351 pDM4_seqF TGTGGAATTCCCGGGAGAGCTCA
VacJ2 SeqR2 CGTGATCCACAGCAGCAC
II 2351 II2350_F CCGATGCGCAGCCGCAAAAG
BT_VacJ2_R ACCGGACGAACGACGGACGATG
#II 2351 LR BT_VacJ2_L TCGATGAATAAGATGCGAACCACCGCG
BT_VacJ2_R ACCGGACGAACGACGGACGATG
BTH_I3000 3000 F TGCTGGTTGCGCTCGGTCAG
3000 R GACCAGTCGAACCCGCAGGC
BTH_I3001 3001 F CCGGATGCTCGGCCAATGGA
bt-3001-UP CGGTCCAGACGCCGACGAAG
BTH_I3002 3002 F CAGCATTTCCGTGTCGCCGC
3002 R TCGACAACATCGGCGGCCTG
BTH_II2350 bthii 2350 F TCTTCTCGTTTCTGCCGACC
bthii 2350 R CAGGTTCTTGCGCGTGATTT
BTH_II2351 bthii 2351 F CGAACAACCTGCTGCAACTC
bthii 2351 R TTCGTCTTCGACGGAGCATT
BTH_II2352 bthii 2352 F GACGAGATTCACGACGACCT
bthii 2352 R CCTGAATTCAATCGCGACACC
* I 3001 MX is a multiplex PCR using primers from pDM4-3001+ I3001 LR.
#II 2351 MX is multiplex PCR using primers from pDM4-2351 and II2351 LR.
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Table 2.7 Other sequencing primers used in this study
Primer name Primer sequence (5’-3’)
VacJ Seq Fwd CCTGCTTGTGTGAGTCGATG
VacJ Seq Rev TGATCGGCCAGTTCCTCTAC
VacJ Seq F2 GCCTGGTAGGTGTTCGTGTC
VacJ Seq R2 AAGGACATCCTGCCGTACAC
I2998_F CCGTTCGGCAGTCCCGCAAA
I3003_R AAGGCGGCGTCGAAGTGTGG
VacJ2 Seq F2 GTCCGATACCGGCAGAAC
VacJ2 Seq Fwd ACGAATCAATCGCAAGGAAT
VacJ2 Seq Rev ATTGCCGTTCGCGGAGT
II2350_F CCGATGCGCAGCCGCAAAAG
II2353_R GGCGGCTCGGGCTTCTTTCA
SP6 ATTTAGGTGACACTATAG
T7 TAATACGACTCACTATAGGG
M13 Fwd (-20) GTAAAACGACGGCCAGT
pJet1.2 Forward CGACTCACTATAGGGAGAGCGGC
pJet1.2 Reverse AAGAACATCGATTTTCCATGGCAG
pDM4 F1 ACGGTTGTGGACAACAAGCCAGG
pDM4 R1 TGCGGGTAACCTGAGCTCTCCC
P6032 CCCTCACTGATCCGCTAGTC
PTAC CGGCTCGTATAATGTGTGGA
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Table 2.8 Oligonucleotide primers used in making complementation
construct for B. thailandensis
Primer name Primer sequence (5’-3’)
3001-DN-KpnI ttttggtaccTCAGTGCAGCCGGATGCTCG
3001-UP-ApaI ttttgggcccTACGAGAGAAGAAGCGAGGGGAAG
2.5.3 Polymerase chain reaction (PCR)
A typical PCR using Taq DNA polymerase (Bioline) contained 1 x MyTaq
Reaction Buffer (with 1mM dNTPs, 3 mM MgCl2), forward and reverse
oligonucleotides (2 pmol/μl), 1.25 U Taq DNA polymerase, 0.1 μg genomic
DNA or 10 ng plasmid DNA, 8 % (v/v) dimethyl sulphoxide (DMSO) and
distilled water to a final volume of 50 μl.
The PCR protocol is shown below.
Typical PCR reaction:
1 cycle
95°C (denaturing) – 1 min
30 cycles
95°C (denaturing) – 15 s
55°C (annealing) – 15 s
72°C (extension) – 15 s
For colony PCR, a single bacterial colony was added to 50 μl dH2O and
boiled for 10 min. 5 μl boilate was used as the template in a standard PCR.
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High-fidelity PCR using Phusion DNA polymerase (Thermo Scientific)
contained 1 x Phusion GC buffer (with 0.2 mM dNTPs, 1.5 mM MgCl2),
forward and reverse oligonucleotides (2 pmol/μl), 0.1 μg genomic DNA, 8 %
(v/v) DMSO and distilled water to a final volume of 50 μl.
The PCR protocol is shown below:
Typical high fidelity PCR reaction:
1 cycle
98°C (denaturing) – 30 s
30 cycles
98°C (denaturing) – 10 s
72°C (extension) – 30 s / kb
72°C (final extension) – 5 min
2.5.4 Agarose gel electrophoresis
PCR products were loaded on 1 % agarose gel (Qbiogene, Cambridge, UK)
containing 0.4 μg/ml ethidium bromide (Promega) in a Hybaid gel tank
(Thermo Hybaid UK, Ashford, Middlesex) containing 1 x TAE buffer. The
electrophoresis was set to run at 100 V, 500 mA. Gels were visualised under
ultraviolet (UV) light using a Syngene bio imaging system (Syngene,
Cambridge, UK).
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2.5.5 Restriction enzyme digest
A typical digest reaction consisted of 1 x restriction enzyme digestion buffer,
1 μg DNA, 6 U restriction enzyme, 2 μg acetylated bovine serum albumin
(BSA) and distilled water. The reaction mix was incubated at 37°C for 1 – 4
hours. The digest products were subjected to agarose gel electrophoresis to
visualise and purify fragments.
2.5.6 Dephosphorylation of vector DNA
The linearized vector DNA was dephosphorylated by incubating 1 to 5 μg
DNA with 5 U Antartic phosphatase (New England Biolabs) and 1 x Antartic
phosphatase reaction buffer at 37°C for 15 min before heat-inactivating the
enzyme at 65°C for 5 min. The product was purified using a PCR purification
kit (Qiagen).
2.5.7 Ligation
A typical ligation reaction consisted of 1 x ligation buffer, 3 U T4 DNA ligase
(Fermentas), vector DNA (25 ng) and insert DNA at a molar ratio of 1:3. The
reaction was incubated at room temperature for 1 h or at 4°C overnight and 1
– 2 μl of the reaction was used in transformation reactions.
68
2.5.8 Preparing electrocompetent E. coli cells
2 ml of overnight culture of E. coli was added to 100 ml of LB broth and
grown in a 37°C shaker incubator until the optical density (OD600) equals 0.4
– 0.6 (log phase growth). Cells were kept at 4°C (or on ice) for the remainder
of the procedure. The culture was centrifuged at 4000 rpm for 15 min and the
supernatant was discarded. The pellet was washed in ice-cold 10 % glycerol
before subjected to centrifugation. The washing step was repeated for two
more times. Cells were resuspended in 1 ml of ice-cold 10 % glycerol and
aliquoted to pre-chilled 1.5 ml microcentrifuge tubes. 100 μl of
electrocompetent cells was used for transformation.
2.5.9 Preparing electrocompetent B. thailandensis cells
Electrocompetent B. thailandensis were prepared as described in Choi et al.
(2008) (Choi et al., 2008). Briefly, 6 ml of B. thailandensis overnight broth
culture was aliquoted into four 1.5 ml microcentrifuge tubes and centrifuged
for 2 min at 16,000 x g at room temperature. The pellet was washed in 1 ml
of 300 mM sucrose solution and subjected to centrifugation for 2 min at
16,000 x g at room temperature. The supernatant was discarded and the
sucrose wash step was repeated. The washed cell pellets were resuspended
in a combined volume of 200 μl of sucrose solution. 100 μl of
electrocompetent cells was used for transformation.
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2.5.10 Electroporation transformation
Electrocompetent E. coli (Invitrogen) or B. thailandensis was transformed
with 1-2 μl of ligation reaction or plasmid by electroporation at 2.5 kV and a
capacitance of 25 μF using the Gene pulser II electroporator (Bio-Rad). 250
μl of SOC medium was added to the mixture and incubated at 37°C for 1 h
with agitation. The mixture was spread onto LB agar plates containing
appropriate antibiotics and incubated at 37°C overnight.
2.5.11 Nucleotide sequencing
Sequencing reactions were performed by Source BioScience (Nottingham,
UK) or carried out using an ABI Prism Terminator Ready reaction mix
(Amersham Biosciences, Buckinghamshire, England) in the following
reaction volumes:
ABI Prism Terminator Ready Reaction Mix 8.0 μL
PCR product 30 – 90 ng
Primer (1 pmol/μl) 4.0 μL
dH2O to 20 μL
Cycling conditions: 25 cycles
96°C – 10 s
50°C – 5 s
60°C – 4 min
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Sequencing products were added to a tube containing 80 μl 75 % (v/v)
isopropanol and incubated at -20°C for 1 h. Samples were then centrifuged
at 13,000 rpm for 30 min and the supernatant was discarded. Samples was
washed with 400 μl 75 % (v/v) isopropanol and centrifuged for a further 5 min
at 13,000 rpm.  The supernatant was removed and the pellet was dried at
room temperature for 20 min. 10 μl Hi-Di solution (Applied Biosystems,
Cheshire, UK) was applied to the pellet and the reaction mixture sequenced
using an ABI3730 DNA Analyzer (Applied Biosystems). DNA sequence data
was visualized using Chromas version 1.61 software (Technelysium Pty Ltd,
Australia) and analysed using NCBI BLAST, ClustalW and BioEdit.
2.5.12 RNA extraction
Bacterial RNA was isolated using RNAProtect® bacteria reagent (Qiagen)
and TRI Reagent® solution (Sigma-Aldrich) according to manufacturer’s
instructions. 1.5 µg of RNA was treated with AMBION TURBO DNAse®
according to manufacturer’s instructions.
2.5.13 Reverse transcription PCR
DNAse treated RNA was then reverse transcribed into cDNA using random
hexamers and Invitrogen Superscript III first strand synthesis kit according to
manufacturer’s instructions and cycling conditions. Synthesised cDNA was
stored at - 20°C until needed for PCR reaction.
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2.5.14 Sodium dodecyl sulphate polyacrylamide gel electrophoresis
(SDS-PAGE)
Bacterial lysates were boiled at 100°C for 30 min and mixed with sample
loading buffer. Samples and the PageRuler Plus Prestained Protein ladder
10-250K (Thermo Scientific) were loaded onto 10 % Bis-Tris gels set up in a
XCell Mini-cell electrophoresis system containing 1 x MOPS SDS running
buffer (Life technologies). Gels were run at 150 V for 1 h 30 min.
2.5.15 Polyacrylamide protein gel staining
The polyacrylamide gels were incubated with Coomassie stain for 1 h with
agitation, followed by rinsing with destain solution for 1 h. Destain solution
was re-applied three times. Coomassie gels were visualized on an
Odyssey® CLx infrared imaging system (LI-COR) using the 800 nm LI-COR
channel.
2.5.16 Western blot
Separated proteins were transferred from the polyacrylamide gel to a
Hybond-C extra nitrocellulose membrane (GE Healthcare) with transfer
buffer (Appendix 1), using the Hoefer SemiPhor System (GE Healthcare) set
at 45 mA for 1.5 h (or 90 mA for two gels).
The nitrocellulose membrane was blocked with 2 % skimmed milk (Tesco,
Cheshunt, UK) in PBST (blocking buffer) for 1 h at room temperature with
agitation at 75 rpm (Platform shaker STR6, VWR-Jencons) or overnight at
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4°C.  The membrane was incubated with 1:1000 dilution monoclonal anti-
LPS (CC6) in blocking buffer for 1 h with agitation, and then washed four
times for 5 min with PBST. The membrane was incubated with 1:5000
dilution IRDye 800CW anti-mouse IgG (H+L) secondary antibody (Li-Cor) for
1 h with agitation and then washed four times for 5 min with PBST. A final
wash in PBS was included. Fluorescence on the membrane was detected
using the Odyssey® CLx infrared imaging system (LI-COR).
2.6 Mutant construction and characterization
2.6.1 Cloning
Splicing by overlapping extension PCR (SOE PCR) was performed for the
gene targeted for in-frame deletion (Heckman and Pease, 2007).
Intermediate segments (the flanks of the target gene) were first amplified,
and then used as template in a subsequent PCR to generate a full length,
spliced product.
Inner primers were designed to encode 20 nucleotides found at the junction
of the adjoining segment. Approximately 600 to 1200 bp flanking regions of
the target gene was first amplified from purified genomic DNA by PCR using
Phusion High-Fidelity PCR master mix (Thermo Scientific) according
manufacturer’s instructions. These intermediate amplicons contain
overlapping regions that hybridize at the 3’ end. 1 μl of the amplicons were
used as template in a subsequent PCR with flanking primers that introduce a
XbaI restriction site for cloning purposes. The assembled amplicon contains
spliced regions of the flanks of the target gene.
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The spliced amplicon was subjected to agarose gel electrophoresis, purified
using a gel purification kit (Qiagen) and cloned into pJet1.2/Blunt vector
(Fermentas) in E. coli Top10 cells according to manufacturer’s instructions.
The constructs were digested using the restriction enzyme corresponding to
the engineered restriction site on the primer pair. The desired DNA fragment
was cloned into the suicide vector pDM4 in E. coli EC100D pir+ and
subsequently E. coli MFD to obtain the deletion construct. The clones were
screened by PCR and sequencing.
2.6.2 Conjugation
The deletion construct was delivered via conjugation into B. pseudomallei or
B. thailandensis. Overnight cultures of the donor strain harbouring the pDM4
deletion construct and the recipient strain (B. pseudomallei K96243 or B.
thailandensis E264) were mixed in a 1:3 volume ratio respectively. 100 µl of
the mixture was applied to a prewarmed LB plate and incubated overnight at
37°C.  Cells were resuspended in PBS and cultured overnight at 37°C on LB
plates containing appropriate antibiotics. Integrants (merodiploids) were
confirmed by colony PCR.
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2.6.3 Sucrose selection
A single integrant colony (merodiploid) was used to inoculate 10 ml LB broth
and incubated at 37°C overnight with agitation. The overnight culture was
diluted in PBS and 100 µl was plated on sucrose agar (Logue et al., 2009).
The plate was incubated at 24°C for 48 h or until colonies were well grown.
Colonies were screened for sensitivity to chloroamphenicol (Cm), which
indicates that the suicide vector, pDM4, has been excised from the genome
by a second recombination event. Cm-sensitive colonies were screened
using PCR and sequencing to confirm the deletion of the target gene.
2.6.4 Complementation
The full length gene bth_i3001 was amplified from B. thailandensis E264
genomic DNA respectively by PCR (Table 2.8) and cloned into the vector
pME6032 or pMEK to generate pMEVacJBT and pMEKVacJBT respectively.
The plasmid was introduced into B. thailandensis E264 VacJ mutants by
electroporation transformation. Conjugates were screened by colony PCR.
The complemented mutant strains were grown in LB broth containing
appropriate antibiotics and 1 mM IPTG.
2.7 In vitro assays
2.7.1 Growth curves
2 ml of overnight broth culture was added to 100 ml LB broth and incubated
at 37°C. At various time points, 1 ml bacterial culture was removed and
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absorbance at 600 nm read using a Biochrom WPA CO8000 cell density
meter (Biochrom). Alternatively, the bacterial culture was serially diluted and
plated onto LB agar and incubated at 37°C overnight.
2.7.2 Antimicrobial sensitivity assay
An in vitro susceptibility testing was performed by a standard broth
microdilution method. Briefly, microtiter plates containing twofold serial
dilutions of antibiotics in cation-adjusted Mueller-Hinton broth (Becton
Dickinson, Cockeysville, Md.) were inoculated with the appropriate dilution of
a log-phase culture. Viable counts were determined immediately after
inoculation to verify that the actual inoculum size was between 105 and 106
CFU/ml. The plates were incubated at 37°C for 24 h. The MIC was defined
as the lowest concentration of antibiotic that completely inhibited visible
growth for 24 h.
2.7.3 Growth inhibition assays in SDS or EDTA
Bacterial cultures were grown overnight in LB broth at 37°C, washed and
diluted to about 1 x 107 CFU/ml in PBS. This was added to a 96-well
microtiter dish in triplicates, and 10-fold dilutions were prepared in PBS. 10 µl
of bacterial culture was transferred from the dish to LB agar with or without
SDS or EDTA at the indicated concentrations. Colonies were counted after 2
days of incubation at 37°C.
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2.7.4 Adhesion assay
A549 cells were seeded at a density of 5 x 105 cells/ml in 24-well plates and
incubated overnight at 37°C with 5 % CO2. An overnight culture of bacteria
was pelleted and diluted in the culture medium. 1 ml bacterial culture was
added to the cells to achieve a multiplicity of infection (MOI) of 5. At
appropriate time points, the cells were washed four times with PBS and lysed
in 0.1 % Triton X-100 for five minutes, serially diluted and plated onto LB
agar plates.
2.7.5 Intracellular survival assay
Burkholderia uptake and survival were quantified utilizing a modified
kanamycin protection assay (Wand et al., 2011). J774A.1 cells were seeded
at a density of 1 x 105 cells/ml in 24-well plates and incubated overnight at
37°C with 5 % CO2. An overnight culture of bacteria was pelleted and diluted
in the corresponding culture medium for the cell line to be infected. 1 ml
bacterial culture was added to the cells to achieve a multiplicity of infection
(MOI) of 10 or 1. The cells were incubated at 37°C for 1 h to allow bacterial
internalisation to occur. Cells were washed with PBS and 1 ml of culture
medium containing 250 μg/ml kanamycin was added to kill extracellular
bacteria. At appropriate time points, cells were washed with PBS and lysed
in 0.1% Triton X-100 in PBS for 5 minutes, serially diluted and plated onto LB
agar plates and incubated overnight at 37°C.
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2.7.6 Immunofluorescence
J774A.1 macrophages grown on glass coverslips placed at the bottom of 24-
well plates were infected with Burkholderia strains as already described. At
appropriate time points, cells were washed three times with PBS and fixed
with 4% paraformaldehyde for 15 minutes at room temperature. Cells were
washed three times with PBS before permeablizing the cells with 0.5% Triton
X-100 in PBS for 15 minutes at room temperature. After three more washes
in PBS, cells were incubated with 5% (vol/vol) FCS in PBS for 1 h at room
temperature. After washing the cells in PBS, coverslips were incubated with
a monoclonal antibody that binds to Burkholderia LPS (CC6, DSTL, 1:1000
dilution), and a primary antibody appropriate for the assay (LAMP-1: rat anti-
LAMP-1 antibody (1D4B, Molecular probes, 1:500 dilution); LC3b: rabbit anti-
LC3b antibody (Molecular probes, 1:500 dilution)) for 1 h at room
temperature. Following three washes in PBS, cells were incubated with
Alexafluor488-conjugated anti-mouse antibody (Molecular probes, 1:1000
dilution) and the appropriate secondary antibodies for 1 h at room
temperature. After several washes in PBS, coverslips were mounted onto
microscopy slides using DPX mounting medium (dibutyl phthalate xylene,
Merck). Samples were analysed using a ZEISS LSM510 confocal-laser
scanning microscope or a CCD fluorescence microscope (Axioplan 2 upright
microscope).
For visualization of actin polymerization, infected cells were stained as
described above without the use of primary antibodies for mammalian
markers. The cells were then incubated with Alexafluor555-phalloidin
conjugate solution (binds F-actin, Molecular probes, 1:50 dilution) and the
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appropriate secondary antibody for 1 h at room temperature. After several
washes in PBS, cells were stained with 300 nM 4’6-diamidino-2-phenylindole
(DAPI, Life Technologies) according to manufacturer’s instructions.
2.7.7 Giemsa staining of MNGCs
J774A.1 macrophages were infected as already described. At appropriate
time points, cells were washed with PBS and treated with 100 % methanol
for 30 minutes at room temperature. Cells were thoroughly washed with PBS
and stained with Giemsa solution for 30 minutes at room temperature. After
washing with PBS, cells were allowed to dry before being visualised under a
light microscope.
2.8 In vivo studies
All mouse challenge studies were carried out by Dr. Natasha Spink and Dr.
Bea Choi. I prepared inocula for the challenge studies and homogenised all
organs following collection for bacterial counting purposes. Groups of 6
female BALB/c age-matched mice (Charles River Laboratories, UK) were
housed together with free access to food and water and subjected to a 12 h
light/dark cycle. All animal experiments were performed in accordance with
Animals (Scientific Procedures) Act 1986 and were approved by local Ethical
Review Committee.
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2.8.1 Mice infection model
For intranasal (i.n.) inoculation, mice were anaesthetised with a combination
of 5 mg/ml Ketamine (Ketaset, Fort Dodge Animal Health Ltd), and 1 mg/ml
Xylazine (Rompum, Bayer), in pyrogen free saline. This dose is based on the
i.p. administration of 200 μl to a 20 g mouse and to ensure the safety and
efficiency of the anaesthetic, mice were weighed and the volume given
adjusted accordingly. When under anaesthetic, the mice were restrained and
dosed by slowly pipetting the 50 μl inoculum into both nostrils. Following
inoculation, mice were held upright for further 30 seconds to allow liquid to
drain into lungs. Mice were monitored twice daily for signs of morbidity and
mortality.
To investigate organ load burdens following infection with B. pseudomallei,
organs were homogenised by pressing through a 70 μm mesh cell-strainer
(Falcon, Becton Dickinson, Oxford, UK) with the plunger from a 2 ml syringe
(Becton Dickinson). Serial 10-fold dilutions of the resulting cell suspensions
were plated onto LB agar plates and viable colonies counted after 48 h
incubation at 37°C. Following cardiac puncture, blood was collected from
mice in tubes containing with 0.1 ml heparin. Serial 10-fold dilutions of blood
samples were plated on LB agar and bacterial counts were normalized to
colony forming units / ml blood.
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2.8.2 Protection studies
Mice were immunized i.n. with the K96243 ΔBPSL3147 mutant or the 7A1 at
doses of 500 CFU. Animal survival was monitored for 45 days.
Surviving vaccinated mice or six naïve controls were then challenged i.n.
with 500 CFU B. pseudomallei K96243 and survival was monitored on a daily
basis.
2.9 Statistical Analysis
Statistical analyses were performed using GraphPad Prism version 6.04
(GraphPad Software, San Diego California USA).
For in vivo mutant characterization, a Log-rank (Mantel-Cox) Test was used
for comparison of survival curves and the Mann-Whitney test was used for
determining bacterial load in organs. The two-way ANOVA and Bonferroni’s
post-test or the unpaired Student’s t-test was used for intracellular survival
assays, MNGC formation assays, serum survival assays.
A p value of less than 0.05 was reported as statistically significant (* p < 0.05;
** p < 0.01; *** p < 0.001).
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3. Chapter 3 – Identification and characterization of B.
pseudomallei VacJ
3.1 Introduction
Novel functional genetic analysis tools that allow large-scale screening of
bacterial transposon mutant libraries are shifting the paradigm for identifying
genes that are essential for growth or virulence and for detecting novel
antimicrobial targets or potential vaccine candidates (Langridge et al., 2009).
The goal is to obtain a system-level understanding of the functional aspects
of biological systems, in this instance, of various genes and regulatory
networks involved in infection of the host (Opperman et al., 2003). Signature-
tagged mutagenesis (STM) is a negative selection tool that is used to identify
virulence associated genes through phenotypic analysis of virulence in
animal models (Hensel et al., 1995). For example, it can be used for high
throughput screening of virulence genes associated with pathogen
colonization or survival in animal models (Atkins et al., 2002a, Cuccui et al.,
2007). Briefly, animals are infected with pools of tagged transposon mutants
(input pool) and individual mutants which are absent or underrepresented in
the infected animals (output pool) due to an inability to survive, grow, or
disseminate can be identified based on their individual signature tags by
comparing the input and output pools. These negatively selected mutants are
considered to be attenuated and are inferred to lack functionality of a gene
required for colonization or survival. A variety of biochemical and genetic in
vitro and in vivo methods may then be used to elucidate and confirm the
functions of these genes.
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Figure 3.1 Schematic representation of the original STM strategy
(Reproduced from (Chiang et al., 1999))
STM has its limitations. For example, the size of mutant pools are limited by
the number of unique tags required constructing libraries and generally only
the most strongly attenuated mutants are identified. In addition, the insertion
site of each transposon must be determined individually through arbitrary
PCR, which is unreliable and time consuming. Recently, a novel technology
known as transposon-directed insertion-site sequencing (TraDIS) has
improved our ability to analyse larger pools of transposon mutants by
exploiting Illumina sequencing technology to obtain the sequence flanking
each transposon insertion (Langridge et al., 2009). This method allows for a
simultaneous sequencing from a very large pool of mutants that provides
coverage of the entire genome. It has been used to define essential genes
and novel targets for antimicrobial development for Salmonella enterica
serovar Typhi (Langridge et al., 2009), S. pneumonia (van Opijnen and
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Camilli, 2010), B. pseudomallei (Moule et al., 2014) and B. thailandensis
(Baugh et al., 2013).
TraDIS can also be used as a negative screening method to identify genes
that are associated with various environment stresses or infection in animal
models (Eckert et al., 2011). In addition to providing the genotype of the
mutants, TraDIS provides a numerical measurement of the fitness score
(log2 fold change) of the mutants through the comparison of the number of
specific sequencing reads derived from input and output pools. In one
application, TraDIS was applied retrospectively to sequence E. coli STM
library screened in cattle, validating and extending the analysis of the STM
mutants by giving information on every mutant and identifying hundreds of
additional novel genes that are potentially involved in infection of cattle and
intestinal colonization (Eckert et al., 2011).
Recently, a number of genes likely to be important for growth and survival of
B. pseudomallei in an in vivo mouse model were identified using signature-
tagged mutagenesis (Atkins et al., 2002a, Cuccui et al., 2007). A separate
study using TraDIS to resequence the B. pseudomallei STM library was
performed and provided confirmation of these genes and large-scale
identification of new genes involved in virulence in mice (Moule and Cuccui,
unpublished data). Mutants defective in aroB (bpsl3168) and wcbC
(bpsl2807) were initially identified in the STM study and were shown to
display total attenuation of virulence and were cleared from the lungs and
spleens in infected mice (Cuccui et al., 2007). This was confirmed in the
TraDIS experiment and correlated to fitness score (log2 fold change) > - 1.6
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in both mutants extracted from both lungs and spleen in the TraDIS
experiments (Table 3.1).
Among the novel genes identified through both the original B. pseudomallei
STM screen performed in Cuccui et al. (2007) and the later TraDIS screen
(Moule, unpublished data), a putative outer membrane lipoprotein encoded
by bpsl3147 appeared to be important for in vivo virulence as evidenced by
the low fitness score of the corresponding mutant 7A1, particularly in spleen
samples. The gene bpsl3147 is located in B. pseudomallei K96243
chromosome 1 and encodes a putative lipoprotein VacJ. Bioinformatic
analyses and comparisons with the relatively avirulent B. thailandensis were
conducted to generate hypothesised roles for this putative lipoprotein and
virulence factor.
85
Table 3.1 Selected examples of a retrospective TraDIS investigation of
STM mutants.
Disrupted genes and their putative functions are listed, along with the
number of observed TraDIS reads for the gene in each sample (pre-infection:
input pool; post-infection: organ). The brackets indicate the log2 fold change
relative to the input to represent the difference in abundance of each mutant
in the organs relative to the input. (Moule, unpublished data)
Gene Putative function Observed reads in sample
(log2 fold change relative to input)
Input
pool
Lung 1 Lung 2 Spleen
1
Spleen
2
bpsl3147
(vacJ)
Lipoprotein VacJ 12632 905
(-1.884)
752
(-2.016)
6
(-5.259)
1
(-6.234)
bpsl3168
(aroB)
Dehydroquinate
synthase
11123 32
(-4.105)
8
(-4.993)
3
(-5.569)
0
(-7.728)
bpsl2807
(wcbC)
Outer membrane
transporter
81918 7870
(-1.686)
1613
(-2.819)
134
(-4.571)
3
(-7.007)
bpsl2808
(wcbB)
Capsular
polysaccharide
glycosyltransferase
biosynthesis protein
41860 10418
(1.000)
11463
(0.932)
65
(4.583)
0
(8.681)
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3.2 Aims
The aim of this chapter is to identify and characterize putative VacJ (MlaA)
lipoproteins in B. pseudomallei and the closely related B. thailandensis
species. Bioinformatics tools were used for the identification of similar genes
and for the characterization of protein sequences. The amino acid
sequences of VacJ homologues in Burkholderia species as well as other
bacterial species were compared.
3.3 Results
3.3.1 Bioinformatic analysis of bpsl3147
The gene bpsl3147 is predicted to encode an outer membrane lipoprotein
VacJ based on BLASTP and Psort analysis. The N-terminal contains the
characteristic lipoprotein signal sequence, (a n-region with positively charged
amino acids in the initial residues, a hydrophobic h-region with 7 to 22
predominantly hydrophobic and uncharged residues, and a lipobox
[LVI][ASTVI][ASG]C), where cleavage and lipid modification typically occurs
at the invariant cysteine residue of the lipobox (Figure 3.2).
Figure 3.2 Amino acid sequence of BPSL3147 in B. pseudomallei
K96243 contains a typical lipoprotein signal peptide sequence.
The N-terminal consists of an n-region with positively charged amino acids, a
hydrophobic region (h region) and a lipobox sequence.
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BLASTP and Pfam analysis showed that BPSL3147 is related to the VacJ
superfamily (cI01073) of surface lipoproteins which are associated with cell
envelope biogenesis (COG2853) and a provisional ABC transporter outer
membrane lipoprotein (PRK15091). VacJ orthologues are found in all
Burkholderia species (with publicly available genomes) and many Gram-
negative bacteria (Table 3.2). VacJ products have also been found in the
outer membrane (OM) proteome of B. pseudomallei and B. mallei (Schell et
al., 2011)
Highly conserved orthologues of bpsl3147 are found in chromosome 1 of the
closely related Burkholderia species B. mallei (bma2723) and B.
thailandensis (bth_i3001), where the respective gene products have 99 %
and 94 % amino acid identities. A homologue of the gene is found in
chromosome 2 of B. pseudomallei and closely related Burkholderia strains (B.
pseudomallei, B. mallei, B. thailandensis and Burkholderia oklahomensis),
with the gene products having 46 to 51 % amino acid identity to BPSL3147.
It is unclear if the vacJ homologue in chromosome 2 is a paralogue (where
the genes are related by duplication within a genome) or a xenologue (where
the gene is acquired by horizontal gene transfer). The signal sequence of the
VacJ homologue encoded by bpss2331 (chromosome 2) contains an alanine
residue instead of a typical [LVI] residue at the -3 position of the predicted
lipobox region. Although the predicted products of both VacJ homologues
within a Burkholderia species only have about 46 % - 50 % amino acid
identity to each other, these gene products are highly conserved between B.
pseudomallei, B. mallei, B. thailandensis and B. oklahomensis (Table 3.2).
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However, a study by Sim et al. (2008) revealed that novel indels are present
in the region surrounding the vacJ homologue in chromosome 2 (bpss2331-
bpss2333) in at least 3 out of 94 Southeast Asian B. pseudomallei strains,
indicating this region may be part of the accessory genome of B.
pseudomallei (Sim et al., 2008).
A comparison of the BPSL3147 amino acid sequence against the NCBI
nonredundant protein database found significant similarity (29 % to 40 %
amino acid identity) to the VacJ lipoprotein in a number of bacterial species,
including S. flexneri, H. influenzae, E. coli and the plant pathogen, Ralstonia
solanacearum (Table 3.2, Figure 3.3).
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Figure 3.3 BLASTP alignment of VacJ protein sequences, showing
percent amino acid identity between different strains.
(Bp: B. pseudomallei, Bm: B. mallei, Bt: B. thailandensis, Bo: B.
oklahomensis). Grey box denotes the amino-terminal region with the
predicted signal peptide sequence (contains lipobox). The boundary for the
signal peptide is based on the amino acid sequence analysis using Psortb
and LipoP. Red (above 60% amino acid identity) or yellow (below 60 %
amino acid identity) regions denote predicted mature lipoprotein sequence.
Striped regions represent protein regions with no similarities. The numbers
displayed within each coding region represent the percent sequence identity
compared to the BPSL3147 coding sequence.
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Table 3.2 Family of VacJ orthologues
Organism Gene product or locus
tag
Description % amino acid
similarity to
BPSL3147
Reference
B. pseudomallei BPSL3147 Putative lipoprotein VacJ, virulence factor found in purified outer membrane preparation 100 % (Cuccui et al., 2007,
Schell et al., 2011)
B. pseudomallei BPSS2331 Putative lipoprotein VacJ, found in purified outer membrane preparation, cross reactive
antigen that reacts with sera from healthy individuals and melioidosis patients
51 % (Schell et al., 2011,
Felgner et al., 2009)
B. mallei BMA2723 Putative lipoprotein VacJ, found in purified outer membrane preparation 99 % (Schell et al., 2011)
B. mallei BMAA2092 Putative lipoprotein VacJ, found in purified outer membrane preparation 49 % (Schell et al., 2011)
B. thailandensis BTH_I3001 Putative lipoprotein VacJ 92 %
B. thailandensis BTH_II2351 Putative lipoprotein VacJ 47 %
B. oklahomensis WP_010106884 Putative lipoprotein 94 %
B. oklahomensis WP_010110855 Putative lipoprotein 46 %
S. flexneri VacJ Lipoprotein exposed on cell surface (virulence-associated chromosome locus J); role in
intercellular spreading
38 % (Suzuki et al., 1994,
Carpenter et al., 2014)
E. coli MlaA Predicted outer membrane lipoprotein, part of the Mla transport system involved in
maintenance of outer membrane lipid asymmetry
37 % (Malinverni and Silhavy,
2009)
H. influenzae VacJ Putative lipoprotein; contributes to outer membrane stability and serum resistance in
nontypeable strains (NTHi) by limiting binding of antibody to exposed lipooligosaccharides
(LOS)
35 % (Nakamura et al., 2011)
R. solanacearum RSc2959 Putative lipoprotein. 53 %
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3.3.2 Predicted roles of VacJ
The VacJ (virulence-associated chromosomal locus J) superfamily of
proteins was first identified in the intracellular bacterium S. flexneri and
shown to be important for intercellular spread (Suzuki et al., 1994, Carpenter
et al., 2014). The gene product is a 251-amino acid lipoprotein with a
predicted molecular mass of 28 kDa that is synthesized as a prolipoprotein.
The prolipoprotein is then processed into a mature lipoprotein, secreted into
the outer membrane and exposed on the bacterial surface. Mutation of this
gene did not affect early steps in pathogenesis. A S. flexneri vacJ mutant
was found to be capable of forming bacterium-containing membranous
protrusions in epithelial cells but had diminished ability to move from the
protrusions into adjacent cells (Suzuki et al., 1994).
More recent studies revealed that VacJ orthologues are found in many
Gram-negative bacteria and are occasionally interspersed with genes
associated with membrane transport (Casali and Riley, 2007) and virulence
(Nakamura et al., 2011). In E. coli, the gene product (VacJ/MlaA) is part of
the maintenance of lipid asymmetry (mla) ATP-binding cassette (ABC)
transport system that actively prevents phospholipid accumulation at the cell
surface in the absence of obvious extracellular stress (Malinverni and Silhavy,
2009) (Figure 3.4), contributing to outer membrane stability. Core
components of the Mla transport system include MlaA (VacJ), MlaB (YrbB),
MlaC (YrbC), MlaD (YrbD), MlaE (YrbE) and MlaF (YrbF). Predicted
functions of each component are as follows (Malinverni 2009): MlaA is a
predicted OM lipoprotein, MlaB is a predicted cytoplasmic protein with a
STAS domain,  MlaC is a predicted substrate binding protein that resides in
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the periplasm, MlaD is a putative substrate-binding protein, and localizes to
the periplasmic face of the inner membrane (IM) by an uncleaved sequence.
MlaE is an integral IM protein and predicted permease with a signature
typically found in ABC import pathways. Finally, MlaF is a classic ABC
transport nucleobinding component. In Gram-negative bacteria, the genes
encoding these factors are often colocalized, and occasionally interspersed
with mlaA (vacJ) (Malinverni and Silhavy, 2009). In E. coli, mlaA is not
genetically linked to the mlaF-B locus. A study on protein-protein interactions
using His-tagged E. coli ORF clone library revealed that MlaA interacts with
the 60 kDa chaperonin encoded by groL (Arifuzzaman et al., 2006). In H.
influenzae, VacJ was shown to act in concert with the Yrb (Mla) ABC
transporter proteins to maintain the outer membrane stability and limit
binding of antibodies to LOS components, contributing to serum resistance in
non-typeable H. influenzae (acapsular) (Nakamura et al., 2011). To date,
there is no information on the function of VacJ in the plant pathogen R.
solanacearum.
Bioinformatic analysis of the genes surrounding bpsl3147 in the B.
pseudomallei K96243 genome revealed orthologues of all genes involved in
the proposed Mla pathway except for mlaB, a gene encoding for a
cytoplasmic protein with an STAS domain. The putative gene product of
bpsl3145 did not share homology to that of mlaB but contains an STAS
domain (Figure 3.5). The organization of the mla locus is preserved around
bth_i3001 in B. thailandensis. In comparison, the genes surrounding the vacJ
homologue in chromosome 2 of B. pseudomallei and B. thailandensis do not
display similarity to the genes from the Mla pathway.
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Figure 3.4 Model of the Mla and PldA PL turnover pathways
(Reproduced from (Malinverni and Silhavy, 2009))
Figure 3.5 Gene organization of the Mla transport system.
Genes related to the Mla transport system in A) E. coli, B) B. pseudomallei
K96243 and C) B. thailandensis E264 are highlighted in grey. Percentages of
amino acid identities are indicated.
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3.4 Discussion
Since bpsl3147 was first identified in a screen for genes related to in vivo
virulence, this study focused on confirming this role, and further
characterizing the gene and associated genes to increase understanding of
B. pseudomallei pathogenesis. In a recent study, a dual function of
maintenance of OM asymmetry and intercellular spread was proposed for
the Mla system (VacJ/Vps) in S. flexneri (Carpenter et al., 2014). To date, it
is unclear if retrograde transport of phospholipids mediates downstream
signalling functions that are critical to the persistence of host infection, or
whether this maintenance of OM asymmetry affects other bacterial factors. It
is possible that alterations to the OM may inhibit the primary virulence factor,
thus indirectly altering virulence characteristics. For example, the T3SS is
required for the escape of S. flexneri from the intracellular double membrane
vacuole during infection (Schuch and Maurelli, 1999). Outer membrane
defects may affect proper assembly of T3SS in the membrane or secretion of
the T3SS effectors (Schuch and Maurelli, 1999, Carpenter et al., 2014).
Characterizing the vacJ gene in B. pseudomallei and B. thailandensis may
help elucidate novel roles in the intracellular lifecycle of the bacteria.
The identification of the Mla pathway in E. coli presents an additional model
by which Gram-negative bacteria may maintain the OM integrity. In Gram-
negative bacteria, maintenance of the OM integrity is critical for protection
against toxic substances and harsh environments. The LPS contributes to
the barrier function of the OM and has been shown to protect the bacteria
from deleterious agents such as complement (Nikaido, 2003, DeShazer et al.,
1998). Disturbances to the OM such as assembly defects, exposure to
95
antimicrobial peptides, or chelating agents (EDTA), could lead to shedding of
the LPS. It is conceivable that without the LPS, other epitopes on the cell
surface may become accessible to host immune molecules such as the
complement factors that forms membrane attack complex for bactericidal
activity (Feingold et al., 1968). Phospholipids from the inner leaflet are forced
to migrate to the breached areas of the outer leaflet, resulting in the
formation of phospholipid bilayer patches and a reduction in the barrier
function. This in turn, could have pleiotropic deleterious effects if the bacteria
is unable to compensate for this defect. For example, disruption in the OM
could lead to decreased resistance in serum, or may change the
presentation of cell surface antigens, and lead to differential host immune
responses that may affect bacterial viability. Given the sequence similarity of
bpsl3147 to other vacJ/mlaA orthologues and the co-localization of the gene
with other members of the mla pathway, I postulate that BPSL3147 may play
similar roles in B. pseudomallei. The presence of a vacJ homologue in
chromosome 2, albeit as part of the accessory genome, may indicate a
functional redundancy of this gene in relation to microbial adaption and
virulence.
In B. pseudomallei, the presence of a polysaccharide capsule may limit
access of molecules to the cell membrane (Roberts, 1996). It would thus be
interesting to characterise VacJ in an acapsular strain, or in B. thailandensis
strains which do not express a polysaccharide capsule for comparison. I
hypothesize that VacJ may contribute to Burkholderia virulence through a
role in outer membrane stability and/or serum resistance, and also possibly
through a role in intracellular spread as has been observed in S. flexneri.
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4. Chapter 4 - Characterizing the role of VacJ in B.
pseudomallei
4.1 Introduction
The ability of B. pseudomallei to cause disease in humans involves a
complex series of events in which the bacteria persist and evade immune
responses in the host environment (e.g. blood), invade and replicate within
host cells, and spread to adjacent cells causing multinucleated giant cell
formation and cellular damage. Virulence factors that contribute to B.
pseudomallei survival and pathogenesis in mammalian hosts have been
identified but it is likely that a multitude of additional factors that contribute to
these roles remain to be discovered (Reckseidler et al., 2001, Atkins et al.,
2002a, Atkins et al., 2002b, Reckseidler-Zenteno et al., 2005, Cuccui et al.,
2007, Wikraiphat et al., 2009, Warawa et al., 2009).
The main aim of this chapter was to evaluate the role of BPSL3147 (VacJ), a
putative virulence determinant of B. pseudomallei, which was selected from a
signature-tagged mutagenesis screen for in vivo virulence. The prototypic
VacJ was first identified as a 30 kDa lipoprotein in S. flexneri that contributes
to intercellular spread (Suzuki et al., 1994) and was later found to affect outer
membrane asymmetry in E. coli and H. influenzae (Malinverni and Silhavy,
2009, Nakamura et al., 2011).
In order to demonstrate a specific role for VacJ in vivo virulence and in vitro
functions, defined mutants were created in a clinical B. pseudomallei isolate,
K96243, through in-frame deletion mutagenesis. This isolate is a fully-
sequenced and annotated reference strain. A range of phenotypic assays
were used to characterize the mutants and define roles for this gene.
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4.2 Aims:
1. To generate unmarked, in frame deletions in B. pseudomallei K96243
2. To characterize the resulting mutants using in vivo and in vitro
methods.
4.3 Results
4.3.1 Unmarked in-frame deletion mutagenesis of bpsl3147 in B.
pseudomallei
4.3.1.1 Production of a deletion construct
The cloning strategy used to produce the construct for deletion of bpsl3147 is
outlined in Figures 4.1 and 4.2. Primers were designed for performing
splicing by overlapping extension PCR (SOE PCR), with engineered
restriction sites (Chapter 2). Upstream and downstream flanking regions of
bpsl3147 were PCR-amplified from B. pseudomallei K96243 genomic DNA.
PCR products were used as the template in a subsequent PCR to produce a
spliced DNA fragment (mutagenesis cassette). The mutagenesis cassette
was cloned into pJET1.2 and the insert confirmed by nucleotide sequencing
(Chapter 2). To form the deletion construct, the mutagenesis cassette was
subcloned into the lambda (λ) pir dependent vector pDM4, which carries the
negative-selectable sacB gene and a chloroamphenicol resistance cassette
(Milton et al., 1996). The deletion construct was transformed into the Mu-free,
auxotrophic E. coli MFD (Ferrières et al., 2010). Colonies containing the
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correct deletion construct were confirmed after PCR and nucleotide
sequencing of the insert DNA.
4.3.1.2 Mutant production
The mutagenesis strategy for making an unmarked bpsl3147 deletion mutant
is outlined in Figure 4.2 (Logue et al., 2009). For mobilization of the pDM4
deletion construct into B. pseudomallei by conjugation, overnight cultures of
E. coli and B. pseudomallei strains were spotted together on LB agar and
grown overnight at 37°C. The first cross-over event resulted in the integration
of the deletion construct into the host chromosome by homologous
recombination. Integrants (merodiploids) were identified on LB agar
containing chloroamphenicol (30 μg/ml) and confirmed by colony PCR.
A single integrant colony (merodiploid) was subcultured and plated on the
counter-selective sucrose agar for selection of clones that underwent the
second cross over event (Logue et al., 2009). Out of six chloroamphenicol-
sensitive colonies screened using PCR analysis (Chapter 2 Section 2.5;
Figure 4.3), one colony was confirmed as a mutant. Sequencing results
confirmed a 1041 bp deletion in the bpsl3147 allele (Figure 4.4A). The
mutant strain is named B. pseudomallei K96243 ΔBPSL3147. Expression of
bpsl3147 was only observed in the wild type and not in the K96243
ΔBPSL3147 mutant (Figure 4.4C). Expression of adjacent genes bpsl3146
(Figure 4.4B) and bpsl3148 (Figure 4.4D) was observed in both the K96243
wild type and the ΔBPSL3147 mutant.
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Attempts to make a deletion mutant for the vacJ homologue (bpss2331) in
chromosome 2 of B. pseudomallei were unsuccessful, despite screening
over 85 colonies. The majority of the colonies remained chloroamphenicol-
resistant merodiploids. Two clones which lost the chloroamphenicol
resistance reverted to wild type.
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Figure 4.1 Cloning strategy to produce the deletion construct.
1. Flanking regions upstream (LF-left flank, shown in yellow) and downstream
(RF-right flank, shown in blue) of the target gene (shown in red) were PCR
amplified from genomic DNA using primers. The outer primers (black)
contain specific restriction sites (green – XbaI). The inner primers (red) were
designed to contain overlapping regions at the junction of the target flank.
2. A second PCR, using products from the first PCR, was performed using the
outer primers with specific restriction sites.
3. The PCR product was cloned into a typical cloning vector pJet 1.2.
4. pDM4 and the insert were digested with specific restriction endonucleases.
5. The insert was ligated into restriction sites in pDM4.
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Figure 4.2 Production of deletion mutant
(Adapted from (Logue et al., 2009)).
1. During the first cross-over event, the deletion construct integrates into the
genome by homologous recombination. The merodiploid integrant is
resistant to chloroamphenicol (due to the presence of the chloroamphenicol
resistance cassette, CmR) but sensitive to sucrose (due to the presence of
the sacB gene).
2. Sucrose is applied to select for bacteria that underwent a second cross-over
event. The pDM4 backbone is excised from the genome, allelic exchange
results in the generation of wild type revertant (cross-over at site 1) or the
target mutant (cross-over at site 2). Strains are resistant to sucrose but
sensitive to chloroamphenicol.
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Figure 4.3 Screening of B. pseudomallei deletion mutants
Screening by PCR was performed using primers BTvacJL and BTvacJR3X (Chapter
2, Section 2.5). Following sucrose selection, Cm-sensitive colonies were screened
for the presence of a smaller PCR product by using primers that flank the targeted
deletion region. Legend: colony number 26, 28, 29, 30, 33, 34; pDM4 ΔvacJBp: PCR
positive control; NTC: no template control. Colony 28 had a deletion in bpsl3147
(PCR product 0.65 kb) and was designated B. pseudomallei ΔBPSL3147. Other
colonies were resolved as wild type bpsl3147 (PCR product 1.6 kb).
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Figure 4.4 Confirmation of ΔBPSL3147 mutant by sequencing and
reverse transcription PCR (RT-PCR) analysis.
(A) Sequence of the B. pseudomallei K96243 ΔBPSL3147 mutant. The region surrounding
bpsl3147 was sequenced using primers specific for the left and right flanks. The consensus
sequence was aligned against the B. pseudomallei K96243 genome using standard
nucleotide BLAST (NCBI). A 1041 bp deletion of bpsl3147 was observed in the mutant.
(B)-(D) Reverse transcription PCR on RNA extracts from overnight cultures of B.
pseudomallei K96243 wild type or K96243 ΔBPSL3147 mutant using primers specific for (B)
bpsl3146, (C) bpsl3147 and (D) bpsl3148. Lanes 1 and 2: K96243 cDNA and RNA (no-RT
control) respectively; lanes 3 and 4 ΔBPSL3147 cDNA and RNA (no-RT control) respectively.
Expression of bpsl3146 (B) and bpsl3148 (D) was observed in both the wild type and mutant.
Expression of bpsl3147 (C) was only observed in the wild type.
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4.3.2 Growth in media
The growth rate of B. pseudomallei K96243 and the mutants used in this
study (K96243ΔBPSL3147, 13H8, 13H8 ΔBPSL3147) was determined in
liquid media. Deletion of bpsl3147 did not result in restricted growth in LB
media (Figure 4.5).
Figure 4.5 Growth curve of B. pseudomallei wild type or VacJ mutants
in LB broth at 37°C.
Growth was monitored by absorbance at 590 nm over 24 h. Values are from
a single experiment performed in duplicates.
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4.3.3 Virulence of B. pseudomallei BPSL3147 mutants in vivo
An acute, intranasal (i.n.) BALB/c mouse model of infection was chosen for
the evaluation of virulence of the newly constructed B. pseudomallei K96243
ΔBPSL3147 deletion mutant and the transposon insertion mutant 7A1 (with
bpsl3147 disrupted) identified from a previous study (Cuccui et al., 2007).
The median lethal dose (MLD) of B. pseudomallei K96243 by the i.n. route in
BALB/c mice was previously determined to be 10 CFU by Titball et al. (Titball
et al., 2008). Groups of six mice were infected via the i.n. route with B.
pseudomallei K96243 (413 colony forming units (CFU)); B. pseudomallei 7A1
(450 CFU) or B. pseudomallei ΔBPSL3147 (467 CFU). All mice challenged
with the wild type B. pseudomallei were moribund and euthanized by day 4
(Figure 4.6). In contrast, all mice challenged with the B. pseudomallei
K96243 VacJ mutants survived over the observed period for 45 days (p <
0.01) (Figure 4.6).
The organ load kinetics of BALB/c mice infected with the B. pseudomallei
K96243 strains was investigated by analysing the viable CFU present in the
lungs and spleens of infected animals (Figure 4.7). Groups of five BALB/c
mice were challenged (i.n.) with B. pseudomallei K96243 (530 CFU) or B.
pseudomallei K96243 ΔBPSL3147 (535 CFU). At 24 h post challenge,
comparable bacterial loads (about 105 CFU /organ) were observed in the
lungs of both groups, indicating a rapid increase in bacterial replication in the
lungs (Figure 4.7A). However, by 48 h, the bacterial counts in the lungs of
mice challenged with the B. pseudomallei K96243 ΔBPSL3147 mutant
dropped to a lower level (about 104 CFU / organ) while in wild type infected
mice, bacterial counts were considerably higher (about 107 CFU / organ)
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(Figure 4.7A). At 24 h post challenge, the bacterial counts in the spleens
were below the detection limit (500 CFU/organ, data not shown). At 48 h post
challenge, the bacterial counts in the spleens of wild type-infected mice
increased to more than 105 CFU / organ, while the bacterial counts in the
spleens of mice infected with the mutant remained low (about 102 CFU /
organ) (Figure 4.7b). At 48 h post challenge, some bacteria (104 CFU /ml)
were recovered from whole blood of wild type-infected mice (detection limit
102 CFU/ml blood) (Figure 4.7C).
Figure 4.6 Survival data of i.n. infection of BALB/c mice.
Groups of six female mice were infected with B. pseudomallei K96243 (x, 413 CFU)
or defined VacJ mutants 7A1 (Δ, 450 CFU) or K96243 ΔBPSL3147 (Ο, 467 CFU)
and monitored for survival. Median survival time of mice infected with B.
pseudomallei K96243 was 4 days.
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Figure 4.7 Differential susceptibility to colonization by B. pseudomallei
mutant ΔBPSL3147 in BALB/C mice.
BALB/c mice (n = 5) were infected (i.n.) with 500 colony-forming units (CFU) B.
pseudomallei wild type strain K96243 or mutant ΔBPSL3147. The lungs (A), spleen
(B) and heparinized blood (C) were harvested on days 1 and 2 post challenge. A, B,
C: Bacterial loads from lungs, spleen and blood, respectively. The horizontal bar
indicates the median value. Statistical significance was determined using the Mann-
Whitney test; ** p < 0.01.
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4.3.4 Infection of mammalian cell lines
B. pseudomallei can survive and replicate in a range of cell lines (Jones et al.,
1996, Harley et al., 1998). To determine if VacJ is required for intracellular
growth and survival, I compared the B. pseudomallei ΔBPSL3147 mutant to
the wild type strain for their abilities to invade, replicate and spread within
cultured cell monolayers.
4.3.4.1 Infection of A549 epithelial cells
A549 human lung epithelial cells were infected with B. pseudomallei K96243
wild type or ΔBPSL3147 at MOI of 5. At 2 and 4 h post infection, infected
cells were lysed and the number of viable bacteria within the cells was
determined (Figure 4.8). No significant difference between the wild type and
the ΔBPSL3147 mutant for adherence of A549 epithelial cells was observed.
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Figure 4.8 Adherence or invasion of A549 epithelial cells by B.
pseudomallei K96243 wild type or ΔBPSL3147 strains.
The mean bacterial recoveries (CFU/ml) ± standard error of mean (SEM) at 2 h
(adhesion) and 4 h (invasion) post infection (MOI 5) are shown. Data is
representative of 2 experiments, performed in duplicates. No significant differences
were observed between the strains.
4.3.4.2 Growth and survival within J774A.1 murine macrophages
J774A.1 murine macrophages were infected with B. pseudomallei K96243
wild type or ΔBPSL3147 strains at MOI of 1. At 2, 4, 6 and 24 h post infection,
infected cells were lysed and the number of viable bacteria within the cells
was determined (Figure 4.9). At the time points tested, there were no
significant differences between the wild type and mutant for intracellular
survival in J774A.1. Following an initial decline in numbers after
internalization, both the wild type and mutant strains were able to replicate
within the macrophage at similar levels, as seen by the increase in
intracellular CFUs at 24 h post infection.
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B. pseudomallei has previously been shown to form multinucleated giant
cells (MNGCs) upon invasion of macrophages (Kespichayawattana et al.,
2000). As previous studies reported that the S. flexneri VacJ mutant showed
impairment in the ability to infect neighbouring cells by intercellular spreading
(Suzuki 1994, Carpenter 2013), I sought to determine if VacJ played a similar
role in B. pseudomallei. No significant contribution of VacJ to multinucleated
giant cell formation was observed (Figure 4.10).
Figure 4.9 Intracellular replication of B. pseudomallei K96243 or
ΔBPSL3147 mutant strain in J774A.1 murine macrophage-like cells.
The mean bacterial recoveries (CFU/ml ± SEM) with triplicate measurements are
shown. Bacteria were recovered from lysed J774A.1 cells at 2, 4, 6 and 24 h post
infection (MOI 1) and enumerated by serial dilution onto LB agar. No significant
differences were observed between the strains. Data is representative of two
experiments performed in triplicates.
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Figure 4.10 Multinucleated giant cell formation was observed in
Giemsa-stained J774A.1 cells infected with (i) B. pseudomallei wild type
or (ii) ΔBPSL3147 mutant strain.
(A) The cells were infected at an MOI of 1 for 18 h, stained with Giemsa and viewed
using bright field microscopy. Scale bar = 150 µm. Arrows indicate the
multinucleated giant cell formation. Data is representative of two experiments.
(B) The percentage of MNGC formation (± SEM) was calculated relative to normal
macrophages. MNGCs were defined as cells containing 3 or more nuclei (% MNGC
formation = Number of nuclei in MNGC / Number of normal macrophages x 100).
The error bars represent the standard error of the mean derived from 8 fields of
view. No significant differences were observed between the mean number of
MNGCs in cells infected with the B. pseudomallei wild type or the mutant strain.
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4.3.5 Serum Survival
Since the in vivo attenuated phenotype of the B. pseudomallei VacJ mutant
could not be attributed to an intracellular growth defect, I next investigated
the survival of VacJ mutants in normal human serum (NHS). B. pseudomallei
was previously shown to display resistance to the killing effects of human
serum by virtue of the presence of LPS and the capsule (DeShazer et al.,
1998, Reckseidler-Zenteno et al., 2005, Woodman et al., 2012). The LPS is
absolutely required for complete resistance to serum. While the capsule is
not essential for B. pseudomallei to resist direct killing by human serum, the
presence of a capsule can improve the survival of a serum sensitive strain by
reducing the deposition of complement protein C3 deposition on the bacterial
cell surface (Reckseidler-Zenteno et al., 2005).
B. pseudomallei wild type and mutant strains were incubated in 30 % NHS
for 2 h and then enumerated by plate counting. No viable E. coli were
detected after 2 h incubation in 30 % NHS, demonstrating the killing activity
of NHS. Direct killing of E. coli was not observed in heat-inactivated serum
(Hi-NHS), indicating the mechanism is mediated by heat labile components
in serum (complement) (Figure 4.11). In agreement with previous reports
(Ismail et al., 1988, DeShazer et al., 1998, Reckseidler-Zenteno et al., 2005,
Woodman et al., 2012, Egan and Gordon, 1996), the viability of the B.
pseudomallei K96243 wild type and the capsular mutant 13H8 were
unaffected by the addition of NHS, confirming these strains are resistant to
serum bactericidal activity (Figure 4.11).
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Initial experiments revealed that the B. pseudomallei ΔBPSL3147 mutant
displayed similar viability with the wild type strain in NHS. Since the presence
of a capsule may contribute to serum resistance, I further explored this
phenotype by constructing an acapsular ΔBPSL3147 mutant (13H8
ΔBPSL3147) using a previously characterized B. pseudomallei K96243
mutant 13H8 (Tn5::wcbB) (Cuccui et al., 2007) as the parent strain using
similar methods outlined in section 4.3.1.2, and investigated the survival of
the mutant in NHS.
The acapsular ΔBPSL3147 mutant (13H8 ΔBPSL3147) displayed significant
susceptibility to the serum bactericidal activity and was unaffected by Hi-NHS
(Figure 4.11).
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Figure 4.11 Serum survival assay on B. pseudomallei.
Bacterial strains were incubated for 2 h at 37 ºC with PBS, 30% pooled complement
human serum (30% NHS, Patricell, UK) or heat inactivated NHS (Hi-NHS). Bacterial
colony forming units (CFU/ml) were enumerated by serial dilution and plating onto
LB agar. The bars represent the means ± standard deviation, representative of two
independent experiments (*** p < 0.001 by unpaired t-test comparing means of
bacterial counts).  # No E. coli colonies were recovered after incubation with 30 %
NHS.
4.3.6 Growth inhibition assays
I next examined the role of VacJ in outer membrane stability. The B.
pseudomallei ΔBPSL3147 mutants were tested for survival in the presence
of either EDTA, a chelator of divalent cations which compromises the outer
leaflet by interrupting intermolecular associations between LPS phosphate
groups, or the anionic surfactant sodium dodecyl sulphate (SDS). Both the
wild type and mutant strains displayed similar sensitivity to EDTA, but the B.
pseudomallei ΔBPSL3147 mutants showed an increased sensitivity to SDS
(Figure 4.12), implying a defect in the barrier function.
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Figure 4.12 Membrane stability of B. pseudomallei K96243 and mutant
strains.
Following overnight culture, bacterial dilutions were plated on LB agar in the
presence or absence of (A) 0.025 % SDS or (B) 25 mM EDTA. Viable counts were
obtained after incubation at 37 ºC for 24 – 48 h. Values represent means ± standard
deviation of two independent experiments performed in triplicate (*** p <0.001 by
one-way ANOVA and Bonferroni’s posthoc test).
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4.3.7 Detection of LPS in B. pseudomallei ΔBPSL3147
Bacterial cultures were grown to log phase in LB and collected by
centrifugation. Cells were heat-killed and loaded on a 10 % Bis-Tris gel for
SDS-PAGE. Separated proteins were transferred onto a nitrocellulose
membrane and detected using an anti-LPS monoclonal antibody (MAb) CC6
(Jones et al., 2002). The B. pseudomallei ΔBPSL3147 mutant appeared to
express LPS at similar levels with the wild type (Figure 4.13).
Figure 4.13 Western blot staining LPS from B. pseudomallei strains.
0.2 OD of heat-killed log phase bacterial culture was loaded on a 10 % Bis-Tris gel
(MOPS buffer). The proteins were transferred onto a nitrocellulose membrane and
detected using an anti-LPS monoclonal antibody CC6 (Jones, 2002). The kDa
ladder shows the size of marker proteins. Lane 1: K96243; lane 2: K96243
ΔBPSL3147.
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4.3.8 Protective effects by infection with B. pseudomallei ΔBPSL3147 in
BALB/c mice
The protective efficacy of the B. pseudomallei BPSL3147 mutants was
determined using a BALB/c mouse infection model. Groups of six mice were
dosed i.n. with 500 CFU of B. pseudomallei K96243 VacJ mutants (7A1 or
ΔBPSL3147). After 7 weeks, these mice were challenged with 500 CFU of
wild type B. pseudomallei K96243 (approximately 50 MLD). Six unvaccinated
mice were included as the naïve control group. The median survival time
increased from 4 days in unvaccinated mice to 10 days in mice vaccinated
with 7A1 and 19 days in mice vaccinated with ΔBPSL3147 (Figure 4.14) (p <
0.01 for both mutants), indicating a protective effect by the VacJ mutant.
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Figure 4.14 Protection assay of BALB/c mice vaccinated with B.
pseudomallei VacJ mutants.
Groups of six mice were vaccinated with B. pseudomallei ΔBPSL3147 (Ο, 467 CFU)
or B. pseudomallei 7A1 (□, 450 CFU). At day 45 post vaccination, the mice were
challenged with 500 CFU of wild type B. pseudomallei K96243. Age-matched
unvaccinated mice (x) were included in this study. Median survival time of the
unvaccinated mice, and mice vaccinated with the ΔBPSL3147 or 7A1 mutant strains
were 4 days, 19 days and 10 days respectively. Statistical significance was
determined using the log-rank Mantel-Cox test; ** p < 0.01, * p < 0.05.
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4.4 Discussion
To study and define a given bacterial gene of interest, interruption of the
gene or mutagenesis is typically performed. Typical mutagenesis strategies
include insertional mutation with a selectable cassette (e.g. antibiotic
cassette), or allelic exchange with a modified allele. Insertional mutation can
cause polar effects when frameshift, nonsense or antisense disruption of an
open reading frame (ORF) within an operon affects upstream or downstream
gene expression, or when there is RNA instability (Reyrat et al., 1998). This
could cause confusion in the assignment of the mutant phenotype. To
minimize the polar effects, in-frame deletions using allelic exchange
mutagenesis was demonstrated (Link et al., 1997, Logue et al., 2009). The
double selection strategy for allelic mutagenesis is useful for the construction
of defined unmarked mutants with changes that are usually undetectable,
such as point mutations or in-frame deletions. In the first step, a vector
harbouring the modified allele is integrated into the genome due to a single
crossover, and the clones selected owing to a selectable antibiotic resistance
gene (merodiploids). In the second step, clones that lose the vector due to a
second crossover are selected by plating on a counterselective medium
(Reyrat et al., 1998). Mutants are screened for the loss of the selectable
antibiotic resistance encoded by the vector and confirmed by PCR analysis.
The Bacillus subtilis sacB gene encoding a levansucrase, which catalyses
sucrose hydrolysis and levan extension, is a popular counter-selectable
marker, particularly for the mutagenesis of Gram-negative bacteria. Cloning
of sacB in E. coli and other Gram-negative bacteria leads to the death of the
transformed bacteria when they are plated in the presence of sucrose, owing
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to undefined mechanisms (Gay et al., 1983). Recently, Logue et al. (2009)
has demonstrated the use of sacB as a counterselectable marker for
generating in-frame deletions in B. pseudomallei (Logue et al., 2009). B.
pseudomallei K96243 is naturally sensitive to sucrose, possibly due to
endogenous expression of sacB, and this may circumvent the generation of
sucrose-resistant clones from a merodiploids. However, appropriate
conditions, such as plating at low cell density and extended incubation (> 72
h), aid the excision of the vector with the counterselectable marker (Eberl,
2006). This method has been chosen to generate unmarked, non-polar
deletion mutants in B. pseudomallei and B. thailandensis.
In this study, I investigated the role of the gene bpsl3147 in B. pseudomallei
pathogenesis by constructing unmarked, non-polar mutants with in-frame
deletions. The gene bpsl3147 encodes a lipoprotein that was identified as
important for in vivo virulence and spleen tropism in the acute intranasal
BALB/c mouse infection model (Cuccui et al., 2007). The lipoprotein
BPSL3147 shared significant amino acid similarity to VacJ orthologues in S.
flexneri, E. coli (MlaA) and H. influenzae. Besides contributing to
maintenance of outer membrane stability in these bacteria (Carpenter et al.,
2014, Malinverni and Silhavy, 2009, Nakamura et al., 2011), VacJ is a
virulence factor that contributes to the intercellular spread of S. flexneri
(Suzuki et al., 1994) and serum resistance in non-typeable H. influenzae
(Nakamura et al., 2011). B. pseudomallei encodes another VacJ homologue
(BPSS2331) on chromosome 2, which may provide redundancy in function to
BPSL3147. Unfortunately I was unable to construct a defined mutant for this
gene at this time.
121
The work described here confirmed that the BPSL3147 VacJ lipoprotein
affect B. pseudomallei virulence dramatically, as evidenced by the total
attenuation of the B. pseudomallei VacJ mutants in infected BALB/c mice.
Several possible mechanisms could account for the attenuation of the B.
pseudomallei VacJ mutant in the i.n. infection model. These include (i)
reduced colonization of tissues, (ii) reduced dissemination from the primary
site of infection (lung) or (iii) reduced tissue damage at key sites of infection.
One of the key findings in this study is that the B. pseudomallei VacJ mutant
was able to replicate rapidly and colonize the lungs during the initial phases
of infection (24 h post infection [p.i.]), but was unable to sustain the infection
in lungs by 48 h, resulting in reduced bacterial counts in the lung. In contrast,
the numbers of wild type bacteria present in the lungs increased over the
course of the experiment. Very few bacterial colony forming units of the
mutant strain were detected in the blood or spleens of infected animals, while
the levels of wild type B. pseudomallei became detectable in blood and
spleen by 48 h p.i. These results imply that VacJ is not critical for initial
colonization of the primary site of infection (lungs), but may be important for
sustaining the infection, overcoming host immune cascade responses and/or
dissemination to distal sites of infection (blood, spleen). In future work it
would be interesting to evaluate the host immune response and extent of
tissue damage at key sites of infection.
I next attempted to investigate the specific role of VacJ during intracellular
infections by examining mutants of B. pseudomallei in a tissue culture model.
As previous studies reported that the S. flexneri VacJ mutant showed
impairment in the ability to infect neighbouring cells by intercellular spreading
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(Suzuki et al., 1994, Carpenter et al., 2014), I sought to determine if VacJ
plays a similar role in B. pseudomallei. I found no obvious defect in the VacJ
mutants for any of the major components of the Burkholderia intracellular life
style, including adherence and invasion into A549 lung epithelial cells and
internalization into J774A.1 murine macrophages and intracellular replication.
Moreover, I found no significant contribution of VacJ to multinucleated giant
cell formation, which is dependent on cell-to-cell spread. It is thus likely that
VacJ does not play a critical role in intercellular spreading of B. pseudomallei
during initial phases of in vitro infection. A previous study by Wikraiphat et al.
(Wikraiphat et al., 2009) demonstrated that the presence of the capsule
correlated with enhanced resistance against intracellular killing of B.
pseudomallei such as by antimicrobial peptides and reactive oxygen
intermediates (ROI) in RAW 264.7 mouse macrophage cell line. Thus, the
presence of a capsule may enhance resistance against intracellular killing
and mask any pleiotropic defects in the B. pseudomallei VacJ mutant in the
time points tested.
As I was unable to ascribe the in vivo attenuation of the B. pseudomallei
VacJ mutants to a defect in intracellular replication or survival, I next sought
to investigate other factors that may affect bacterial fitness during
mammalian infection, such as sensitivity to bactericidal activity of human
sera. While the B. pseudomallei VacJ mutant was insensitive to killing by
human sera, I found that a double mutant lacking both VacJ and a functional
polysaccharide capsule displayed sensitivity to human serum. One likely
explanation for this phenotype is that the presence of a capsule contributes
to survival in serum by reducing deposition of the complement factor C3b on
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the bacterial surface (Reckseidler-Zenteno et al., 2005) and may inhibit the
effectiveness of the complement cascade on the B. pseudomallei VacJ
mutant. Previous studies reported the addition of purified capsule increased
the survival of a serum-sensitive B. pseudomallei mutant (Reckseidler-
Zenteno et al., 2005). The complement system plays an integral role in host
innate immune system in killing pathogenic microorganisms (Taylor, 1983,
Rooijakkers and van Strijp, 2007). Activation of the various complement
pathways (classical, lectin and the alternative pathways) are triggered by
various proteins that recognise bacterial ligands, and lead to deposition of
opsonins and/or assembly of pore-forming membrane attack complex (MAC)
on microbial surfaces and bacterial elimination. In order to establish an
infection, many pathogens utilize multiple evasion strategies to control host
complement response and evade opsonophagocytic killing or direct lysis.
These strategies include having the barrier function of the outer membrane
components (Taylor, 1983), binding of complement regulatory proteins,
binding or production of complement inhibitors, and production of proteases
with specificity for complement factors (Blom et al., 2009). Consequently,
these strategies prevents the deposition of complement to critical levels on
the cell surface or influence deposition to non-critical sites such as the
polysaccharide, without affecting the outer membrane (Frank et al., 1987). B.
pseudomallei has been shown to be a potent activator of complement, but is
able to subvert the complement cascade at later time points of infection,
including preventing the MAC from depositing at a microbicidal location on
the bacterial surface (Ismail et al., 1988, Egan and Gordon, 1996, Feingold
et al., 1968). The O-polysaccharide (O-PS) moiety of the B. pseudomallei
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LPS is essential for serum resistance, but the mechanism for resistance to
direct killing by complement is not fully understood (DeShazer et al., 1998,
Woodman et al., 2012). Since the bpsl3147 mutation did not affect the LPS,
it is likely that the VacJ is an additional factor that affects serum resistance,
possibly by affecting the outer surface. Although the serum sensitivity was
only observed in the acapsular 13H8ΔBPSL3147 mutant, complementation
would be required to confirm this phenotype. Given the restrictions on the
introduction of selectable antibiotic cassettes in B. pseudomallei, the choice
of selectable antibiotic resistance markers that can be used in vectors for
complementing the kanamycin-resistant 13H8 ΔBPSL3147 mutant becomes
limited. It may be useful to knockout the capsular genes in the K96243
ΔBPSL3147 mutant using unmarked deletion methods as described above
for further studies.
Compared to wild type, the VacJ mutants have similar sensitivity to EDTA,
but appeared to be more sensitive to the bacteriolytic effect of SDS,
indicating a possible defect in the outer membrane. Typically, EDTA disrupts
the LPS and consequently leads to perturbations of outer membrane
structure and function, and can lead to cell death; while detergents (e.g. SDS)
solubilize cell membrane proteins and lipids and lyse cells. Orthologues of
VacJ have been attributed with a similar function in maintenance of outer
membrane stability, particularly in maintaining the stability of the outer leaflet
by recycling phospholipids from the outer leaflet to the inner leaflet and
determining key characteristics of cell surface (Malinverni and Silhavy, 2009).
VacJ is also attributed to tight packing of the phospholipid surface layer of H.
influenzae, thereby limiting access to oligosaccharide epitopes recognized by
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bactericidal antibodies (Nakamura et al., 2011). Disruption in the outer
membrane may cause pleiotropic effects on presentation of cell surface
antigens, and lead to the differential host immune responses which may
affect bacterial viability. I postulate that mutation of VacJ altered cell surface
characteristics, allowing the MAC to gain access to microbicidal locations on
the bacterial surface. The instability of the outer membrane could also lead to
reduced resistance to other host defence systems such as
opsonophagocytosis (initiated through the binding of opsonins to the
bacterial membrane), antimicrobial peptides (binding to target bacterial
membrane) or intracellular oxidative stress (where free radicals may attack
DNA, RNA, proteins, and polyunsaturated fatty acids in lipids, leading to
complex chain reactions that affect viability). Lipid peroxidation may result in
decrease in membrane fluidity and altered membrane properties, as well as
the degradation of the polyunsaturated fatty acids to aldehydes that can
damage protein molecules (reviewed in (Cabiscol et al., 2000).
With the increasing incidence of B. pseudomallei infections
(Limmathurotsakul et al., 2010a, Currie et al., 2008, Currie et al., 2010) and
its classification as a Tier 1 biological agent by the CDC, there is an urgent
need for a protective vaccine against this organism. The intracellular nature
of B. pseudomallei confers major challenges in vaccine development as
elimination of the pathogen would be highly reliant on the cell-mediated
immune responses (Choh et al., 2013). Live attenuated vaccines have been
used to prevent a number of infectious diseases such as polio and
tuberculosis. They are advantageous over subunit vaccines because of the
wider repertoire of antigens presented to the host, and can stimulate both the
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antibody-mediated and cellular arms of immune responses (Atkins et al.,
2002b, Silva and Dow, 2013). The in vivo phenotypes observed for the B.
pseudomallei VacJ mutant suggest that it has potential as a live vaccine
candidate.I found that vaccination with the B. pseudomallei VacJ mutant
resulted in a significantly increased time to death in mice that were
subsequently challenged i.n. with 50-fold minimal lethal dose of B.
pseudomallei K96243 compared to unvaccinated mice. However, all
vaccinated mice did not acquire sterilizing immunity, eventually succumbed
to infection, and died. To date, some of the investigated B. pseudomallei live
attenuated vaccines such as auxotrophic mutants and the T3SS mutants
have demonstrated significant but incomplete protection from acute
challenge with Burkholderia (reviewed in (Silva and Dow, 2013, Choh et al.,
2013)). Of interest, a capsular mutant did not provide protection against
virulent challenge (Atkins et al., 2002a). Given that the B. pseudomallei VacJ
mutant displayed attenuation of virulence in mice and significant level of
protection against an acute intranasal virulence challenge, there is
considerable scope to optimize this vaccine, and perhaps use it in
combination with conventional antibiotic therapy to promote bacterial
clearance.
To date, development of live attenuated vaccines for B. pseudomallei
involves knockout of a single gene, and there may be major concerns
regarding the reversion of an attenuated strain to wild type strain in the
environment. One alternative approach is to exploit two or more independent
site-specific knockouts using genetic techniques used in this study, but
caution should be taken to ensure there is no over attenuation that may lead
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to reduced immunogenicity (Choh et al., 2013). Ultimately, understanding the
specific mechanisms behind Burkholderia pathogenesis and host-pathogen
interactions will provide a stronger platform for the development of potential
vaccines and antimicrobial agents.
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5. Chapter 5 Characterization of VacJ in Burkholderia
thailandensis
5.1 Introduction
The VacJ lipoprotein (BPSL3147) is an outer membrane protein that is
required for causing in vivo virulence in B. pseudomallei (Cuccui et al., 2007)
(Chapter 4). VacJ was first identified in S. flexneri to be a lipoprotein required
for intercellular spread. It was also found to be required for the maintenance
of outer membrane asymmetry (Mla) in E. coli and in non-typeable H.
influenzae VacJ contributes to serum resistance. In Chapter 3, BTH_I3001
was identified as a VacJ orthologue in B. thailandensis highly similar to
BPSL3147 (92 % amino acid identity). Similar to B. pseudomallei, the
organization of the mla locus surrounding bth_i3001 is preserved (Figure 3.2).
Similar to B. pseudomallei, a second VacJ homologue, BTH_II2351, with 47 %
amino acid identity to BPSL3147, was identified in B. thailandensis. The
genes surrounding bth_ii2351 did not display similarity to the genes from the
mla pathway.
Although B. thailandensis is considered relatively nonpathogenic in humans,
it exhibits similar intracellular life cycles with B. pseudomallei and can cause
fulminant, lethal infections following aerosol challenge of mice (West et al.,
2008). Because of the highly similar and syntenic genome, several studies
used the closely related B. thailandensis as a surrogate to investigate B.
pseudomallei virulence factors, such as T3SS (Haraga et al., 2008, French et
al., 2011, Woodman et al., 2012). The aim of the work described in this
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chapter was to evaluate the role of VacJ in B. thailandensis. The approach
used was construction of unmarked VacJ deletion mutants (ΔBTH_I3001 and
ΔBTH_II2351) in B. thailandensis and characterize the mutants for
phenotypic defects in the infection of cell lines and serum resistance.
5.2 Aims:
1. To generate unmarked, in frame deletions in B. thailandensis E264
2. To characterize the resulting mutants using in vitro methods
5.3 Results
5.3.1 Deletion of Burkholderia thailandensis putative VacJ homologues.
The cloning strategy used to produce the construct for deletion of bth_i3001
and bth_ii2351 was outlined in Figure 4.1. Primers were designed for
performing splicing by overlapping extension PCR (SOE PCR), with
engineered restriction sites (Chapter 2). Upstream and downstream flanking
regions of bth_i3001 or bth_ii2351 were PCR-amplified from B. thailandensis
E264 genomic DNA. For each gene, PCR products were used as the
template in a subsequent PCR to produce a spliced DNA fragment
(mutagenesis cassette). The mutagenesis cassette was cloned into pGEM-T
Easy vector or pJET1.2 and the insert confirmed by nucleotide sequencing.
The mutagenesis cassette was subcloned into the lambda (λ) pir dependent
vector pDM4. E. coli MFD colonies containing the deletion construct were
confirmed by PCR and nucleotide sequencing of the insert DNA.
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5.3.2 Mutant production
The mutagenesis strategy is outlined in Figure 4.2 (Logue et al., 2009). For
mobilization of the pDM4 deletion construct into B. thailandensis by
conjugation, overnight cultures of E. coli and B. thailandensis strains were
spotted together on LB agar and grown overnight at 37°C. The first cross-
over event resulted in the integration of the deletion construct into the host
chromosome by homologous recombination. Integrants (merodiploids) were
identified on LB agar containing chloroamphenicol (30 μg/ml) and confirmed
by colony PCR.
A single integrant colony (merodiploid) was subcultured and plated on the
counter-selective sucrose agar for selection of clones that underwent the
second cross over event. Clones were screened for loss of chloramphenicol
resistance and a deletion of the target gene by PCR analysis and
sequencing. Sequencing results confirmed a 969 bp and 1038 bp in-frame
deletion in the bth_i3001 and bth_ii2351 alleles respectively (Figure 5.1 to
5.4). The mutant strains are named B. thailandensis E264 ΔBTH_I3001 and
B. thailandensis E264 ΔBTH_II2351.
Using similar methods outlined above, a double mutant (ΔBTH_I3001
ΔBTH_II2351) was generated using the B. thailandensis E264 ΔBTH_II2351
as the parent strain. The mutant strain is named B. thailandensis E264 DB.
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Figure 5.1 Screening for B. thailandensis deletion mutant (E264
ΔBTH_I3001).
Screening by multiplex PCR (I3001 MX) was performed using primers
pDM4_seqF, VacJ seqR3, BT_VacJ_L, BT_VacJ_R. After subjecting the
merodiploid to the sucrose selection method, resultant Cm-sensitive colonies
were screened via PCR for the absence of deletion construct DNA (117 bp
and 462 bp) and the presence of a smaller PCR product that indicates the
deletion of the target gene (mutant = 117 bp, wild type = 1086 bp).
Figure 5.2 Sequence of the B. thailandensis E264 ΔBTH_I3001 mutant
surrounding the deleted region.
The sequence in grey indicates the predicted intergenic regions where the
deletion was made.
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Figure 5.3 Screening for B. thailandensis deletion mutant
(E264ΔBTH_II2351).
Screening by multiplex PCR (II 2351 MX) was performed using primers
pDM4_seqF, VacJ2 seqR2, BT_VacJ2_L, BT_VacJ2_R. After subjecting the
merodiploid to the sucrose selection method, resultant Cm-sensitive colonies
were screened via PCR for the absence of deletion construct DNA (65 bp,
315 bp and 726 bp) and the presence of a smaller PCR product that
indicates the deletion of the target gene (mutant = 65 bp, wild type = 1103
bp).
Figure 5.4 Sequence of the B. thailandensis ΔBTH_II2351 mutant
surrounding the deleted region.
The sequence in grey indicates the predicted intergenic regions where the
deletion was made.
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5.3.3 Complementation of mutant strain
The gene bth_i3001 was PCR amplified from B. thailandensis E264 using
primers 3001-DN-KpnI and 3001-UP-ApaI (with engineered restriction sites)
(Chapter 2, Section 2.7), and cloned into multiple cloning site of pUT-mini-
Tn5 Km2 at the ApaI and KpnI sites. The gene was excised from the vector
at the KpnI and EcoRI sites and ligated into the shuttle vector pME6032 or
pMEK (pME6032-derivative, Appendix). Ligations were transformed into E.
coli Top10 and plated onto selective LB agar containing 50 µg/ml tetracycline
(pME6032) or 400 µg/ml kanamycin (pMEK). Colonies containing the correct
construct were confirmed by restriction digest, PCR and nucleotide
sequencing.
The complementation construct was transferred to B. thailandensis
ΔBTH_I3001 by electrotransformation using methods outlined in Choi et al.
(2006) (Choi et al., 2006). Briefly, electrocompetent B. thailandensis cells
were prepared by washing cells twice in 300 mM sucrose solution at room
temperature before use. Mutant bacteria containing the complementation
plasmid were plated onto selective agar containing the appropriate antibiotics.
Expression of BTH_I3001 was induced by addition of 0.25 mM IPTG to
bacterial broth cultures. The complemented mutant was named B.
thailandensis ΔBTH_I3001 +pME VacJBT or B. thailandensis ΔBTH_I3001
+pMEK VacJBT.
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5.3.4 Growth in media
The growth rate of B. thailandensis ΔBTH_I3001 and the double VacJ
mutant B. thailandensis DB (ΔBTH_I3001 ΔBTH_II2351) was determined in
liquid media. Deletion of bth_i3001 or both bth_i3001 and bth_ii2351 did not
result in restricted growth in LB media (Figure 5.5).
Figure 5.5 Growth curves of B. thailandensis wild type and VacJ
mutants in LB broth at 37°C.
Growth was monitored by viable counts or absorbance at 590 nm over 12 h.
Values are from a single experiment performed in triplicates.
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5.3.5 Serum survival
VacJ plays a role in serum resistance in non-typeable H. influenzae
(acapsular) (Nakamura et al., 2011). To investigate the role of VacJ in B.
thailandensis in serum resistance, wild type and mutant strains were
incubated in 30 % normal human serum (NHS) for 2 h and then enumerated
by plate counting. For plasmid-complemented mutants, 0.25 mM IPTG was
added for induction of VacJ expression. No viable E. coli were detected after
2 h incubation in 30 % NHS, demonstrating the killing activity of NHS.
In agreement with previous reports (Ismail et al., 1988, DeShazer et al., 1998,
Reckseidler-Zenteno et al., 2005, Woodman et al., 2012, Egan and Gordon,
1996), the viability of the B. thailandensis wild type was unaffected by the
addition of NHS, confirming the inherent resistance to serum bactericidal
activity (Fig. 5.6). In contrast, the VacJ mutants (ΔBTH_I3001 and DB)
displayed significant susceptibility to the bactericidal effects of human serum.
For the ΔBTH_I3001 mutant, there was a one-log decrease in colony-forming
units upon incubation with NHS. The serum resistance phenotype was
restored in the complemented mutant (ΔBTH_I3001+pMEKVacJBT). For the
double VacJ mutant (DB), the serum susceptibility is much more pronounced,
as no bacteria were recovered after incubation with 30 % NHS. The double
mutant complemented with pMEKVacJBT displayed a partial restoration of
the serum resistance phenotype. Direct killing of E. coli and B. thailandensis
mutants was not observed in heat-inactivated serum (Hi-NHS), indicating the
mechanism is mediated by heat labile components in serum (complement)
(Figure 5.6).
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As the LPS of the ΔBTH_I3001 mutant did not appear to be altered as the
mutant was able to bind to anti-LPS antibodies (Figures 5.9-5.11), it is likely
that VacJ is an additional factor that affects serum resistance. This is
analogous to the phenotype observed in the acapsular B. pseudomallei VacJ
mutant. Interestingly, the double VacJ mutant (E264 DB) was more
pronounced in susceptibility to bactericidal effects of human serum. A further
investigation revealed that while the wild type and the ΔBTH_I3001 mutant
remained resistant to polymyxin B up to 128 mg/ml, the double VacJ mutant
was less resistant to polymyxin B (MIC: 32 mg/ml, Table 5.1). Polymyxin B
acts like cationic detergents, interacts with the lipopolysaccharide of the
cytoplasmic outer membrane of Gram-negative bacteria (Zavascki et al.,
2007), or inhibits respiratory enzymes in the bacterial inner membrane (Deris
et al., 2014), altering membrane permeability and causing cell death.
Expression of BTH_I3001 in E264 DB did not complement the polymyxin B
resistance phenotype.
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Figure 5.6 Serum survival assay for B. thailandensis.
Bacteria was incubated for 2 h at 37 ºC with PBS, 30 % pooled complement
human serum (30% NHS, Patricell, UK) or heat inactivated NHS (HiNHS).
Bacterial colony forming units (CFU) were enumerated by serial dilution and
plating onto LB agar. (A) The bars represent the mean values from three
separate experiments ± standard deviation, each carried out in duplicates.
Bacterial counts for the strains incubated with heat-inactivated NHS were
similar to that of the PBS control. (B) The bars represent the mean values
from an experiment carried out in triplicate ± standard deviation. **** p <
0.0001 by unpaired Student’s t-test comparing means of bacterial counts. #
No colonies were recovered after incubation with 30% NHS (limit of detection
100 CFU / ml).
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Table 5.1 Minimal inhibitory concentration (MIC) of antibiotics on B.
thailandensis
Antibiotic E264 ΔBTH_I3001 DB ΔBTHI_3001
+ pMEK
VacJBT
DB
+ pMEK
VacJBT
Polymyxin B
(mg/ml)
>128 >128 32 >128 32
Ceftazidime
(µg/ml)
2 2 2 2 2
5.3.6 Infection of mammalian cell lines
Similar to B. pseudomallei, B. thailandensis can survive and replicate in a
range of cell lines and adopt an intracellular life cycle (Jones 1996, Harley
1998). To determine if VacJ is required for intracellular growth and survival, I
compared the B. thailandensis ΔBTH_I3001 mutant to the wild type strain for
their abilities to invade, replicate and spread within cultured cell monolayers.
5.3.6.1 Growth in J774 macrophages
J774A.1 murine macrophages were infected with B. thailandensis E264 wild
type or ΔBTH_I3001 mutant strains at MOI of 10. After incubation for 1 h to
allow uptake of bacteria, extracellular bacteria were killed with 250 µg/ml
kanamycin. Infected cells were lysed at different time points and the number
of viable bacteria within the cells was determined (Figure 5.7).
Following infection of J774A.1 macrophages with the wild type B.
thailandensis E264 or the B. thailandensis ΔBTH_I3001 mutant, both strains
were taken up into the cell in similar numbers (Figure 5.7a). There were no
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significant differences in the invasion and the intracellular replication of the
mutant strain in J774A.1 macrophages up to 12 h post-infection. However, at
24 h post infection, there were 7-fold fewer mutant bacteria present when
compared to the wild type strain (Figure 5.7b, p < 0.001). The plasmid-
complemented mutant displayed partial restoration of the intracellular
survival phenotype at 24 h post infection (Figure 5.7b, p < 0.011 when
compared to the wild type strain).
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Figure 5.7 Intracellular replication of B. thailandensis E264 wild type or
the ΔBTH_I3001 mutant strain in J774A.1 macrophages.
Cells were incubated with bacteria for 1 h at an MOI of 10, after which the
monolayers were washed and kanamycin (250 µg/ml) was added to the
media to suppress the growth of extracellular bacteria. Intracellular bacterial
numbers were determined at (A) 2, 4, 6, 8, 12 and 24 h after infection. Each
bar represents the mean values from triplicate experiments ± standard errors.
(B) Cells were infected with B. thailandensis E264 wild type, ΔBTH_I3001
mutant or complemented mutant (ΔBTH_I3001 + pMEVacJBT). Values
shown are mean values ± standard errors from a single experiment
performed in triplicates.
The asterisk indicates that the data differs significantly from the wild type
strain (***: p < 0.001 by Student’s t-test).
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5.3.6.2 Adherence to A549 epithelial cells
The A549 human epithelial cell lines were infected with B. thailandensis
E264 wild type or B. thailandensis mutants (ΔBTH_I3001 and DB) at MOI of
5. At 2 h post infection, infected cells were lysed and the number of viable
bacteria within the cells was determined (Figure 5.8). There were no
significant differences between the wild type strain and the VacJ mutants for
adherence into A549 epithelial cells.
Figure 5.8 Adherence of A549 epithelial cells by B. thailandensis wild
type or VacJ mutants (ΔBTH_I3001 and DB).
The mean bacterial recoveries (CFU/ml) ± standard error of mean (SEM) at 2
h post infection (MOI 5) are shown. Data is representative of 2 experiments,
performed in duplicates. No significant differences were observed between
the strains (One-way ANOVA).
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5.3.6.3 Escape from endocytic vacuoles, evasion of autophagy and
actin polymerization
The defect in intracellular survival of the B. thailandensis ΔBTH_I3001
mutant may be associated with the intracellular behaviour of the bacteria.
Following invasion, B. thailandensis escapes from endocytic vesicles by
lysing endosome membranes and avoid degradation through the lysosomal
system (Harley et al., 1998, Haraga et al., 2008). The bacteria avoid host
autophagic attack, where a portion of cytoplasm becomes enclosed within an
isolation membrane (phagophore), generating a double membrane vesicle
(autophagosome) that subsequently fuses with endosome and lysosome,
targeting the contents for degradation (Ravikumar et al., 2010). B.
pseudomallei and B. thailandensis are able to induce cellular actin
rearrangement and membrane protrusions for intracellular and intercellular
motility (Kespichayawattana et al., 2000, French et al., 2011).
J774A.1 murine macrophages were infected with B. thailandensis E264 wild
type or ΔBTH_I3001 mutant strains as described before and the co-
localization with mammalian cell markers was examined. The cells were
fixed at 6 h post infection and observed using confocal microscopy for
bacterial association with the lysosome marker, LAMP-1 (lysosome-
associated membrane glycoprotein-1) (Figure 5.9) and the autophagy marker
LC3b (microtubule-associated protein 1A/1B-light chain 3) (Figure 5.10). LC3
recruitment to phagosomes stimulates bacterial killing (D'Cruze et al., 2011).
The results showed that both the intracellular wild type and ΔBTH_I3001
mutant strain were rarely associated with the LAMP-1 or the LC3b in
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J774A.1 cells at 6 h post infection, indicating both strains possess similar
abilities to evade the host lysosomal and autophagic degradation system.
At 8 h post infection, cells were fixed and observed using fluorescence
microscopy for bacterial association with filamentous actin (F-actin) (Figure
5.11). Both the B. thailandensis wild type and ΔBTH_I3001 mutant formed
typical actin tails at one pole of the bacterium, an indication of successful
escape from endosomes. The bacteria also appeared to be forming
membrane protrusions for intercellular spread. This demonstrates that VacJ
was not involved in actin-based motility.
5.3.6.4 Multinucleated giant cell (MNGC) formation
Like B. pseudomallei and B. mallei, B. thailandensis is able to induce cell
fusion and the production of MNGCs for the spread of bacteria from cell-to-
cell (Harley et al., 1998, Kespichayawattana et al., 2000, Wand et al., 2011,
French et al., 2011). A cell was considered to be a MNGC if there were three
or more nuclei present. The ability of the bacteria to induce MNGC formation
is predicted to be important for the evasion of host immune responses,
persistence of B. pseudomallei within host or even access to nutrients in
uninfected macrophages (Galyov et al., 2010, Burtnick et al., 2011).
At 8 h post infection, MNGC formation was observed in J774A.1 murine
macrophages infected with either the wild type or mutant B. thailandensis
(Figure 5.12). Giemsa staining of infected macrophages was performed to
assess the level of MNGC formation at later time points. At 16 h post
infection, large multinucleated giant cell formation (> 20 nuclei) was observed
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in macrophages infected by wild type B. thailandensis E264, while numerous
but smaller giant cells (fewer nuclei) were observed in those infected by the
B. thailandensis ΔBTH_I3001 mutant. The ΔBTH_I3001 mutant was less
able to form giant cells at 16 h post infection, but the level of MNGC
formation increased by 24 h post infection.
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Figure 5.9 Association of intracellular B. thailandensis with LAMP-1.
Confocal micrographs showing the association of intracellular B.
thailandensis wild type or the ΔBTH_I3001 mutant strain with vesicles
containing LAMP-1 in J774A.1 cells 6 h post infection (MOI 10). Bacteria
were stained with MAb anti-B. pseudomallei LPS (CC6) and anti-mouse Ig-
Alexa Fluor488 (green). LAMP-1 was labelled with rat anti-LAMP-1 (ID4B)
and anti-rat Ig-Cy5 (red) antibodies (magnification x630). Extracellular
bacteria were killed with kanamycin and removed by extensive washing
before staining. Bacteria were confirmed to be located in an intracellular
niche by viewing optical sections above and below the plane of focus. The
wild type and ΔBTH_I3001 mutant bacteria were rarely seen in association
with regions of LAMP-1 labelling.
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Figure 5.10 Association of intracellular B. thailandensis with autophagy
marker LC3b.
Confocal micrographs showing the association of intracellular B.
thailandensis wild type or the ΔBTH_I3001 mutant strain with the autophagy
marker protein LC3b in J774A.1 cells 6 h post infection (MOI 10). Bacteria
were stained with MAb anti-B. pseudomallei LPS (CC6) and anti-mouse Ig-
Alexa Fluor488 (green). LC3b was stained with rabbit anti-LC3b and anti-
rabbit Ig-AlexaFluor594 (red) (magnification x630). Extracellular bacteria
were killed with kanamycin and removed by extensive washing before
staining. The wild type and ΔBTH_I3001 mutant bacteria were rarely seen in
association with regions of LC3b staining.
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Figure 5.11 Association of B. thailandensis with F-actin.
Visualization of actin tail polymerization by B. thailandensis strains using
fluorescence light microscopy. J774A.1 macrophages were infected with (a)
B. thailandensis E264 or (b) ΔBTH_I3001 mutant for 8 h at an MOI of 10.
Bacteria were stained for LPS with MAb CC6 and anti-mouse Ig-Alexa
Fluor488 (green). Filamentous actin (F-actin) was labeled with Alexa Fluor
555-conjugated phalloidin (red). Mammalian cell nuclei were stained using
DAPI. Scale bars: 14 µm.
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Figure 5.12 MNGC formation in J774A.1 murine macrophages.
Cells were (A) mock-infected or infected with (B) B. thailandensis E264 or (C) the
BTH_I3001 mutant at an MOI of 10 for 16 h and stained with Giemsa. Arrows
indicate the multinucleated giant cell formation (MNGC) containing three or more
nuclei. Scale bars = 70 µm. The micrographs are representative of two independent
experiments. (D) The percentage of MNGCs was calculated relative to normal
macrophages at 16 h and 24 h post-infection. The error bars represent the standard
error of the mean derived from at least nine fields of view at 10 x magnification.
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5.4 Discussion
B. thailandensis share extensive genome similarity with B. pseudomallei and
exhibits a similar intracellular lifestyle (Kim et al., 2005b, Yu et al., 2006).
Although B. thailandensis is able to cause lethal inhalational infections in
mice at high doses (≥ 3 x 104 CFU deposited / lung) (West et al., 2008), it is
considered as relatively avirulent in human and it rarely causes human
disease (Lertpatanasuwun et al., 1999, Glass et al., 2006). Because of the
relative avirulence of B. thailandensis, the containment requirements are
much less stringent than that for B. pseudomallei, rendering it more
accessible for manipulation in the laboratory setting. Several studies have
used B. thailandensis as a surrogate model system to investigate various
aspects of B. pseudomallei biology (Haraga et al., 2008, Chandler et al.,
2009). However, it is important to consider the differences between the two
species before extrapolating the data to B. pseudomallei (French et al.,
2011).
B. thailandensis E264 genome encodes many orthologues of known and
putative B. pseudomallei virulence determinants, including the VacJ
orthologue, BPSL3147. BPSL3147 was shown to be required for in vivo
virulence and share homology with S. flexneri VacJ, E. coli MlaA and H.
influenzae VacJ. Similar to that in B. pseudomallei, orthologues to genes
encoding the Mla proteins in E. coli are found in close proximity to bth_i3001.
Like B. pseudomallei, a second vacJ homologue is found in chromosome 2
of B. thailandensis E264 (bth_ii2351).
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In this study, unmarked in-frame VacJ deletion mutants of B. thailandensis
E264 were constructed using a similar strategy for making deletion mutants
in B. pseudomallei (Logue et al., 2009). Using the deletion mutants, I
investigated factors that could affect bacterial fitness during mammalian
infection, such as sensitivity to human sera. The B. thailandensis VacJ
mutants displayed reduced serum resistance compared to the wild type
strain. The complement system plays an integral role in host innate immune
system in killing pathogenic microorganisms. Activation of the various
complement pathways (classical, lectin, and the alternative pathways) are
triggered by various proteins that recognise bacterial ligands, and lead to the
deposition of opsonins and/or assembly of pore-forming membrane attack
complex (MAC) on microbial surfaces and lead to bacterial elimination. The
O-polysaccharide (O-PS) moiety of the B. pseudomallei LPS is essential for
outer membrane integrity and complete serum resistance, although the
mechanism for resistance to direct killing by complement is not fully
understood (DeShazer et al., 1998, Reckseidler-Zenteno et al., 2005,
Woodman et al., 2012). It was suggested that B. thailandensis could display
similar serum-resistance mechanisms with B. pseudomallei because of the
similarities in the O-PS structure (Woodman et al., 2012). Since the
BTH_I3001 mutation did not affect the LPS, it is likely that VacJ is a novel
factor that affects serum resistance. Interestingly, a double knockout mutant
(B. thailandensis DB) displayed complete susceptibility to bactericidal effects
of human serum and partial serum resistance can be restored with a trans-
complementation of bth_i3001. It is possible that the knockout of the vacJ
homologue (bth_ii2351) affected the LPS; contributing to a defect in
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resistance to serum and polymyxin B. Future work to complement both
genes in the double mutant would help to elucidate the function of both vacJ
genes in B. thailandensis.
During in vitro infections, the B. thailandensis ΔBTH_I3001 mutant did not
display any defects for invasion of epithelial cells or uptake by macrophages,
and was able to replicate intracellularly during initial phases of infection.
However, the same ΔBTH_I3001 mutant exhibited reduced intracellular
numbers in J774A.1 macrophages after 24 h. This could be due to an
intracellular bacterial growth defect at later time point, an inability to
overcome host intracellular defence mechanisms, or due to the destruction of
the macrophage monolayer at late time points, resulting in less intracellular
bacteria numbers. A cytotoxicity test, such as measurement of the lactate
dehydrogenase (LDH), should be used to rule out the latter possibility.
The number of bacteria at the initial time points post infection was similar for
both the B. thailandensis E264 wild type and the ΔBTH_I3001 mutant, so the
distinct phenotypes could not be explained by differences in its uptake by
phagocytes, indicating that BTH_I3001 may be involved in other intracellular
events by modulating the phagocytic compartment.
In B. pseudomallei and B. thailandensis, the T3SS is associated with escape
from the endosome, which influences downstream events such as cell fusion
and intercellular spread and replication (Haraga et al., 2008, French et al.,
2011). The T6SS-1 functions downstream of invasion and endosome escape,
and facilitate intercellular spread by fusing cell membranes or killing cells by
compromising membrane integrity. Both the wild type and the ΔBTH_I3001
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mutant escaped from vacuoles, formed actin tails and induced MNGC
formation. However, at later time points of infection, the ability for the
ΔBTH_I3001 mutant to form giant cells appeared to be delayed. This may
have contributed to the reduced intracellular growth at later time points of
infection due to the delayed ability to access nutrient rich, uninfected
macrophages through cell-to-cell spread and fusion. The mechanisms
behind the delayed ability for giant cell formation by the B. thailandensis vacJ
mutant remain to be elucidated. In S. flexneri, the vacJ mutant has a
defective outer membrane, was able to spread within the cytoplasm of the
primary infected epithelial cells, but was less efficient in its release from
vacuoles after cell-to-cell spread (Suzuki et al., 1994, Carpenter et al., 2014).
Although the mechanisms by which the VacJ protein functions for Shigella
intercellular spread remains to be elucidated, Carpenter et al. hypothesized
that the outer membrane protein may act in one or more ways, including:
assembly of the T3SS in the membrane, the secretion of effector proteins of
intracellular bacteria or the signalling activities via the proposed ABC
transporter activity for the eventual lysis of vacuoles (Carpenter et al., 2014).
Since no defect is observed in the escape from endosomes, it is unlikely that
VacJ affects the T3SS. It is possible that VacJ affects the assembly of T6SS
or secretion of T6SS effectors that affects cell fusion. Alternatively, the
mutation of BTH_I3001 may result in alteration of outer membrane properties
such as presentation of cell surface antigens that lead to differential host
immune responses which may affect bacterial viability, or reduced resistance
to other host defence mechanisms such as antimicrobial peptides.
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In conclusion, a VacJ orthologue, encoded by bth_i3001, represents a novel
virulence determinant in B. thailandensis. Like the non-typeable H.
influenzae), inactivation of vacJ increased sensitivity to human serum,
suggesting a defect in outer membrane and resistance to complement
deposition. This phenotype is similar to that of the acapsular B. pseudomallei
VacJ mutant (ΔBPSL3147). The presence of a second vacJ homologue in
both Burkholderia species suggests there may be functional redundancy, as
highlighted in the serum sensitivity assay. The ΔBTH_I3001 mutant exhibited
reduced survival and MNGC formation in macrophages during late
intracellular events. These intracellular defects were not observed in the
ΔBPSL3147 mutant in B. pseudomallei, which highlights the need for caution
in extrapolating data derived with B. thailandensis for B. pseudomallei. The
difference in observed phenotypes for serum resistance and intracellular
fitness may be due to the presence of the capsule in B. pseudomallei or
other inherent differences between the two strains.
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Chapter 6 – General Discussion and Future Work
With the emergence of melioidosis cases around the world (Currie 2008),
there is a growing need to better understand the nature of pathogenesis of B.
pseudomallei in order to devise rational strategies for the treatment of this
disease. Currently there is no vaccine available against melioidosis and the
infections can be difficult to treat due to the resistance of the bacteria to
multiple antibiotics and the ever-changing nature of disease manifestations
(Cheng 2005). The development of new vaccines and antimicrobials will
benefit from a more thorough understanding of mechanisms of resistance. A
key first step in this process would involve the identification of novel virulence
determinants, followed by further characterization for the basis of virulence
and function (Wu et al., 2008).
Some strategies for the large scale screening for novel virulence
determinants in B. pseudomallei have been developed (Atkins et al., 2002a,
Cuccui et al., 2007, Moule et al., 2014). In a study that screened for
transposon mutants defective for intercellular spreading, genes involved in
the purine, histidine and para-aminobenzoate biosynthetic pathways were
found to be important for intracellular replication and survival, which leads to
intercellular spread (Pilatz et al., 2006).  In a signature tagged mutagenesis
(STM) screen comparing microarray signals from mutant pools before and
after mice infection, genes involved in amino acid synthesis pathway (aroB),
capsular polysaccharide synthesis (wcbC) and putative lipoprotein VacJ
(bpsl3147) were identified to be important for in vivo virulence (Cuccui et al.,
2007). The attenuation of the aroB and wcbC mutants was confirmed in a
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separate mouse infection experiment (Cuccui et al., 2007). The capsular
polysaccharide has been shown to be important for virulence and contributes
to serum resistance (DeShazer et al., 1998, Woodman et al., 2012). A
TraDIS experiment that resequenced the STM library (Cuccui et al., 2007)
provided a quantitative measure of fitness scores, and revealed the
attenuation of in vivo virulence for these mutants (Moule and Cuccui,
unpublished data, Chapter 3). Lipoproteins may play diverse roles, including
those in pathogenesis (Kovacs-Simon et al., 2011). The correlation of the
VacJ lipoprotein to in vivo virulence presented a novel opportunity to
investigate the role of this putative lipoprotein in B. pseudomallei
pathogenesis. The putative lipoprotein VacJ (BPSL3147) identified by Cuccui
et al. 2007 was further studied and became the focus of the present thesis.
The role of VacJ in B. pseudomallei was evaluated in Chapter 4 by
construction of a deletion mutation in bpsl3147. In this work, I had first
validated the attenuation of the ΔBPSL3147 mutant by infecting mice with
the transposon mutant 7A1 and a defined, non-polar deletion mutant
(K96243 ΔBPSL3147), and showed that both mutants were attenuated in
mice. I then investigated the kinetics of infection of the deletion mutant
(K96243 ΔBPSL3147) and found that the mutant was able to replicate to
wild-type levels in mice lungs within the first day, but was unable to sustain
the infection beyond day 2 of infection.
I hypothesized that the attenuation of the VacJ mutant may be due to a
defect in intercellular spreading, serum resistance and/or outer membrane
stability as observed in similar mutants of other bacteria (Suzuki et al., 1994,
Malinverni and Silhavy, 2009, Nakamura et al., 2011). As B. pseudomallei is
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considered as an ACDP category three pathogen which requires strict
biocontainment conditions, I have also constructed VacJ deletion mutants in
the relatively avirulent B. thailandensis as an accessible surrogate to model
melioidosis (West et al., 2008, Haraga et al., 2008) (Chapter 5).
Reminiscent of the S. flexneri VacJ mutant (Carpenter et al., 2014, Suzuki et
al., 1994), the B. thailandensis ΔBTH_I3001 mutant was able to escape from
the endosomes, polymerise actin and replicate intracellularly (Chapter 5).
The B. thailandensis ΔBTH_I3001 appeared to have a defect in intercellular
spread, as evidenced by the delay in MNGC formation (Chapter 5). In
contrast, I found no obvious defect in the B. pseudomallei K96243
ΔBPSL3147 mutant for the major components of the Burkholderia
intracellular lifestyle, including invasion, intracellular survival, and MNGC
formation (Chapter 4).
To spread intercellularly, S. flexneri propels itself via actin polymerization
through the host cytoplasm and into a protrusion of a double membrane
barrier, forming a vacuole between two host cells. It would then lyse the
vacuole in the recipient cell, where the intracellular lifecycle repeats. The S.
flexneri VacJ mutant was less able to lyse the double membrane vacuole
through undefined mechanisms (Suzuki et al., 1994, Carpenter et al., 2014).
Although B. pseudomallei and B. thailandensis exhibit cytoplasmic motility
which promotes contact with cell membranes and formation of membranous
protrusions (Stevens et al., 2006, Galyov et al., 2010), several studies
proposed that the primary mechanism of cell-to-cell spread involves cell
fusion mediated by the activity of a T6SS, leading to the formation of MNGCs
(Burtnick et al., 2011, French et al., 2011, Toesca et al., 2014). The
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underlying mechanisms behind the delayed MNGC formation and defective
intracellular survival of the B. thailandensis ΔBTH_I3001 mutant remain
unclear as there was no apparent defect in the early stages of the
intracellular cycle, including uptake, escape from endosomes, and actin
polymerization. Mutation of BTH_I3001 may have affected the proper
assembly of the T6SS, or the timing of secretion of the effector proteins,
which in turn, can influence the fusogenic properties of B. thailandensis.
Alternatively, the B. thailandensis ΔBTH_I3001 mutant may have a defect in
escape from the double membrane vacuole following cell-to-cell spread via
membranous protrusions, but retains fusogenic activity. A third hypothesis is
that mutation of BTH_I3001 affects the bacterial outer membrane, which may
result in the alteration of presentation of cell surface antigens to the host
immune system, or may render the bacteria less resistant against host
defence mechanisms such as antimicrobial peptides. The difference in
intracellular phenotypes between the B. pseudomallei and B. thailandensis
VacJ mutants may be due to the presence of a capsule in B. pseudomallei,
which may contribute to resistance against intracellular killing (Wikraiphat et
al., 2009). The intracellular survival defect in the B. thailandensis
ΔBTH_I3001 mutant may be due to increased susceptibility to intracellular
killing or the delayed ability to access nutrient rich macrophages through
fusion and cell-to-cell spread. This study also highlights the risk of using B.
thailandensis as a surrogate for studying melioidosis.
In consideration of future work, studies could involve construction of an
unmarked, acapsular B. pseudomallei VacJ (BPSL3147) mutant or a VacJ
mutant using the capsular B. thailandensis E555 (Sim et al., 2010) as a
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parent strain for comparison of intracellular phenotypes. It would be
interesting to determine if the VacJ mutants elicit any differential host
responses, such as reactive oxygen species (ROS) production or
immunological markers, which may contribute to intracellular killing and
clearance of bacteria.
Serum resistance, a complex phenotype determined by multiple elements, is
an important virulence trait that allows the evasion of the host innate
immunity mechanisms. A recent paper identified 56 genes in the serum
resistome of an uropathogenic E. coli EC958 using TraDIS (Phan et al.,
2013). The gene list included those involved in LPS biosynthesis (O-antigen
and lipid A core biosynthesis), as well as those encoding lipoproteins,
membrane proteins, regulators and hypothetical proteins. Although the LPS
(lipid A core and O-antigen) was crucial for serum resistance in E. coli
EC958, non-LPS genes such as lpp (encodes murein lipoprotein), bamB
(encodes BamB lipoprotein), genes encoding for proteins that make up the
Tol-Pal system (for maintenance of the outer membrane integrity) were also
important for serum resistance. For B. pseudomallei, the LPS and the
capsule contributes to serum resistance, with the former absolutely required
for complete resistance (DeShazer et al., 1998, Reckseidler-Zenteno et al.,
2005, Woodman et al., 2012).  Woodman et al. (2012) suggested that the
LPS attracts C3 deposition but does not allow membrane attack complex
(MAC) formation, and the similarity in the O-antigen of B. pseudomallei and
B. thailandensis may represent a common serum-resistance mechanism
between these closely related species (Woodman et al., 2012). As
demonstrated with the presence of non-LPS genes in the serum resistome of
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the uropathogenic E. coli, it is likely that there are other factors that
contribute to evasion of complement-mediated lysis in B. pseudomallei and B.
thailandensis.
One major finding of this work is that VacJ affects the resistance of B.
pseudomallei and B. thailandensis to human serum. In this work, I have
shown that the B. thailandensis VacJ mutant (E264 ΔBTH_I3001), but not
the B. pseudomallei VacJ mutant (K96243 ΔBPSL3147), was susceptible to
human serum. I hypothesized this was due to the presence of a capsule in B.
pseudomallei, which may reduce complement deposition on the bacterium’s
surface (Reckseidler-Zenteno et al., 2005), and shown that an acapsular B.
pseudomallei VacJ mutant (13H8 ΔBPSL3147) was susceptible to human
serum. This finding also emphasizes the importance of the capsule in
contributing to serum resistance. In future work to confirm the serum
sensitive phenotype of the acapsular B. pseudomallei VacJ mutant, an
unmarked double mutant with the deletion of the capsule could be
constructed in the B. pseudomallei, and complemented by introduction of a
wild type copy of bpsl3147. Alternatively, purified preparations of BPSL3147
may be added to the serum killing assay to determine if the presence of
BPSL3147 increases the survival of 13H8ΔBPSL3147.
The disruption of both VacJ homologues in B. thailandensis resulted in
complete susceptibility to serum, suggesting that VacJ is a novel determinant
for serum resistance, particularly for B. thailandensis. Future work could
include characterizing the double VacJ mutant in B. thailandensis, such as
examination of the LPS profile and pathogenesis. A double mutant with
disruptions to both vacJ homologues in B. pseudomallei was not constructed
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at this point. Alternative strategies such as construction of conditional
mutants may be employed for future work (Moule et al., 2014).
Future studies could investigate the specific mechanisms by which VacJ
functions in B. pseudomallei and B. thailandensis. For example, the
predominant pathways by which VacJ mutants affect C3 deposition and
activate the complement system may be examined. Since deletion of
BPSL3147 affects the outer membrane stability (Chapter 4), future work
could involve examination of the outer membrane characteristics of the
mutant strains, such as surface hydrophobicity (through the measurement of
the rate of uptake of membrane permeant 1-N-phenylnaphthylamine (NPN)),
and comparison of amounts of surface phospholipids.
To date, I was unable to ascribe the in vivo attenuation of the B.
pseudomallei VacJ mutant to a defect in intracellular replication or survival in
murine macrophages. As I did not observe any defects in the early stages of
mouse infection studies and in vitro infection, it is likely that the B.
pseudomallei ΔBPSL3147 mutant display similar virulence properties as
compared to the wild type during  initial phases of infection. Since bpsl3147
encodes a protein that is found in the proteome of the outer membrane
(Schell et al., 2011), depletion of the protein may lead to outer membrane
defects such as exposure of hidden immunogens. This could have a
consequential effect on the elicitation of host immune responses. For
example, as the intracellular B. pseudomallei escapes into the cytosol,
antigenic B. pseudomallei proteins present could be processed by the
proteasome in the endogenous pathway and presented to CD8+ T cells by
class I major histocompatibility complex (MHC), inducing T cell mediated
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immunity (Haque et al., 2006). Future work may involve the investigation of
immunological correlates during infection of macrophages. It may be useful
to infect pre-activated macrophages with the B. pseudomallei K96243
ΔBPSL3147 mutant to investigate the role of VacJ in bacterial survival and
other intracellular events such as multinucleated cell formation.
Although no sterilizing immunity was achieved, this work has shown that the
B. pseudomallei K96243 ΔBPSL3147 mutant is a potential live attenuated
vaccine candidate, which provides significant protection against a pulmonary
infection. Future studies could focus on defining the correlates of protective
immunity conferred by vaccination with the B. pseudomallei VacJ mutant.
Also, since the reversion of an attenuated strain to a wild type strain in the
environment may be a major concern for using live attenuated bacteria as
vaccines, two or more independent site-specific knockouts could be
considered (Choh et al., 2013).
In conclusion, I have shown that VacJ is a novel factor that contributes to
serum resistance of B. pseudomallei and B. thailandensis, independent of
the LPS. This study represents a follow up on the STM screen for in vivo
virulence and confirmed the lipoprotein VacJ as a virulence determinant in B.
pseudomallei and B. thailandensis. Lastly, I have shown that the B.
pseudomallei ΔBPSL3147 mutant is a potential live attenuated vaccine
candidate that confers protection against pulmonary melioidosis.
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A. Appendices
Appendix 1
Table A.1 Solutions used in this study
Reagent/buffer Components Use
TE buffer 100 mM Tris HCl pH 8.0,
200 mM NaCl, 5 mM
EDTA, 0.2 % SDS (Fischer
scientific Loughborough,
Leicestershire, UK)
Genomic DNA extraction and
electrophoresis solutions
Tris acetate EDTA (TAE)
Buffer (50 x stock
solution)
242 g Tris base, 100 ml 0.5
M EDTA, 57.1 ml Acetic
acid to a final volume of 1 L
(1 x = 40 mM Tris-acetate,
1 mM EDTA)
Gel electrophoresis
Sample loading buffer (2
x)
100 mM Tris.HCl, pH 6.8,
20 % (v/v) glycerol, 2 %
SDS, 0.02 % (w/v)
bromophenol blue, 0.1 M
DTT
SDS-PAGE
20 x MOPS SDS Running
buffer (NuPAGE®)
50 mM MOPS, 50 mM Tris
base, 0.1 % SDS, 1 mM
EDTA, pH 7.7
SDS-PAGE
Coomassie Stain 0.1 % Coomassie R250, 10
% acetic acid, 40 %
methanol
SDS-PAGE
Destain solution 20 % methanol, 10 %
acetic acid
SDS-PAGE
Tris-glycine running buffer 25 mM Tris-HCl pH 8.3,
250 mM glycine, 0.1 % (v/v)
SDS
Western Blot
Transfer buffer (1x) 25 mM Tris, 200 mM
glycine, 20 % methanol,
0.02% (v/v) SDS
Western Blot
PBST Phosphate buffered saline
(PBS), 0.01 % (v/v) Tween
20
Western Blot,
immunofluorescence assay
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Appendix 2
Construction of complementation vector with kanamycin resistance
The shuttle plasmid pME6033 was derived from pME6032 (a gift from Jo
Stevens (Heeb et al., 2002)), where the tetracycline resistance cassette was
replaced at the BamHI and XbaI sites with the PCR-amplified kanamycin
resistance cassette from the plasmid vector pUT-Km2-A1 (Lorenzo et al.,
1990).
Table A.2 Primers used in replacement of antibiotic cassette in
pME6032
Primer Sequence (5’ to 3’) Use Reference
Km-Up-
BamHI
aaaag↓gatc↑cCAACAAAGCCACGTTGTGTCTCAAA PCR
amplification
of
kanamycin
cassette
This study
Km-Dn-
XbaI
aaaat↓ctag↑aAGTCAGCGTAATGCTCTGCCAGT
P6033F TGGAAAGCGGGCAGTGAGCG Sequencing
primer to
check
replacement
of KanR
cassette
This study
Km2
UR
ATGCAACCGGCGCAGGAACA
pME6033 is a shuttle vector with E. coli p15A origins and Pseudomonas
plasmid pVS1 for stable replication in E. coli and B. pseudomallei. The p15A
origin is a medium copy origin, about 15-25 copies per cell, and can be used
in combination with pBR322-derived plasmids as a stable 2-plasmid system.
The Pseudomonas plasmid pVS1, has about seven copies per cell is
compatible with IncP-1 and IncP-4 replicons.
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Figure A.1 Plasmid map of pMEK
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>pMEK 8013 nt
TGATCCAACCCCTCCGCTGCTATAGTGCAGTCGGCTTCTGACGTTCAGTGCAGCCGTCTTCTGAAAACGACAT
GTCGCACAAGTCCTAAGTTACGCGACAGGCTGCCGCCCTGCCCTTTTCCTGGCGTTTTCTTGTCGCGTGTTTT
AGTCGCATAAAGTAGAATACTTGCGACTAGAACCGGAGACATTACGCCATGAACAAGAGCGCCGCCGCTGGC
CTGCTGGGCTATGCCCGCGTCAGCACCGACGACCAGGACTTGACCAACCAACGGGCCGAACTGCACGCGGC
CGGCTGCACCAAGCTGTTTTCCGAGAAGATCACCGGCACCAGGCGCGACCGCCCGGAGCTGGCCAGGATGC
TTGACCACCTACGCCCTGGCGACGTTGTGACAGTGACCAGGCTAGACCGCCTGGCCCGCAGCACCCGCGAC
CTACTGGACATTGCCGAGCGCATCCAGGAGGCCGGCGCGGGCCTGCGTAGCCTGGCAGAGCCGTGGGCCGA
CACCACCACGCCGGCCGGCCGCATGGTGTTGACCGTGTTCGCCGGCATTGCCGAGTTCGAGCGTTCCCTAAT
CATCGACCGCACCCGGAGCGGGCGCGAGGCCGCCAAGGCCCGAGGCGTGAAGTTTGGCCCCCGCCCTACC
CTCACCCCGGCACAGATCGCGCACGCCCGCGAGCTGATCGACCAGGAAGGCCGCACCGTGAAAGAGGCGGC
TGCACTGCTTGGCGTGCATCGCTCGACCCTGTACCGCGCACTTGAGCGCAGCGAGGAAGTGACGCCCACCGA
GGCCAGGCGGCGCGGTGCCTTCCGTGAGGACGCATTGACCGAGGCCGACGCCCTGGCGGCCGCCGAGAAT
GAACGCCAAGAGGAACAAGCATGAAACCGCACCAGGACGGCCAGGACGAACCGTTTTTCATTACCGAAGAGA
TCGAGGCGGAGATGATCGCGGCCGGGTACGTGTTCGAGCCGCCCGCGCACGTCTCAACCGTGCGGCTGCAT
GAAATCCTGGCCGGTTTGTCTGATGCCAAGCTGGCGGCCTGGCCGGCCAGCTTGGCCGCTGAAGAAACCGAG
CGCCGCCGTCTAAAAAGGTGATGTGTATTTGAGTAAAACAGCTTGCGTCATGCGGTCGCTGCGTATATGATGC
GATGAGTAAATAAACAAATACGCAAGGGGAACGCATGAAGGTTATCGCTGTACTTAACCAGAAAGGCGGGTCA
GGCAAGACGACCATCGCAACCCATCTAGCCCGCGCCCTGCAACTCGCCGGGGCCGATGTTCTGTTAGTCGAT
TCCGATCCCCAGGGCAGTGCCCGCGATTGGGCGGCCGTGCGGGAAGATCAACCGCTAACCGTTGTCGGCAT
CGACCGCCCGACGATTGACCGCGACGTGAAGGCCATCGGCCGGCGCGACTTCGTAGTGATCGACGGAGCGC
CCCAGGCGGCGGACTTGGCTGTGTCCGCGATCAAGGCAGCCGACTTCGTGCTGATTCCGGTGCAGCCAAGC
CCTTACGACATATGGGCCACCGCCGACCTGGTGGAGCTGGTTAAGCAGCGCATTGAGGTCACGGATGGAAGG
CTACAAGCGGCCTTTGTCGTGTCGCGGGCGATCAAAGGCACGCGCATCGGCGGTGAGGTTGCCGAGGCGCT
GGCCGGGTACGAGCTGCCCATTCTTGAGTCCCGTATCACGCAGCGCGTGAGCTACCCAGGCACTGCCGCCG
CCGGCACAACCGTTCTTGAATCAGAACCCGAGGGCGACGCTGCCCGCGAGGTCCAGGCGCTGGCCGCTGAA
ATTAAATCAAAACTCATTTGAGTTAATGAGGTAAAGAGAAAATGAGCAAAAGCACAAACACGCTAAGTGCCGGC
CGTCCGAGCGCACGCAGCAGCAAGGCTGCAACGTTGGCCAGCCTGGCAGACACGCCAGCCATGAAGCGGGT
CAACTTTCAGTTGCCGGCGGAGGATCACACCAAGCTGAAGATGTACGCGGTACGCCAAGGCAAGACCATTAC
CGAGCTGCTATCTGAATACATCGCGCAGCTACCAGAGTAAATGAGCAAATGAATAAATGAGTAGATGAATTTTA
GCGGCTAAAGGAGGCGGCATGGAAAATCAAGAACAACCAGGCACCGACGCCGTGGAATGCCCCATGTGTGGA
GGAACGGGCGGTTGGCCAGGCGTAAGCGGCTGGGTTGTCTGCCGGCCCTGCAATGGCACTGGAACCCCCAA
GCCCGAGGAATCGGCGTGAGCGGTCGCAAACCATCCGGCCCGGTACAAATCGGCGCGGCGCTGGGTGATGA
CCTGGTGGAGAAGTTGAAGGCCGCGCAGGCCGCCCAGCGGCAACGCATCGAGGCAGAAGCACGCCCCGGT
GAATCGTGGCAAGCGGCCGCTGATCGAATCCGCAAAGAATCCCGGCAACCGCCGGCAGCCGGTGCGCCGTC
GATTAGGAAGCCGCCCAAGGGCGACGAGCAACCAGATTTTTTCGTTCCGATGCTCTATGACGTGGGCACCCG
CGATAGTCGCAGCATCATGGACGTGGCCGTTTTCCGTCTGTCGAAGCGTGACCGACGAGCTGGCGAGGTGAT
CCGCTACGAGCTTCCAGACGGGCACGTAGAGGTTTCCGCAGGGCCGGCCGGCATGGCCAGTGTGTGGGATT
ACGACCTGGTACTGATGGCGGTTTCCCATCTAACCGAATCCATGAACCGATACCGGGAAGGGAAGGGAGACA
AGCCCGGCCGCGTGTTCCGTCCACACGTTGCGGACGTACTCAAGTTCTGCCGGCGAGCCGATGGCGGAAAG
CAGAAAGACGACCTGGTAGAAACCTGCATTCGGTTAAACACCACGCACGTTGCCATGCAGCGTACGAAGAAGG
CCAAGAACGGCCGCCTGGTGACGGTATCCGAGGGTGAAGCCTTGATTAGCCGCTACAAGATCGTAAAGAGCG
AAACCGGGCGGCCGGAGTACATCGAGATCGAGCTAGCTGATTGGATGTACCGCGAGATCACAGAAGGCAAGA
ACCCGGACGTGCTGACGGTTCACCCCGATTACTTTTTGATCGATCCCGGCATCGGCCGTTTTCTCTACCGCCT
GGCACGCCGCGCCGCAGGCAAGGCAGAAGCCAGATGGTTGTTCAAGACGATCTACGAACGCAGTGGCAGCG
CCGGAGAGTTCAAGAAGTTCTGTTTCACCGTGCGCAAGCTGATCGGGTCAAATGACCTGCCGGAGTACGATTT
GAAGGAGGAGGCGGGGCAGGCTGGCCCGATCCTAGTCATGCGCTACCGCAACCTGATCGAGGGCGAAGCAT
CCGCCGGTTCCTAATGTACGGAGCAGATGCTAGGGCAAATTGCCCTAGCAGGGGAAAAAGGTCGAAAAGGTC
TCTTTCCTGTGGATAGCACGTACATTGGGAACCCAAAGCCGTACATTGGGAACCGGAACCCGTACATTGGGAA
CCCAAAGCCGTACATTGGGAACCGGTCACACATGTAAGTGACTGATATAAAAGAGAAAAAAGGCGATTTTTCCG
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CCTAAAACTCTTTAAAACTTATTAAAACTCTTAAAACCCGCCTGGCCTGTGCATAACTGTCTGGCCAGCGCACA
GCCGAAGAGCTGCAAAAAGCGCCTACCCTTCGGTCGCTGCGCTCCCTACGCCCCGCCGCTTCGCGTCGGCCT
ATCGCGGCCGCTGGCCGCTCAAAAATGGCTGGCCTACGGCCAGGCAATCTACCAGGGCGCGGACAAGCCGC
GCCGTCGCCACTCGACCGCCGGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGACTCATACCAGGGCAA
TGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGG
ATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAAT
CTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCG
TAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTC
ACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAAT
TTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTTTCGTTCCACT
GAGCGTCAGACCCCTTAATAAGATGATCTTCTTGAGATCGTTTTGGTCTGCGCGTAATCTCTTGCTCTGAAAAC
GAAAAAACCGCCTTGCAGGGCGGTTTTTCGAAGGTTCTCTGAGCTACCAACTCTTTGAACCGAGGTAACTGGC
TTGGAGGAGCGCAGTCACCAAAACTTGTCCTTTCAGTTTAGCCTTAACCGGCGCATGACTTCAAGACTAACTCC
TCTAAATCAATTACCAGTGGCTGCTGCCAGTGGTGCTTTTGCATGTCTTTCCGGGTTGGACTCAAGACGATAGT
TACCGGATAAGGCGCAGCGGTCGGACTGAACGGGGGGTTCGTGCATACAGTCCAGCTTGGAGCGAACTGCCT
ACCCGGAACTGAGTGTCAGGCGTGGAATGAGACAAACGCGGCCATAACAGCGGAATGACACCGGTAAACCGA
AAGGCAGGAACAGGAGAGCGCACGAGGGAGCCGCCAGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGG
GTTTCGCCACCACTGATTTGAGCGTCAGATTTCGTGATGCTTGTCAGGGGGGCGGAGCCTATGGAAAAACGGC
TTTGCCGCGGCCCTCTCACTTCCCTGTTAAGTATCTTCCTGGCATCTTCCAGGAAATCTCCGCCCCGTTCGTAA
GCCATTTCCGCTCGCCGCAGTCGAACGACCGAGCGTAGCGAGTCAGTGAGCGAGGAAGCGGAATATATCCTG
TATCACATATTCTGCTGACGCACCGGTGCAGCCTTTTTTCTCCTGCCACATGAAGCACTTCACTGACACCCTCA
TCAGTGCCAACATAGTAAGCCAGTATACACTCCGCTAGCGCTGAGGTCTGCCTCGTGAAGAAGGTGTTGCTGA
CTCATACCAGGCTAGTCCGAGGAGCTTTATGCTTGTAAACCGTTTTGTGAAAAAATTTTTAAAATAAAAAAGGGG
ACCTCTAGGGTCCCCAATTAATTAGTAATATAATCTATTAAAGGTCATTCAAAAGGTCATCCACCGGATCAATTC
CCCTGCTCGCGCAGGCTGGGTGCCAAGCTCTCGGGTAACATCAAGGCCCGATCCTTGGAGCCCTTGCCCTCC
CGCACGATGATCGTGCCGTGATCGAAATCCAGATCCTTGACCCGCAGTTGCAAACCCTCACTGATCCGCTAGT
CCGAGGCCTCGAGATCTATCGATGCATGCCATGGTACCCGGGAGCTCGAATTCTGTTTCCTGTGTGAAATTGT
TATCCGCTCACAATTCCACACATTATACGAGCCGATGATTAATTGTCAACAGCTCATTTCAGAATATTTGCCAGA
ACCGTTATGATGTCGGCGCAAAAAACATTATCCAGAACGGGAGTGCGCCTTGAGCGACACGAATTATGCAGTG
ATTTACGACCTGCACAGCCATACCACAGCTTCCGATGGCTGCCTGACGCCAGAAGCATTGGTGCACCGTGCAG
TCGATAAGCCCGGATCAGCTTGCAATTCGCGCGCGAAGGCGAAGCGGCATGCATTTACGTTGACACCATCGAA
TGGTGCAAAACCTTTCGCGGTATGGCATGATAGCGCCCGGAAGAGAGTCAATTCAGGGTGGTGAATGTGAAAC
CAGTAACGTTATACGATGTCGCAGAGTATGCCGGTGTCTCTTATCAGACCGTTTCCCGCGTGGTGAACCAGGC
CAGCCACGTTTCTGCGAAAACGCGGGAAAAAGTGGAAGCGGCGATGGCGGAGCTGAATTACATTCCCAACCG
CGTGGCACAACAACTGGCGGGCAAACAGTCGTTGCTGATTGGCGTTGCCACCTCCAGTCTGGCCCTGCACGC
GCCGTCGCAAATTGTCGCGGCGATTAAATCTCGCGCCGATCAACTGGGTGCCAGCGTGGTGGTGTCGATGGT
AGAACGAAGCGGCGTCGAAGCCTGTAAAGCGGCGGTGCACAATCTTCTCGCGCAACGCGTCAGTGGGCTGAT
CATTAACTATCCGCTGGATGACCAGGATGCCATTGCTGTGGAAGCTGCCTGCACTAATGTTCCGGCGTTATTTC
TTGATGTCTCTGACCAGACACCCATCAACAGTATTATTTTCTCCCATGAAGACGGTACGCGACTGGGCGTGGA
GCATCTGGTCGCATTGGGTCACCAGCAAATCGCGCTGTTAGCGGGCCCATTAAGTTCTGTCTCGGCGCGTCTG
CGTCTGGCTGGCTGGCATAAATATCTCACTCGCAATCAAATTCAGCCGATAGCGGAACGGGAAGGCGACTGGA
GTGCCATGTCCGGTTTTCAACAAACCATGCAAATGCTGAATGAGGGCATCGTTCCCACTGCGATGCTGGTTGC
CAACGATCAGATGGCGCTGGGCGCAATGCGCGCCATTACCGAGTCCGGGCTGCGCGTTGGTGCGGATATCTC
GGTAGTGGGATACGACGATACCGAAGACAGCTCATGTTATATCCCGCCGTTAACCACCATCAAACAGGATTTTC
GCCTGCTGGGGCAAACCACGTGGACCGCTTGCTGCAACTCTCTCAGGGCCAGGCGGTGAAGGGCAATCAGCT
GTTGCCCGTCTCACTGGTGAAAAGAAAAACCACCCTGGCGCCCAATACGCAAACCGCCTCTCCCCGCGCGTT
GGCCGATTCATTAATGCAGCTGGCACGACAGGTTTCCCGACTGGAAAGCGGGCAGTGAGCGCAACGCAATTA
ATGTAAGTTAGCGCGAATTGCAAGCTGGCCGACGCGCTGGGCTACGTCTTGCTGGCGTTCGGATCCCAACAA
AGCCACGTTGTGTCTCAAAATCTCTGATGTTACATTGCACAAGATAAAAATATATCATCATGAACAATAAAACTG
TCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGCCATATTCAACGGGAAACGTCTTGCTCGAGGCCGC
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GATTAAATTCCAACATGGATGCTGATTTATATGGGTATAAATGGGCTCGCGATAATGTCGGGCAATCAGGTGCG
ACAATCTATCGATTGTATGGGAAGCCCGATGCGCCAGAGTTGTTTCTGAAACATGGCAAAGGTAGCGTTGCCA
ATGATGTTACAGATGAGATGGTCAGACTAAACTGGCTGACGGAATTTATGCCTCTTCCGACCATCAAGCATTTT
ATCCGTACTCCTGATGATGCATGGTTACTCACCACTGCGATCCCCGGGAAAACAGCATTCCAGGTATTAGAAG
AATATCCTGATTCAGGTGAAAATATTGTTGATGCGCTGGCAGTGTTCCTGCGCCGGTTGCATTCGATTCCTGTT
TGTAATTGTCCTTTTAACAGCGATCGCGTATTTCGTCTCGCTCAGGCGCAATCACGAATGAATAACGGTTTGGT
TGATGCGAGTGATTTTGATGACGAGCGTAATGGCTGGCCTGTTGAACAAGTCTGGAAAGAAATGCATAAGCTTT
TGCCATTCTCACCGGATTCAGTCGTCACTCATGGTGATTTCTCACTTGATAACCTTATTTTTGACGAGGGGAAAT
TAATAGGTTGTATTGATGTTGGACGAGTCGGAATCGCAGACCGATACCAGGATCTTGCCATCCTATGGAACTG
CCTCGGTGAGTTTTCTCCTTCATTACAGAAACGGCTTTTTCAAAAATATGGTATTGATAATCCTGATATGAATAAA
TTGCAGTTTCATTTGATGCTCGATGAGTTTTTCTAATCAGAATTGGTTAATTGGTTGTAACACTGGCAGAGCATT
ACGCTGACTTCTAGAACTAGCTAGAACTA
Figure A.2 pMEK DNA sequence
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Table A.3 Features of pMEK
Gene Product Coordinates Protein ID
orf1
ORF1; pVS1 resolvase; not
required for stable maintenance 195..881 ABG33931.1
orf2
ORF2; hypothetical protein, not
required for stable maintenance
878..1093 ABG33932.1
staA StaA; pVS1 partitioning protein 1180..1809 ABG33933.1
parG ParG; pVS1 partitioning protein 1830..2045 ABG33934.1
repA RepA; pVS1 replication protein 2238..3311 ABG33935.1
oriVpVS1 pVS1 origin of replication 3377..3571 -
oriVp15A p15A origin of replication 4264..5089 -
oriT p15A origin of transfer 5068..5089 -
TT4 T4 transcription terminator 5148..5414 -
P6032 sequencing oligonucleotide 5402..5421 -
MCS multiple cloning site 5416..5473 -
Tac
tac promoter, 5'UTR and RBS
followed by EcoRI
compl(5468..5542) -
lacIQ LacIQ repressor 5977..6792 ABG33936.1
kanR Kanamycin resistance protein 7130..7945 AAC79083.1
